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ABSTRACT 
 
The main aim of this manuscript is to provide a comprehensive and critical verification of 
methodology commonly used for sample collection, storage and preparation in studies concerning the 
analysis of pharmaceuticals and illicit drugs in aqueous environmental samples with the usage of 
SPE-LC/MS techniques. This manuscript reports the results of investigations into several sample 
preparation parameters that to the authors’ knowledge have not been reported or have received very 
little attention. This includes: (i) effect of evaporation temperature and (ii) solvent with regards to 
solid phase extraction (SPE) extracts; (iii) effect of silanising glassware; (iv) recovery of analytes 
during vacuum filtration through glassfibre filters and (v) pre LC-MS filter membranes. All of these 
parameters are vital to develop efficient and reliable extraction techniques; an essential factor given 
that target drug residues are often present in the aqueous environment at ng L
-1 
levels. Presented is 
also the first comprehensive review of the stability of illicit drugs and pharmaceuticals in wastewater. 
Among the parameters studied are: time of storage, temperature and pH. Over 60 analytes were 
targeted including stimulants, opioid and morphine derivatives, benzodiazepines, antidepressants, 
dissociative anaesthetics, drug precursors, human urine indicators and their metabolites. The lack of 
stability of analytes in raw wastewater was found to be significant for many compounds. For instance, 
34 % of compounds studied reported a stability change > 15 % after only 12 hours in raw wastewater 
stored at 2 ˚C; a very important finding given that wastewater is typically collected with the use of 24 
hr composite samplers. The stability of these compounds is also critical given the recent development 
of so-called ‘sewage forensics’ or ‘sewage epidemiology’ in which concentrations of target drug 
residues in wastewater are used to back-calculate drug consumption. Without an understanding of 
stability, under (or over) reporting of consumption estimations may take place.  
 
KEYWORDS: illicit drugs, drugs of abuse, pharmaceuticals, wastewater, surface water, river water, 
environment, LC-MS/MS, sewage, SPE, multi-residue, silanisation, stability study, sample 
preparation, sewage forensics, sewage epidemiology 
1 INTRODUCTION 
 
Illicit drugs and drugs of abuse are the latest group of emerging environmental contaminants that are 
receiving a considerable amount of attention [1]. The presence of these compounds in the aqueous 
environment is important from both a forensic and an environmental perspective. From a forensic 
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perspective, the concentration of target drug residues in wastewater influent may be used to back-
calculate drug consumption for local communities, thereby offering significant advantages over 
currently used indirect estimation tools such as population surveys [2]. Furthermore, drug residues 
present in wastewater can reach surface waters. This is primarily due to insufficient removal at 
wastewater treatment plants (WWTPs). Therefore, from an environmental perspective, the presence of 
compounds in the environment has to be investigated as these compounds have been specifically 
designed to have an impact on humans and could have a negative effect on both humans and wildlife 
[3]. 
 
Consequently, we and several other authors have developed analytical methodologies that study drugs 
of abuse in the aqueous environment. These methodologies and their analytical aspects have been 
comprehensively summarised in Table 1. Typically, analytes are analysed through the usage of liquid 
chromatography (LC) coupled with mass spectrometry (MS). Since most drugs of abuse are present in 
wastewater influent at ng L
-1
 range, (and lower in effluent and surface waters) it is crucial that an 
effective pre-concentration procedure is performed to make samples amenable to LC-MS detection 
limits. This is most commonly carried out through the use of solid phase extraction (SPE), which 
subsequently involves evaporation of extracts, reconstitution and injection into the LC-MS system. A 
full understanding of the performance of the above mentioned sample preparation methodology is a 
critical, although very often overlooked, aspect of the whole analytical process.  As can be observed 
in Tab. 1, certain aspects of sample preparation procedures are in several cases not studied or 
unreported. Therefore, it might be difficult to draw any constructive conclusions regarding the overall 
performance of these methods. 
 
There are two major aims of this work; the first is to address some of the important preparation steps 
that affect recovery of compounds and to the authors’ knowledge have not been investigated or 
received very little attention. The factors investigated include: (i) effect of evaporation temperature 
and (ii) solvent with regards to SPE extracts; (iii) effect of silanising glassware; (iv) recovery of 
analytes during vacuum filtration through glassfibre filters and (v) pre LC-MS filter membranes. The 
second aim is to address perhaps one of the most important factors that to date has not been 
comprehensively evaluated, the stability of compounds in environmental matrix. Therefore this work 
presents the results of a detailed stability study of over 60 analytes. Stability is of considerable 
importance as certain compounds may degrade significantly over a period of only several hours, a 
factor that must be considered if using a 24 hour composite sampler for collection and if storing 
samples for any period of time. 
2 EXPERIMENTAL 
2.1 Chemicals and materials 
 
Analyte names and acronyms, CAS number, molecular formula, log Kow, pKa and supplier are shown in Table S1. 
Surrogate/internal standards were all purchased from LGC, with exception of caffeine-d9 (Sigma-Aldrich). All 
standards and internal standards were of the highest purity available (>97%). Individual stock solutions were 
purchased or prepared from powdered substance in either acetone or methanol at a concentration of 1 or 0.1 g L
−1
 and 
stored in the dark at −20 ◦C. Mixed standard solutions were prepared at 10mg L
−1
 in methanol and diluted as 
necessary to prepare working solutions. Mobile phase solvents and additives were all of LC–MS quality and 
purchased from Sigma–Aldrich, with the exception of H2O which was purchased from Fisher. Hydrochloric acid 
(37%), 5% dimethylchlorosilane (DMDCS) in toluene and ammonium hydroxide (30%) were purchased from Sigma–
Aldrich. Ultra pure water was obtained from a water purification system (UHQ-PS, ELGA, UK). Solid phase 
extraction (SPE) was carried out with Gilson SPE, Aspec XL4 (Anachem, UK). Oasis 60 mg MCX and 60 mg HLB 
cartridges were purchased from Waters (Waters, UK). SPE samples were eluted into borosilicate glass tubes (12mm x 
75mm, Fisher, UK) and evaporated with a TurboVap LV concentration workstation (Caliper, UK). The procedure to 
deactivate the glassware consisted of rinsing (once) with reagent (5% DMDCS/toluene) for 15 s, toluene (twice) and 
finally methanol (thrice). 
 
3 
 
2.2 LC-MS/MS 
 
The aforementioned drug residues and associated metabolites were measured with a fully validated, highly selective 
and sensitive LC-MS/MS method [4]. Briefly, separation was achieved with the usage of Waters ACQUITY UPLC
TM
 
system (Waters, UK) consisting of ACQUITY UPLC
TM
 binary solvent manager and ACQUITY UPLC
TM
 sample 
manager. Analytes were analysed with an AQUITY UPLC BEH C18 (1.7 µm; 1mm × 150 mm) column,  with a 
mobile phase consisting of mobile phase A (pH 2.9): 79.7%H2O, 20%MeOH, 0.3%CH3COOH and mobile phase B 
(pH 3.3): 99.7%MeOH, 0.3%CH3COOH at a flow rate of 0.04 mL min
-1 
and a temperature of 30 °C. The gradient 
programme was as follows: 0min – 100% A, 17 min – 41.3% A, 17.2 min – 0% A, 20.2 min – 0% A, 20.3 min – 
100% A, 34.0 min – 100% A. An injection volume of 20 µL was used. 
 
A triple quadrupole mass spectrometer (TQD, Waters, UK), equipped with an electrospray ionisation source, was used 
for the quantification of target analytes. The analyses were performed in positive mode. The mass spectrometer was 
operated in selected reaction monitoring (SRM) mode, measuring the fragmentation of the protonated pseudo-
molecular ions of each compound. Masslynx 4.1 software (Waters, UK) was used to collect and analyse all data. 
 
2.3 Effect of temperature and elution solvent during evaporation 
 
The optimal temperature for evaporation of the SPE extract was evaluated under a gentle stream of nitrogen (5-10 
psi). At this stage in the method development, the use of Oasis® HLB or MCX cartridges was still under 
investigation, thus the elution solvents used for both cartridges were assessed. Oasis® HLB and MCX elution 
solvents, methanol (3 mL) and 7 % NH4OH/MeOH (v/v) (3 mL, pH 11.8) respectively, were spiked with an 
environmentally realistic amount (50 ng) of each compound (equating to 500 ng/L in the aqueous environment with a 
sample volume of 100 mL), with exception of creatinine at 400 ng. Samples were evaporated to dryness in silanised 
vials at temperatures of 20, 30, 40, 50 and 60 °C and removed from the evaporator immediately after the solvent was 
fully removed. Samples were reconstituted in 0.3 % CH3COOH, 5 % MeOH/H2O (v/v) (500 µl). 
 
2.4 Impact of silanisation of glassware 
 
To investigate the interaction of basic molecules with charged silanols on the surface of glassware, the impact of 
silanising the vials used to hold the SPE extract during the evaporation step was investigated. Oasis® HLB and MCX 
elution solvent, methanol (3 mL) and 7% NH4OH/MeOH (3 mL, pH 11.8) respectively, were spiked with 50 ng of 
each compound, except creatinine at 400 ng. Samples were then evaporated at 40 °C in non-silanised or silanised vials 
under a stream of nitrogen to dryness, and reconstituted in 0.3 % CH3COOH, 5 % MeOH/H2O (v/v) (500 µL).  
 
2.5 SPE method 
 
Following several other optimisation steps including sample volume, wash solvent and elution volume (results not 
reported), the final SPE procedure was as follows: Initially the Oasis MCX was conditioned with MeOH (2 mL) and 
equilibrated with 2% HCOOH/H2O (2mL, pH 2) both at a flow rate of 3 mL min
−1
. Acidified (pH 1.8 with HCl) river 
water (500 mL), wastewater influent (100 mL) or effluent (100 mL) were passed through the MCX cartridge at a rate 
of 6 mL min
−1
. Immediately following loading, cartridges were washed with 2 % HCOOH/H2O (2 mL, pH 1.8) at a 
flow rate of 3 mL min
−1
 and subsequently wrapped in aluminium foil and stored at −20 ˚C no longer than one week 
before being eluted. Cartridges were washed with 0.6 % HCOOH/MeOH (2 mL, pH 1.8) at a flow rate of 3 mL min
−1
 
followed by elution with 7 % NH4OH/MeOH (3 mL) at a flow rate of 1 mL min
−1
 into silanised vials. Extracts were 
evaporated to dryness (40 ˚C, N2, 2–10 psi) and reconstituted with 0.3 % CH3COOH/5 % MeOH/H2O (v/v) (500 µL). 
All samples were filtered through 0.2 µm PTFE filters (Whatman, Puradisc, 13mm) before being transferred to 
maximum recovery deactivated vials with PTFE septa (Waters, UK). 
 
2.6 Stability study 
 
Key parameters influencing the stability of compounds in wastewater were investigated: pH (2 and 7), temperature (2 
and 19 ˚C) and time of storage. Additionally, the influence of suspended solids on stability of analytes in the aqueous 
phase was evaluated. Stability tests were carried out in duplicate, with all samples stored in the dark in silanised 
amber glass bottles. All samples were spiked at a concentration of 1000 ng L
-1
 for each compound (in addition to the 
concentration already present in the wastewater sample, see Table S4). In parallel to the spiked sample, a non-spiked 
‘control’ stability sample was carried out in duplicate alongside each of the spiked samples and processed in exactly 
the same conditions as those samples which were spiked. Samples were analysed immediately after spiking and then 
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subsequently at 12, 24 and 72 hour time points. After the extraction of each time point, cartridges were stored at -20 
˚C for a maximum of 7 days before elution. SPE was carried out as described in section 2.5. 
 
Long term storage of compounds on to Oasis MCX sorbent was evaluated. Wastewater (filtered, pH 2) was spiked at a 
concentration of 1000 ng L
-1
 for each compound and extracted in duplicate as described in section 2.5. After the 
loading of the sample, cartridges were washed with 2 % (v/v) HCOOH/H2O (2 mL, pH 1.8), dried, and then stored in 
an air-tight freezer bag at -20 ˚C. One set of cartridges were eluted immediately, with the remaining cartridges eluted 
in duplicate after 2, 4 and 6 weeks. 
 
The wastewater influent used in this study was collected as a grab sample (pH of 7.4), after primary screening in a 
winter month (11/12/10) during relatively dry weather at an urban WWTP (population served 238,000). After the 
collection of samples, wastewater was transported back to the laboratory on ice and spiked with compounds within 
five hours.  
3 RESULTS AND DISCUSSION  
 
Several sample collection, storage and preparation parameters were investigated. Among them are: (i) 
effect of evaporation temperature and (ii) solvent with regards to solid phase extraction (SPE) 
extracts; (iii) effect of silanising glassware; (iv) SPE sorbent; (v) recovery of analytes during vacuum 
filtration through glass fibre filters and (vi) pre LC-MS filter membranes, and (vii) stability of 
analytes in environmental matrix at different storage time, temperature and pH. Only the effect of 
evaporation temperature and solvent with regards to SPE, the effect of silanising glassware, and 
stability of analytes in environmental matrix at different storage time, temperature and pH are 
discussed below. Detailed discussion regarding other aspects of this study can be found in the 
Supplementary Material section.  
 
3.1 Effect of evaporation temperature and solvent 
 
Initially, the optimum temperature for evaporation of SPE extracts was investigated. Attention was 
paid to the drying of extracts by Clauwaert et al. [5], who found that up to 50 % of free MDA and 
MDMA was lost on evaporation of compounds in hexane-ethyl acetate at 35 ˚C. Liquid-liquid 
extraction was used for extraction of these compounds from biological matrices. To improve 
recoveries, the authors decided to convert the amines to their corresponding hydrochloric salts before 
drying to ensure non-volatility of the drugs, and prevent the over-drying of extracts for long periods 
(> 30 min). These modifications resulted in improved recovery and reproducibility. Similarly, Cheung 
et al. [6] found poor reproducibility of amphetamine and methamphetamine when evaporated to 
dryness in ethyl acetate. To rectify, samples were evaporated to around 0.2 – 0.4 mL at 40 ˚C before 
the next analytical step to prevent the over-drying of samples. Jensen et al. [7] examined the 
evaporation of the well-known herbicide dichlobenil (2,6-dichlorobenzonitrile) and its associated 
degradation products. During this study, compounds were spiked into acetonitrile and evaporated 
under nitrogen. The authors found no loss of compounds up to 40 ˚C, while at 50 ˚C a decrease in 
recoveries of around 25 % was observed for four out of six analytes. 
 
Surprisingly, given the importance of the evaporation step, to the authors’ knowledge there are no 
published manuscripts that discuss the evaporation step with regards to drugs of abuse. In the 
published material the effect of the evaporation is often taken into account during evaluation of SPE 
recoveries. However, the effect of evaporation has not been published separate to that of the overall 
SPE procedure. This results in misleading conclusions potentially being drawn, assigning low 
recoveries as a consequence of the SPE sorbent when in fact compounds could be lost during the 
evaporation step. The lack of importance assigned to this variable is shown in manuscripts within this 
field, with 8 out of the 18 published manuscripts that used evaporation not reporting which 
temperature was used (see Table 1). In the manuscripts that reported temperature, the majority of 
procedures used temperatures of 35 or 40 ˚C, with the highest evaporation temperature reported at 45 
˚C [8,9]. 
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In this study, compounds were spiked into two types of elution solvent utilised in Oasis MCX and 
Oasis HLB methodologies: 7 % NH4OH/MeOH (v/v) (3 mL, pH 11.8) and methanol (3 mL), 
respectively. Drying of these extracts was evaluated at 20, 30, 40, 50 and 60 ˚C. Absolute recoveries 
were calculated against a directly spiked sample diluent standard solution.  
 
When first assessing the impact of temperature in basic methanol (Figure 1a), overall the majority of 
compounds presented optimal recoveries at 20 ˚C as opposed to the higher evaporation temperatures. 
A full list of numerical values for the recovery of each compound in basic methanol is supplied in the 
Supplementary Material section, Table S2. Cocaine and associated metabolites benzoylecgonine, 
norcocaine, norbenzoylecgonine and cocaethylene showed relatively consistent recoveries over the 
full spectrum of temperatures, whereas ecgonine methyl ester, anhydroecgonine methyl ester and 
ecgonidine all showed significant losses over 40 ˚C. For instance, 72 % of ecgonine methyl ester was 
recovered at 40 ˚C in comparison to 45 % at 50 ˚C. Both amphetamine and methamphetamine were 
negatively affected by increasing temperature. Evaporation at 40 ˚C for amphetamine and 
methamphetamine provided respective recoveries of 88 and 89 %, in comparison to recoveries at 50 
˚C of 66 and 68 %. Loss of other amphetamine-like compounds at higher temperatures was not as 
severe. The vast majority of opioids reported similar recoveries in all temperatures studied, including 
morphine, codeine, methadone and dihydrocodeine. The benzodiazepines and antidepressants all 
showed good recoveries between the temperatures 20 – 40 ˚C; with the exception of nitrazepam which 
decreased by 21 % between the same temperatures. Ketamine and norketamine both showed 
decreasing recoveries with an increase in temperature.  
 
With regards to temperature in methanol extracts, Figure 1b, the results provided a similar trend to 
that in basic methanol, although the decrease in recovery with temperature was not as pronounced. A 
full list of numerical values for the recovery of each compound in methanol is supplied in the 
Supplementary Material section, Table S3.  Cocaine and associated metabolites showed relatively 
little change in recovery with temperature, including ecgonine methyl ester and ecgonidine which had 
previously shown lower recoveries. On the other hand, anhydroecgonine methyl ester still showed 
loss at higher temperature, with a recovery of 73 % at 40 ˚C and 61 % at 50 ˚C. Amphetamine and 
methamphetamine, in contrast to basic methanol, did not show any pattern with changes in 
temperature in methanol. The majority of opioids also showed consistent recoveries over the 
temperature range. Benzodiazepines and antidepressants presented recoveries which were similar with 
all evaporation temperatures, with the exception of nitrazepam. Ketamine and norketamine, as in 
basic methanol, showed a decline in recovery with higher temperatures. 
 
In this study, heroin reported low recovery in basic methanol elution solution. Similarly, Bones et al. 
[10] during SPE method found the Strata XC with basic methanol elution solvent to provide the 
highest recovery for the majority of their selected compounds, with the exception of a low heroin 
recovery (26 %). The authors of this paper speculated that this may be due to hydrolysis of heroin to 
morphine under acidic sample conditions, as morphine achieved an increased recovery of 124 %. The 
data from this study would in fact suggest that the low recovery could be due to decomposition during 
the evaporation step. In contrast to Bones and co-workers, in this study the decrease in heroin 
appeared to reflect deacetylation with an increase in 6-acetylmorphine observed and no apparent 
increase in morphine (6-acetylmorphine was not monitored by Bones et al. [10] so cannot be 
compared). Low recoveries of heroin were reported by Rook et al. [11] while developing a method to 
analyse plasma using an Oasis MCX sorbent with basic methanol elution solvent. The authors of this 
work rectified this problem and increased the recovery of heroin from 40 to 93 % by lowering the 
temperature of the eluent to -20 ˚C during SPE elution, shortening the elution time to 10 seconds, and 
collecting the elution solvent in an acidic buffer before evaporating the solvent. Without this 
observation, low heroin recovery would have probably been attributed to the SPE performance rather 
than the evaporation step.  
 
In contrast to heroin, fluoxetine reported low recoveries over the temperature range (25 - 55 %) when 
evaporated in methanol as opposed to basic methanol. Gros et al. [12] extracted fluoxetine and 28 
other multi-class pharmaceuticals using Oasis HLB sorbent with methanol elution solvent. The 
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authors generally reported low recovery (decoupled from matrix effects) of fluoxetine at two 
concentrations in WWTP influent (1000 ng L
-1 
= 67 %; 10,000 ng L
-1 
= 108 %), WWTP effluent (100 
ng L
-1 
= 74 %; 1000 ng L
-1 
= 60 %), and river water (50 ng L
-1 
= 74 %; 1000 ng L
-1 
= 105 %). 
Although it cannot be said with any certainty, it may be that low recovery in this method for 
fluoxetine was due to the effects of the evaporation step. Other published methods for the analysis of 
fluoxetine used an Oasis MCX with basic methanol elution solvent [13] and an Oasis HLB with 70 % 
methanol in 2 % acetic acid elution solvent [14], with both papers reporting recoveries greater than 87 
%.   
 
Amphetamine showed an approximately 20 % decrease in recovery when evaporated in basic 
methanol as opposed to methanol at temperatures between 20 – 40 ˚C. Similarly, morphine showed a 
loss when recovered from methanol. Benzodiazepines presented similar results in both solvents, 
although a slight increase of around 10 % in all compounds was observed in methanol at the majority 
of temperatures. Antidepressants, with the exception of venlafaxine, generally showed losses of 
around 20 % in methanol, although this loss was higher in the case of fluoxetine and its metabolite 
norfluoxetine. 
 
In conclusion, both temperature and the solvent in which the compounds are evaporated impact on the 
recovery of compounds. When looking at trends with regards to temperature, the highest recovery for 
almost all compounds was achieved at 20 ˚C. Temperature was found to be most influential in basic 
methanol, with temperature effects less apparent in methanol. Although it cannot be said with 
certainty, it is assumed that this is due to the pH in basic solvent being higher than the pKa of basic 
analytes. The analytes are consequently non-ionised and more non-polar which will increase their 
volatility. However, evaporation at 20 ˚C leads to a time-consuming evaporation step. In this study, to 
compromise between time taken for evaporation and recovery of compound, an evaporation 
temperature of 40 ˚C was selected. Solvent used for evaporation can have a significant impact on the 
recovery of compounds and should be considered when evaluating an SPE procedure. As previously 
mentioned, within published methodologies the evaporation temperature typically used is 35 – 40 ˚C 
in either methanol or basic methanol. This means it is likely that loss of compounds to some extent 
would have occurred in all these procedures. 
 
3.2 Effect of silanisation of glassware 
 
In trace analysis, loss of compounds due to adsorption onto glassware surfaces can be significant [15]. 
Untreated glassware contains silicate and silanol groups that act as ion-exchange and nucleophilic 
centres [16]. Consequently, compounds may be lost where they come into contact with glassware, 
such as during sample collection and evaporation of SPE extracts. Amines are especially prone to loss 
onto the slightly acidic surface of glass [17]. To prevent the loss of compounds, glassware used for 
trace analysis can be silanised or ‘deactivated’. Silanisation involves masking the polar Si-OH groups 
and decreasing its hydrophilicity by chemically binding a non-adsorptive silicone layer on to the 
surface of the glassware. Ahrer et al. [18] investigated the loss of 27 endocrine disrupting compounds 
and PPCPs in both water and SPE extracts and found ‘remarkable’ improvement in recoveries after 
silanisation. However, recovery values were not reported in the manuscript.   
 
To assess the influence of non-silanised and silanised glassware during the evaporation step, methanol 
(3 mL) and basic methanol (3 mL, pH 11.8), were spiked at environmentally realistic concentrations 
(50 ng of each compound) and evaporated at 40 ˚C which therefore simulated the drying of SPE 
extracts in Oasis HLB and MCX elution solvents. Recoveries were calculated against spiked sample 
diluent at the same spiking level. 
 
The results are listed in Table 2 and show several significant improvements in recovery between non-
silanised and silanised vials in both solvents, with the majority of increases observed in basic 
methanol. Cocaine reported a 34 % increase in recovery between non-silanised and silanised vials in 
basic methanol, whereas in methanol recovery was high in both types of glass. Similar results were 
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reflected in that of norcocaine and cocaethylene. On the other hand, cocaine metabolites 
benzoylecgonine and norbenzoylecgonine showed high recoveries in both vials and solvents. 
Anhydroecgonine methyl ester presented an increase in recovery when vials were deactivated of 47 
and 46 % in basic methanol and methanol, respectively. Surprisingly, ecgonidine reflected the 
opposite trend, with lower recoveries in the silanised vials as opposed to the non-silanised. 
 
The suite of amphetamine-like compounds showed exceptional increases in recovery with the 
deactivation of vials in basic methanol. Increases were also observed in methanol, although not to 
such a large extent. For example in basic methanol, respective amphetamine and methamphetamine 
recoveries were 16 and 23 % in non-silanised vials, with these figures increasing to 88 and 89 % 
respectively in silanised vials. Recovery of LSD showed minor improvement with silanisation, 
whereas its main metabolite 2-oxo-3-hydroxy-LSD reported an improvement of 13 and 16 % when 
vials were silanised in basic methanol and methanol respectively. 
 
The silanisation of vials had little effect on the recovery of heroin or 6-acetylmorphine in both 
solvents. Similar results were also evident for many other opioids including oxycodone, 
buprenorphine, and fentanyl. Interestingly, a number of compounds in this group showed little change 
in basic methanol, whereas a decrease in recovery was observed in the case of deactivated vials in 
methanol only. This was the case for the following compounds: codeine, norcodeine, morphine, 
normorphine and dihydrocodeine. Methadone and its metabolites EDDP and EMDP all showed 
significant improvements when vials were silanised in basic methanol. Most notably the recovery of 
EDDP increased from 16 % in non-silanised vials to 89 % in silanised vials. 
 
In general there appeared to be little influence on the benzodiazepines through silanisation. The same 
was also found for antidepressants, with exception of venlafaxine which was found to increase with 
the silanisation of glassware in basic methanol. Ketamine and norketamine increased significantly 
with the silanisation of glass in both solvents. Ketamine recovery increased from 20 % in basic 
methanol to 84 % when vials were deactivated. 
 
Given the potential for loss of analytes on glassware without silanisation, it is surprising that only 
three published manuscripts in relation to drugs of abuse in the environment mention the silanisation 
of their glassware. The remaining 16 papers do not report whether or not deactivation has been carried 
out. Of these 16 papers, four have reported sample preparation recoveries decoupled from matrix 
effects. A review of these four papers for the recovery of amphetamine (one of the most influenced 
compounds by silanisation) showed recoveries of 70 % [19], 102 % [20], 90 % [21] and 74 % [22]. It 
is difficult to interpret these results with regards to silanisation as the deactivation of glassware was 
not reported and there are several factors which may have affected recovery. Nevertheless, it is 
possible that the lower amphetamine recovery reported in two of these manuscripts was due to 
glassware not being deactivated. 
 
The results clearly demonstrate that for many of the compounds studied in this investigation, the 
silanisation of glassware used to evaporate extracts provides improvements in recovery. The results 
suggest deactivation was more influential in basic methanol as opposed to methanol.  The most 
significant improvements were observed for amphetamine type compounds and methadone and 
associated metabolites. This study can conclude that all glassware should be silanised that is used 
during the evaporation step. Furthermore, there is the possibility that all glassware that comes into 
contact with the sample could adsorb certain compounds; hence all glassware throughout the sample 
preparation should be silanised. 
 
3.3 Stability studies 
 
Improving understanding of the stability of drugs of abuse in the environment is crucial for several 
reasons [23]: currently no uniform way of sample collection and handling exists; few stability studies 
have been conducted in wastewater; the majority of pharmaceuticals and drugs of abuse are bioactive 
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and hence may be metabolised or degraded by bacteria in wastewater or by other transformation 
reactions. Thus, depending on stability, quantifying a compound in wastewater that has been excreted 
several hours previously may in fact lead to a significant over or under estimation of the actual 
amount of residue originally present. 
 
The stability of drugs of abuse in wastewater to date has not been comprehensively addressed. 
Castiglioni et al. [24] investigated the stability of several illicit drugs and metabolites in raw 
wastewater influent stored at 4 ˚C with samples analysed immediately after spiking and three days. 
(pH not mentioned, although this would be assumed to be around pH 7, the normal pH of wastewater 
influent). This was the first publication to address the stability of illicit drugs in wastewater, although 
this work was limited due to only one storage condition and one time point being addressed. 
Gheorghe et al. [25] followed up this work by monitoring the stability of cocaine and 
benzoylecgonine in pond water, with pH (2 and 6) and temperature (-20, 4 and 20 ˚C) modified and 
time-points of 24, 72, and 120 hours. In the same publication, the stability of cocaine, 
benzoylecgonine and ecgonine methyl ester were assessed in wastewater influent at 20 ˚C and pH 6 
(as the authors intention was to recreate the conditions present in the environment this wastewater was 
presumably unfiltered, although this information is not mentioned in the manuscript). This publication 
provided evidence for the preservation of cocaine at an acidic pH. However, the drawback of this 
work was the small number of compounds monitored and the use of pond water rather than 
wastewater in all but one study. More recently, González-Marino et al. [26] monitored the stability of 
several illicit drugs in filtered wastewater in the dark at 4 ˚C. The same experiment was also 
duplicated with the addition of a preserving agent NaN3 (0.2 %). Target analytes were spiked at 100 
µg L
-1
 with stability monitored at 1, 3, 5 and 7 days. In the same study, wastewater was spiked and 
extracted onto Oasis HLB cartridges which were then stored at -20 ˚C for 12 weeks. The addition of a 
concentration of 100 µg L
-1
 of each compound is a cause for concern in this work as such a high 
concentration is environmentally unrealistic.  
 
The various storage conditions tested in this study recreate many of the conditions encountered during 
environmental analysis. The most commonly employed method for the collection of wastewater is 
through the use of a 24 hr (often temperature controlled) composite sampler (see Table 1). The 
various methods of sample collection were well-discussed by Ort et al. [27], although this article did 
not mention potential stability issues. Target analytes will also be present in wastewater for a certain 
period of time (often hours) as the sample travels through the sewage system to the WWTP composite 
sampler. Further still, the sample then has to be transported to the laboratory where it may then be 
kept at a refrigerated temperature for up to three days [1] before analysis. Consequently, to assess 
stability, untreated raw (unfiltered) wastewater influent was spiked with target analytes and stored at 2 
and 19 ˚C and analysed over a period of three days. 
 
Acidification of samples is widely known to prevent bacterial activity, and in turn preserves the 
sample [28]. Gheorge et al. [25] investigated the stability of cocaine and principal metabolites in 
surface water at different pH values (2 and 6) and temperatures (-20, 4 and 20 ˚C). It was found that 
storage of samples at an acidic pH was the primary factor in improving stability. Acidification of 
samples is also a requirement if basic molecules are to be extracted by SPE with mixed mode cation 
exchange sorbents; hence the pH of samples does need to be adjusted. For these reasons the stability 
of compounds was assessed in acidified (pH 2) wastewater (filtered) stored at 2 and 19 ˚C. 
 
A further set of conditions assessed was the storage of analytes in filtered wastewater as opposed to 
unfiltered wastewater. The removal of suspended wastewater particulates may improve the stability of 
analytes as it prevents potential adsorption onto particulates. For this reason filtered wastewater was 
spiked with analytes and stored at 2 and 19 ˚C. 
 
A control sample (not spiked) was analysed alongside each of the spiked samples. The stability 
patterns for compounds present in the control sample were very similar to those in the spiked sample, 
although often the change (either increase or decrease) was more severe in the control sample than the 
spiked sample. As the ratio of compound to bacteria in the control samples was lower, this may be 
9 
 
one possible reason to account for the difference. As both the control and spiked samples reported 
similar degradation patterns, it was decided that spiking wastewater at 1000 ng L
-1
 (in addition to the 
concentration already present in the control sample, see Table S4) would still provide an accurate 
estimate of stability. The stability of all compounds in raw (unfiltered) wastewater are listed in Table 
3, acidified filtered wastewater in Table 4 and filtered wastewater at pH 7 in Table 5. 
 
In the stability tests performed in the present study, benzoylecgonine reported a high stability in all 
storage conditions, although a slight increase in its concentration was shown when stored at an 
unadjusted pH. The increase in benzoylecgonine was likely due to the hydrolysis of cocaine to 
benzoylecgonine [25]. These results are in good agreement with previously reported findings [24-26]. 
With regards to cocaine, as was the case in the work by Gheorghe et al. [25], the main factor 
influencing the stability was found to be pH, with stability significantly improved at an acidic pH. 
Stored in filtered wastewater at pH 2 and 7 (both at 19 ˚C) the stability of cocaine after three days was 
found to decrease by 6.4 and 28.3 % respectively. In contrast to previous authors findings [24-26], the 
degradation of cocaine in this study was shown to be less severe at a natural pH. For example, after 
three days in raw (unfiltered) wastewater stored at 2 ˚C, a stability decrease of 8.2 % was found in 
contrast to Castiglioni et al. [24] of 36.1 %. More severe still, Gheorghe et al. [25] reported a 
reduction in cocaine of nearly 90 % after 24 hours in ambient temperature at pH 6. The contrast in 
findings could be due to the wastewater used in each of these studies. All of these studies have been 
conducted in different countries, thus the composition of wastewater may vary significantly 
depending on factors such as inhabitants, industrial input and time of year. Cocaine metabolites 
norcocaine, norbenzoylecgonine and cocaethylene all showed good stability in the various storage 
conditions in filtered water. After three days, in raw (unfiltered) wastewater at pH 7 and stored at 2 
˚C, norcocaine, norbenzoylecgonine and cocaethylene reported a stability decrease of 14.4, 6.0, and 
9.4 % respectively, which is good agreement with the findings by Castiglioni et al. [24] decreasing by 
15.4, 13.0 and 13.0 %. However, after 72h storage of unfiltered wastewater at 19 ˚C a significant 
degradation of these compounds was observed (31.5% and 19% for norcocaine and cocaethylene 
respectively).   Crack cocaine compounds anhydroecgonine methyl ester and ecgonidine both showed 
good stability at pH 2 regardless of temperature with less than a 15 % change reported after 72 hours. 
However, when stored in filtered wastewater at pH 7 and at 19 ˚C these compounds reported 
significant increases in concentration, with an increase of 45.3 and 43.3 % reported for 
anhydroecgonine methyl ester and ecgonidine, which suggests transformation processes occurring. 
 
With regards to amphetamine like compounds, in general, these analytes showed good stability in all 
storage conditions, especially when stored in acidic wastewater. After 72 hours in raw (unfiltered) 
wastewater at pH 7 and at 2 ˚C, methamphetamine reported a decrease of 6.0 % which agrees well 
with the value of 0.3 % determined by Castiglioni et al. [24]. Similarly, the stability of MDA and 
MDMA in the same sample in this study reported a change of 3.5 and 3.1 % which again compares 
well with Castiglioni et al. [24] of 4.4 and 0.8 %. In contrast, amphetamine reported a significant 
upsurge in concentration, which differs to that of Castiglioni et al. [24] and Gonzalez-Marino et al. 
[26] with both reporting good stability of amphetamine. As previously mentioned, the stability of 
methamphetamine was in good agreement with Castiglioni et al. [24], although in contrast to these 
two studies, Gonzalez-Marino [26] reported almost complete degradation of methamphetamine after 
three days. Methcathinone, MBDB and BDB showed good stability in wastewater at pH 2, but their 
stability was significantly deteriorated at pH 7, especially in the case of methcathinone, which after 
three days at pH 7 and at 2 ˚C reported a stability decrease of -60.3 %. 
 
Heroin reported a dramatic decrease in stability in all samples stored at pH 7 in this study, as opposed 
to an acidic pH where the decrease was less than 15 % after three days. A similar pattern, although not 
to the same extent, was observed for 6-acetylmorphine. After three days in filtered wastewater at pH 7 
and at 2 ˚C, heroin reported a decrease of 68.4 %, which is in good agreement with Gonzalez-Marino 
et al. [26] who showed a decrease of around 80 %. The stability of heroin and 6-acetylmorphine was 
adversely affected through the presence of suspended solids. After 24 hours in filtered waster at pH 7 
and at 2 ˚C, heroin and 6-acetylmorphine reported a stability decrease of 38.7 and 11.0 % 
respectively, whereas in the presence of suspended solids at the same storage conditions their 
10 
 
respective stabilities decreased by -82.3 and -32.5 %. Furthermore, only 12h storage at neutral pH 
(temp, 2 ˚C) led to a 66% decrease in concentration of heroin. This outcome questions currently used 
24h-sampling as a technique of choice in sewage epidemiology, where accurate measurement of 
heroin and its metabolites in wastewater is critical in order to estimate heroin’s abuse. 
 
Morphine and its glucuronide conjugate showed good stability at an acidic pH, whereas in all samples 
stored at pH 7, morphine reported an increase between 45.3 and 89.1 % after three days. This 
significant increase of morphine was paralleled by the decrease in the stability of morphine-3β-
glucuronide. These findings are supported by the results of Castiglioni et al. [24], who attributed the 
decrease of the conjugate to its deconjugation by the β-glucuronidase enzymes of faecal bacteria. In 
raw (unfiltered) wastewater at pH 7 and at 2 ˚C, after 12 hours morphine reported an increase of 46.2 
% and its conjugate reported a decrease of 80.5 %. Normorphine was determined to be stable in all 
conditions assessed. Codeine, norcodeine, oxycodone, dihydrocodeine, buprenorphine and 
norbuprenorphine were all found to be relatively stable in all storage conditions, with stability in raw 
(unfiltered) wastewater at 19 ˚C of less than 17.4 %. Methadone and its primary metabolite EDDP 
after three days in raw wastewater at 2 ˚C showed a decrease of 10.9 and 17.1 %, which is close to the 
respective values reported by Castiglioni et al. [24] of 5.2 and 1.6 %.  
 
In contrast to all of the other compounds targeted in this study, benzodiazepines temazepam and 
oxazepam showed lower stability in acidic wastewater as opposed to pH 7, with stability at pH 2 and 
at 19 ˚C after three days decreasing by 62.7 and 29.4 %. Stability was improved in the same sample 
through a cooler storage temperature of 2 ˚C to provide a decrease in stability at the same time point 
of 23.4 and 8.6 %. In contrast, the remaining benzodiazepines, diazepam, nordiazepam, nitrazepam, 7-
aminonitrazepam and chlordiazepoxide showed greater stability when the wastewater was acidified. 
The stability of nitrazepam shows a particularly sharp decline when stored in filtered wastewater at 
pH 7 and at 19 ˚C, with a stability decrease of 77.2 % after 24 hours. The stability of this compound 
was improved through acidification, although even when wastewater was acidified the stability of 
nitrazepam still decreased by 35.1 % after three days at pH 2 and at 2 ˚C. The above suggests that 
transformation processes occur in wastewater even in a short timescale of 12h and raises a question of 
the validity of composite sampling in the analysis of these compounds in wastewater. A decrease of 
concentrations of some benzodiazepines and an increase in concentrations of others might simply 
result from the fact that benzodiazepines share common metabolism patterns and additionally they are 
often excreted as glucuronic acid conjugates, which might be broken down with the formation of free 
compounds. 
 
The stability of antidepressants dosulepin, fluoxetine, amitriptyline and venlafaxine in this study was 
found to decrease by 25.4, 15.1, 23.6 and 15.1 % respectively, when stored at pH 2 and at 2 ˚C for 
three days in filtered wastewater. Furthermore, a significant decrease of their concentrations was 
observed unfiltered wastewater stored at pH 7.4 and at 2 ˚C for 72h and denoted 72.3, 54.8, 61.2 and 
43.6% for dosulepin, fluoxetine, amitriptyline and venlafaxine respectively. Nortriptyline and 
norfluoxetine showed poor stability in all storage conditions, for instance stability in acidified 
wastewater at 2 ˚C was 32.6 and 36.4 % respectively after three days. Ketamine and its metabolite 
were found to have excellent stability with very little change in stability after three days in all storage 
conditions tested. 
 
Table 6 summarises each of the time points in the various storage conditions by showing the 
percentage of compounds (65 compounds were analysed in total) reporting a stability change greater 
than 15 %. The table shows clearly that after 12 hours nearly all compounds are stable at an acidic pH, 
regardless of temperature, in contrast to wastewater at pH 7 with between 23 - 35 % of compounds 
reporting a significant change in stability. After 24 hours, nearly half of all the compounds monitored 
reported a stability change at neutral pH, in comparison to acidified wastewater with only 8 % of 
analytes. After 72 hours, stability was especially poor in raw (unfiltered) wastewater at 19 ˚C with 69 
% of compounds reporting a significant stability change.  
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Concerning the various parameters modified in the study, pH was the most important factor with a 
significant improvement in the stability of compounds overall when wastewater was acidified. This 
was also the finding of Gheorghe et al. [25] for cocaine and benzoylecgonine. Storage temperature of 
samples was also found to affect stability, although to a lesser extent than pH. After three days in raw 
(unfiltered) wastewater at temperatures of 2 and 19 ˚C the percentage of compounds reporting a 
significant stability change were 54 and 69 % respectively. A similar increase in stability was also 
observed when storing samples at 2 ˚C for filtered wastewater at pH 7. In contrast, acidified 
wastewater actually presented slightly better stability at a temperature of 19 ˚C, although this 
difference was minimal at 8 % between the two temperatures. The influence of suspended solids in 
the samples was found to decrease concentrations of analytes in the aqueous matrix, with the 
percentage of compounds reporting a concentration change in raw (unfiltered) wastewater at 19 ˚C of 
69 % in comparison to filtered wastewater of 54 %. These findings are of critical importance when 
assessing validity of the usage of composite sampling and indicate the need for re-evaluation of 
current sampling approaches.  
 
3.3.1 Long term storage stability 
 
After the collection of environmental samples it is often necessary for the long term storage of 
samples (a few weeks), perhaps due to instrument issues or analyst time restrictions. The stability of 
several illicit drugs and metabolites in wastewater stored at -20 ˚C was investigated by Chiaia et al. 
[29]. This group reported the stability of compounds for three weeks. However, storage in this way 
can be problematic with a large number of samples due to space restrictions and the time required 
waiting for samples to thaw. González-Marino et al. [26] investigated the storage of compounds 
stored at -20 ˚C, after their extraction onto Oasis HLB cartridges, and found no stability issues. 
 
In this study, spiked wastewater influent was extracted on to Oasis MCX cartridges, washed with 2 % 
HCOOH/H2O, blow dried, and stored at -20 ˚C, with the exception of two cartridges which were 
eluted immediately and served as time point 0. Results are presented in Figure S1 as a normalised 
percentage against time point 0. Within the six weeks evaluated no degradation of compounds was 
experienced, therefore this method of storage is ideal for the multi-class compounds studied and may 
be a more suitable method than freezing large volumes of aqueous samples. 
4 CONCLUSION 
 
In conclusion, for the first time a comprehensive stability study of >60 drugs of abuse has been 
presented over a period of three days in an environmental matrix.  The data shows that from the 
perspective of stability, composite samplers are unsuitable with regards to some compounds. For 
instance heroin and 6-acetylmorphine reported a decrease in stability of 66 and 26 % respectively 
after only 12 hours in raw (unfiltered) wastewater at 2 °C. Acidification of samples was found to 
improve stability for the majority of compounds. One possible way to improve stability would be 
through the addition of a small volume of acid over regular intervals during a 24 hr composite sample 
collection. It has to be however remembered here that acidification might influence partitioning of 
certain drugs between aqueous solution and (suspended) solids. If this is the case both aqueous 
solution and solids have to be analysed for the presence of studied compounds. 
 
This manuscript has also presented results for several previously underreported parameters. A 
summary of the range of recoveries from each studied parameter are presented in Table 7.  This table, 
through colour coordination, clearly demonstrates the most critical factors that affect recovery are 
stability, silanisation of glassware, and the solvent and temperature used during the evaporation of 
SPE extracts. Silanisation of glassware used during the evaporation of SPE extracts was found to 
significantly improve recoveries of some compounds, especially amphetamine type compounds. The 
elution solvent was found to affect recoveries, for instance in the case of heroin which achieved a 
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lower recovery when dried in basic methanol as opposed to methanol. The evaporation temperature 
caused the loss of some compounds, and for the majority of compounds should be no higher than 40 
°C. To summarise, the findings of the above presented research clearly indicate the need for more 
rigorous reporting of method validation data (including sample collection, preservation and 
preparation) as these often underreported parameters might have major impact on the overall method 
performance. 
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SUPPLEMENTARY MATERIAL 
Supplementary material includes:  
Figure S1. Stability of analytes on Oasis MCX cartridges, extracted from the spiked WWTP 
influent, and stored at -20 ˚C over a 6 week period (n = 2 at each time-point) 
Figure S2. SPE sorbent evaluation, total recovery of Oasis HLB and MCX for all compounds 
from UHQ water (n = 3)    
Table S1. Selected pharmaceuticals and their properties 
Table S2. Absolute recovery of analytes in basic methanol after the evaporation of solvent 
Table S3. Absolute recovery of analytes in methanol after the evaporation of solvent 
Table S4. Stability study - concentration of compounds in control wastewater sample at time-
point zero  
Table S5. Filter membrane investigation (recoveries < 90 % highlighted) 
Table S6. Recovery of analytes after filtration through glass fibre filters 
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FIGURES 
Figure 1 – Recovery (n = 3) of selected compounds after evaporation temperatures 20, 30, 40, 50 and 60 °C 
from a) 7% NH4OH in methanol and b) methanol 
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Table 1 – Sample preparation and analysis reported for the determination of drugs of abuse and related compounds in the environment 
 
Analyte
s 
Sampl
e 
collecti
on 
Storage 
and 
prepara
tion 
Extraction Sample 
volume; 
enrichme
nt factor 
SPE 
extract 
evapor
ation 
and 
reconst
itution 
Absolute recovery 
(%) 
Pre 
LC-
MS 
filter 
Separ
ation-
ionisa
tion-
detec
tion 
(acqui
sition 
mode
) 
Method: MDL, MQL 
(ng L-1) 
Observations Ref. 
2 x ALC, 
1 x 
antidep
ressant 
POCIS 
– 28 to 
30 
days 
deploy
ment 
Not 
reporte
d 
Polar 
organic 
chemical 
integrative 
sampler 
(POCIS) 
Not 
reported 
Extract 
concent
rated 
(proced
ure not 
reporte
d) 
Not reported None 
repor
ted 
RP-
HPLC-
ESI(+)-
ITMS 
(Full 
scan 
and 
SIM)                                                         
Water: (IDLf) MAMP, 
0.19; MDMA, 0.25; 
FLU, 20 
• First paper 
reporting 
analytical 
method for the 
detection of 
illicit drugs                                                                         
• Full scan 
results 
confirmed with 
CID 
• Silanisation of 
glassware not 
reported 
Jones-
Lepp 
et al. 
[30] 
5 x 
cocainic
s, 5 x 
ALC, 5 x 
opiates, 
1 x 
cannabi
noid 
24 h 
compo
site 
sample
s - 
collect
ed 
every 
20 min 
Sample
s stored 
at 4 ˚C 
and 
extracte
d within 
3 days. 
Sample
s 
filtered 
through 
1.6  µm 
glass 
microfi
ber 
filters 
SPE - Oasis 
MCX 60 mg                                                            
Condition: 
6 mL 
MeOH, 3 
mL H2O, 3 
mL H2O 
(pH 2)                                                                                                                                 
Wash: 
None                                                                                                            
Elution: 3 
mL MeOH, 
3 mL 
MeOH:2 % 
NH3 
WWinf: 
50 mL 
(pH 2); 
250 x 
Extract 
evapor
ated 
(tempe
rature 
not 
reporte
d). 
Reconst
ituted
in 200 
µL H2O. 
WWinfc: COC, 96±5; 
BE, 107±9; COE, 
109±4; nor-COC, 
112±7; nor-BE, 85±5; 
AMP, 110±5; MAMP, 
112±7; MDA, 102±3; 
MDMA, 104±2; 
MDEA, 107±4; MOR,
88±7; M3G, 90±11; 
6ACM, 106±5; MET,
112±7; EDDP, 88±3; 
THC-COOH, 51±1 
Sampl
es 
centri
fuged 
RP-
HPLC-
ESI(+/
-)-
QqQ 
(2 
SRM) 
WWinf: (MQL) COC, 
1.4; BE, 1.98; COE, 
0.95; nor-COC, 1.92; 
nor-BE, 0.94; AMP, 
5.4; MAMP, 3.7; 
MDA, 8.7; MDMA, 
6.3; MDEA, 4.19; 
MOR, 3.95; M3G, 
0.63; 6ACM, 5.3; MET, 
1.14; EDDP, 1.64; 
THC-COOH, 1.75 
• The first 
'comprehensive
' analytical 
method for 
drugs of abuse 
in the 
environment                                                                            
• Stability 
studies                                               
• Internal 
standard 
quantification 
(15 deuterated 
standards) 
• Silanisation of 
glassware not 
reported 
Castig
lioni 
et al. 
[24] 
WWeff: 
50 mL 
(pH 2);                                            
250 x 
WWeffc: COC, 94±4; 
BE, 107±2; COE, 
98±2; nor-COC, 
119±2; nor-BE, 
104±3; AMP, 103±4; 
MAMP, 97±3; MDA, 
98±3; MDMA, 97±3; 
MDEA, 89±3; MOR, 
75±3; M3G, 67±0; 
6ACM, 93±8; MET, 
90±2; EDDP, 85±4; 
THC-COOH, 61±4 
WWeff: (MQL) COC, 
0.99; BE, 0.92; COE, 
0.66; nor-COC, 0.67; 
nor-BE, 0.56; AMP, 
2.8; MAMP, 1.11; 
MDA, 2.6; MDMA, 
1.74; MDEA, 1.64; 
MOR, 3.2; M3G, 0.48; 
6ACM, 3.08; MET, 
0.97; EDDP, 0.6; THC-
COOH, 0.94 
1 x 
cocainic
s, 6 x 
opiates, 
4 x 
benzodi
azepine
s (+9 
Grab 
sample
s 
Sample
s stored 
at 4 °C 
and 
extracte
d within 
1 day. 
Sample
SPE - Oasis 
HLB 200 
mg                                                                                                    
Condition: 
2 mL n-
heptane, 2 
mL 
acetone, 3 
WWinf: 
100 mL;                                            
200 x
Extracts 
evapor
ated to
approx. 
50 µL 
and 
made 
up to 
WWinfa: BE, 40±5; 
COD, 48±2; DICOD, 
36±1; MET, 44±2; 
MOR, 29±1; OXYC, 
50±5; TRAM, 20±1; 
DIAZ, 18±1; nor-DIAZ, 
18±3; OXAZ, 42±5; 
TEM, 19±7 
None 
repor
ted 
RP-
HPLC-
ESI(+)-
QqQ 
(2 
SRM) 
WWinf: (MQL) BE, 10; 
COD, 20; DICOD, 20; 
MET, 50; MOR, 10; 
OXYC, 20; TRAM, 20; 
DIAZ, 10; nor-DIAZ, 
n.r; OXAZ, 20; TEM, 
10 
• Matrix effects 
evaluated: 
WWinfe: 28 - 90 
%; WWeffe: 10 - 
45 % ; RWe: 3 - 
20 %                                                  
• Internal 
standard 
Hum
mel et 
al. 
[31] 
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addition
al 
compou
nds) 
s 
filtered 
through 
< 1 µm 
glass 
fibre 
filters  
x 3 mL 
MeOH, 4 x 
2 mL water 
(pH 7)                                                                                  
Wash: 
None                                                                         
Elution: 4 x 
2 mL 
acetone 
WWeff: 
200 mL;                                                           
400 x 
approx. 
500 µL 
H2O:10 
%
MeOH 
WWeffa: BE, 42±2; 
COD, 64±6; DICOD, 
70±5; MET, 77±2; 
MOR, 43±8; OXYC, 
69±10; TRAM, 49±15; 
DIAZ, 61±2; nor-DIAZ, 
69±2; OXAZ, 61±7; 
TEM, 57±4 
WWeff: BE, 5; COD, 
10; DICOD, 10; MET, 
25; MOR, 5; OXYC, 10; 
TRAM, 10; DIAZ, 5; 
nor-DIAZ, n.r,; OXAZ, 
10; TEM, 5 
quantification 
(8 deuterated 
standards) 
• Silanisation of 
glassware not 
reported 
RW: 1000 
mL;                                              
2000 x 
RWa: BE, 70±5; COD, 
76±5; DICOD, 92±5; 
MET, 83±7; MOR, 
86±8; OXYC, 86±6; 
TRAM, 74±9; DIAZ, 
84±5; nor-DIAZ, 93±3; 
OXAZ, 93±9; TEM, 
78±4  
RW: BE, 1; COD, 2; 
DICOD, 2; MET, 5; 
MOR, 1; OXYC, 2; 
TRAM, 2; DIAZ, 1; nor-
DIAZ, n.r.; OXAZ, 2; 
TEM, 1 
GW: 
1000 mL;                                             
2000 x 
GWa: 71 - 123 %,    
DW: 
1000 mL;                                                    
2000 x 
DWa: 25 - 102 %,    
2 x 
cocainic
s, 5 x 
ALC, 2 x 
dissocia
tive 
anesthe
tics, 1 x 
lysergic, 
1 x 
opiate, 
4 x 
urine 
indicato
rs,  
24 h 
compo
site 
sample
s at 
WWTP
; grab 
sample
s from 
RW 
Sample
s stored 
at 4 °C 
and 
extracte
d within 
1 day. 
Sample
s 
filtered 
through 
1.6 µm 
glass 
microfi
ber 
filters 
SPE - Oasis 
HLB 200 
mg                                                                                       
Condition: 
10 mL 
MeOH, 10 
mL H2O                                                                                   
Wash: 8 
mL H2O:5 
% MeOH                                                                        
Elution: 6 
mL MeOH 
WWinf: 
100 mL;                                        
200 x
Extract 
evapor
ated at
35 °C. 
Reconst
ituted 
in 500 
µL 
H2O:5 
% 
MeOH 
WWinfb: COC, 86±6; 
BE, 92±6; AMP, 70±7; 
MAMP, 80±4; MDA, 
74±5; MDEA, 101±5; 
MDMA, 88±6; LSD, 
75±5; KET, 85±5; PCP, 
85±4; FENT, 80±4; 
CAFF, 83±6; PARAX, 
71±6; NIC, 80±5; COT, 
78±6
  
0.2 
µm 
filterg 
RP-
UPLC-
ESI(+)-
QqQ 
(2 
SRM) 
WWinf: (MQL) COC, 
0.2; BE, 0.2; AMP, 1; 
MAMP, 0.9; MDA, 
1.0; MDEA, 2.1; 
MDMA, 1.5; LSD, 2.0; 
KET, 5.0; PCP, 2.0; 
FENT, 4.0; CAFF, 5.0; 
PARAX, 850; NIC, 800; 
COT, 500 
• Stability of 
extracts 
investigated; 
Compounds 
stable in 
methanol 
extract at -20 
°C and 4 °C 
(except 
paraxanthine) 
for 7 days.                                                                                                        
• Internal 
standard 
quantification 
(13 deuterated 
standards and 
13C-Caffeine) 
• Silanisation of 
glassware not 
reported 
Huert
a-
Fontel
a et 
al. 
[19] 
WWeff: 
100 mL;                                               
200 x 
RW: 100 
mL;                                                 
200 x 
RWb: COC, 90±4; BE, 
95±4; AMP, 75±4; 
MAMP, 83±2; MDA, 
75±4; MDEA, 99±3; 
MDMA, 90±5; LSD, 
7±4; KET, 85±5; PCP, 
88±2; FENT, 82±3; 
CAFF, 85±5; PARAX, 
80±5; NIC, 82±3; COT, 
81±4  
RW: (MQL) COC, 0.12; 
BE, 0.12; AMP, 0.45; 
MAMP, 0.41; MDA, 
0.43; MDEA, 0.43; 
MDMA, 0.52; LSD, 
0.71; KET, 0.47; PCP, 
0.54; FENT, 0.98; 
CAFF, 0.96; PARAX, 
72.2; NIC, 103.0; COT, 
83.9  
9 x 
opiates, 
2 x 
cannabi
noids 
24 h 
compo
site 
sample
s 
Sample
s stored 
at 4 °C 
and 
extracte
d within 
3 days. 
Sample
s 
filtered 
through 
1.6 µm 
glass 
microfi
SPE - Oasis 
HLB 200 
mg                                         
Condition: 
5 mL 
MeOH, 5 
mL H2O                                                                   
Wash: 3 
mL H2O                                                                                            
Elution: 8 
mL MeOH 
WWinf: 
200 mL;                                                                           
400 x
Extracts 
evapor
ated at 
40 °C to 
500 µL. 
One 
aliquot
(250 
µL)
remove
d (for 
cannabi
noids). 
The 
WWinfc: HER, 65; 
6ACM, 90; MOR, 83;
nor-MOR, 95; COD, 
94; nor-COD, 89; 
MET, 75; EDDP, 68; 
FENT, 72; THC, 42; 
THC-COOH, 96 
0.2 
µm 
GHP 
filter 
RP-
UPLC-
ESI(+)-
QqQ 
(2 
SRM) 
WWinf: (MQL) HER, 
20.0; 6ACM, 3.1; 
MOR, 7.1; nor-MOR, 
25.0; COD, 2.5; nor-
COD, 5.0; MET, 0.3; 
EDDP, 0.7; FENT, 1.7; 
THC, 8.3; THC-COOH, 
12.5  
• Cannabinoids 
injected in a 
separate 
methanol 
fraction to 
ensure 
resolution and 
sensitivity                                           
• Internal 
standard 
quantification 
(9 deuterated 
standards) 
• Silanisation of 
Boled
a et 
al. 
[32] 
WWeff: 
200 mL;                                                                       
400 x 
WWeffc: HER, 75; 
6ACM, 95; MOR, 99;
nor-MOR, 86; COD, 
85; nor-COD, 94; 
MET, 97; EDDP, 69; 
FENT, 95; THC, 44; 
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ber 
filters 
second 
aliquot 
(250 
µL) 
evapor
ated to 
dryness 
and 
reconst
ituted 
in H2O 
(volum
e not 
specifie
d).  
THC-COOH, 86 glassware not 
reported 
 
RW: 200 
mL;                                 
400 x 
  RW: (MQL) HER, 1.5; 
6ACM, 0.9; MOR, 2.9; 
nor-MOR, 12.5; COD, 
0.5; nor-COD, 1.6; 
MET, 0.1; EDDP, 0.4; 
FENT, 0.4; THC, 7.0; 
THC-COOH,  10.0 
3 x 
cocainic
s, 1 x 
ALC, 3 x 
opiates, 
1 x 
lysergic, 
1 x 
antidep
ressant 
2 x 
benzodi
azepine
s 
24 h 
compo
site 
sample
s at 
WWTP
;                               
Grab 
sample
s from 
RW 
Sample
s 
extracte
d within 
1 day. 
Sample
s
filtered 
through 
1.2 µm 
glass 
microfi
ber 
filters 
SPE - 
Strata-XC 
200 mg                                                                                           
Condition: 
2 x 6 mL 
MeOH, 2 x 
6 mL H2O                                                                                   
Wash: 50 
mL H2O:10 
% MeOH, 
100mM 
HCOOH                                                            
Elution: 10 
mL 5 % 
(v/v) 
NH4OH in 
1:1 
acetone:et
hyl acetate 
WWinf: 
500 mL 
(pH 6.0);
2500 x 
Extract 
reduce
d in
volume 
with 
heating
. 
(tempe
rature 
not 
reporte
d)
Reconst
ituted 
in 200 
µL 
H2O:30 
% 
MeOH 
(v/v), 5 
mM 
CH3CO
ONH4 
(pH 4.5) 
RWa: COC, 56±2; BE, 
53±3; COE, 65±3; 
MDMA, 52±1; MOR, 
4±0; MET, 55±0; 
EDDP, 59±2; LSD, 
51±3; KET, 51±3; FLU, 
33±2; TEM, 59±3; 
DIA, 55±3 
None 
repor
ted 
RP-
HPLC-
ESI(+)-
ITMS 
(1 
SRM) 
RW: (MQL) COC, 2; 
BE, 2; COE, 5; MDMA, 
22; MOR, 856; MET, 
14; EDDP, 7; LSD, 10; 
KET, 4; FLU, 312; 
TEM, 23; DIA, 127                                                       
(MDL) COC, 1; BE, 1; 
COE, 1; MDMA, 7; 
MOR, 257; MET, 4; 
EDDP, 2; LSD, 3; KET, 
1; FLU, 93; TEM, 7; 
DIA, 38                    
• Cocaine 
stability 
investigated                                          
• Internal 
standard 
quantification 
(1 internal 
standard; 
papaverine) 
• Silanised 
glassware 
Bones 
et al. 
[10] 
WWeff: 
500 mL 
(pH 6.0);
2500 x 
RW: 500 
mL (pH 
6.0);                                  
2500 x
3 x 
cocainic
s, 4 x 
ALC, 3 x 
lysergic
s, 3 x 
opiates, 
3 x 
cannabi
noids 
24 h 
compo
site 
sample
s 
Sample
s 
filtered 
through 
1 µm 
glass 
microfi
ber 
filters 
and 
0.45 µm 
nylon 
filters. 
Sample
s then 
stored 
at - 20 
°C 
SPE - PLRPs 
and Oasis 
HLB (for 
cannabinoi
ds)                                               
Condition: 
1 mL AcN                                                                                   
Wash: 1 
mL H2O                                                                        
Elution: LC 
mobile 
phase  
WWinf: 5 
mL 
N/A - 
online 
SPE 
WWinfa: COC, 59; BE, 
8; COE, 52; AMP, 15; 
MAMP, 20; MDMA, 
27; EPH, 15; LSD, 17; 
nor-LSD, 22; O-H-LSD, 
11; MOR, 14; HER, 
22; 6ACM, 21; THC, 9; 
nor-THC, 13; OH-THC, 
37
None 
repor
ted 
RP-
HPLC-
ESI(+/
-)-
QLIT 
(2 
SRM) 
WWinf: (MQL) COC, 
2.40; BE, 5.24; COE, 
0.69; AMP, 0.92; 
MAMP, 0.75; MDMA, 
2.93; EPH, 2.21; LSD, 
0.89; nor-LSD, 1.81; 
O-H-LSD, 2.60; MOR, 
5.97; HER, 2.07; 
6ACM, 5.17; THC, 
3.37; nor-THC, 1.13; 
OH-THC, 1.45                                                                                
(MDL) COC, 0.18; BE, 
0.67; COE, 0.07; AMP, 
0.34; MAMP, 0.28; 
MDMA, 1.10; EPH, 
0.78; LSD, 0.27; nor-
LSD, 0.68; O-H-LSD, 
0.97; MOR, 1.51; HER, 
0.78; 6ACM, 1.94; 
• On-line SPE                                                     
• M6G and 
M3G not 
effectively 
extracted by 
any of the 
tested 
cartridges                                                                
• Matrix effects 
evaluated: 
WWinfe: 45 - 95
%                                                  
• Relative 
recovery: 
WWinf: 71 - 
745 %                                                                     
• Internal 
standard 
quantification 
Postig
o et 
al. 
[33] 
WWeff: 5 
mL 
RW: 5 mL
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THC, 1.26; nor-THC, 
0.43; OH-THC, 0.54   
(12 deuterated 
standards) 
3 x 
cocainic
s 
24 h 
compo
site 
sample
s at 
WWTP
;                                
Grab 
sample
s from 
RW 
Sample
s 
adjuste
d to pH 
2 and 
stored 
at -20
˚C. 
Sample
s 
filtered 
though 
qualitati
ve filter 
paper 
followe
d by 
glass 
microfi
ber 
filter 
SPE - Oasis 
HLB 500 
mg                                                                          
Condition: 
3 mL 
MeOH, 3 
mL H2O                                                                
Wash: 3 
mL H2O:5 
% MeOH                                                                 
Elution: 2 x 
4 mL 
MeOH 
WWinf: 
100 mL 
(pH 6);                          
667 x 
Extract 
evapor
ated
(tempe
rature 
not 
reporte
d). 
Reconst
ituted
in 150 
µL 
MeOH:
LC 
mobile 
phase A 
(1:1, 
v/v) for 
RPLC 
and in 
150 µL 
AcN/M
eOH 
(3:1, 
v/v) for 
HILIC 
TWa: COC, 96±6; BE, 
92±2; EME, 73±5 
Sampl
es 
centri
fuged 
RP-
HPLC-
ESI(+)-
ITMS 
(1 
SRM) 
WWinf: (MQL) RP-
HPLC, COC, 4; BE, 2                                                   
HILIC-HPLC, COC, 0.5; 
BE, 1; EME, 20                                                                            
• Stability 
studies for COC
and BE                                                                            
• First
methodology 
employing 
HILIC                                                               
• Matrix effects 
evaluated: Win, 
< 10 %; RW, < 
10 %                                                    
• Internal 
standard 
quantification 
(3 deuterated 
standards) 
• Silanisation of 
glassware not 
reported 
 
Gheor
ge et 
al.
[25]
RW: 500 
mL (pH 
6);                                
3333 x 
 
  
4 x 
cocainic
s, 7 x 
ALC, 3 x 
opiates, 
3 x 
dissocia
tive 
anesthe
tics, 2 x 
Lysergic
s, 1 x 
benzodi
azepine, 
3 x 
urine 
indicato
rs 
24 h 
compo
site 
sample
s - flow 
normal
ised 4 
°C 
Sample
s stored 
at - 20 
°C and 
analyse
d within 
3 
weeks. 
N/A - large 
volume 
direct 
injection 
WWinf: 7 
mL 
N/A - 
large 
volume 
direct 
injectio
n 
N/A - large volume 
direct injection 
Sampl
es 
centri
fuged 
RP-
HPLC-
ESI(+)-
QqQ 
(1 or 2 
SRM) 
Water: (MQL) AMP, 
10.0; MAMP, 10.0; 
MDMA, 2.5; MDA, 
2.5; MDEA, 5.0; 
MBDB, 5.0; EPH, 10.0; 
COC, 2.5; BE, 10.0; 
nor-COC, 2.5; nor-BE, 
5.0; HYDC, 2.5; OXYC, 
2.5; MET, 2.5; KET, 
5.0; nor-KET, 5.0; 2-
OXO-LSD, 5.0; LSD, 
2.5; PCP, 5.0; FLUN, 
2.5; COT, 250; CAFF, 
250; CREA, 50000                                                                 
(MDL) AMP, 1.5; 
MAMP, 1.5; MDMA, 
1.0; MDA, 2.0; MDEA, 
3.5; MBDB, 4.0; EPH, 
2.5; COC, 2.0; BE, 1.0; 
nor-COC, 2.0; nor-BE, 
2.5; HYDC, 2.0; OXYC, 
2.0; MET, 2.0; KET, 
4.0; nor-KET, 3.5; 2-
• Creatinine 
used to 
estimate local  
population                                                   
• Large volume 
direct injection                                      
• Stability study                                        
• No loss of 
compound 
after 
centrifugation 
(95 % CI)                                                              
• Internal 
standard
quantification 
(16 deuterated 
standards) 
Chiaia 
et al. 
[29] 
19 
 
OXO-LSD, 2.5; LSD, 
0.5; PCP, 2.5; FLUN, 
1.5; COT, 4.5; CAFF, 
6.0; CREA, 250 
2 x 
cocainic
s, 1 x 
ALC, 2 x 
opiates, 
1 x 
antidep
ressant 
(plus 
addition
al 
PPCPs)  
Grab 
sample
s 
Sample
s 
adjuste
d to pH 
2 and 
stored 
at  4 °C. 
Sample
s 
filtered 
through 
2.7 µm 
and 0.7 
µm 
GF/F 
glass 
microfi
ber 
filters 
SPE - Oasis 
MCX 60 mg                                                  
Condition: 
2 mL 
MeOH, 2 
mL H2O:2 
% HCOOH                                            
Wash: 2 
mL H2O:2 
% HCOOH                                   
Elution: 2 
mL MeOH, 
2 mL 
MeOH:5 % 
NH4OH 
WWinf: 
250 mL 
(pH 2); 
500 x 
Extracts 
evapor
ated at 
40 °C. 
Reconst
ituted 
in 500 
µL LC 
mobile 
phase A 
WWinfa: COC, 43-47; 
BE, 61-69; AMP, 73-
105, COD, 51-51; 
TRAM, 101-145; 
AMIT, 2-4 
0.2 
µm 
PTFE 
filter 
RP-
UPLC-
ESI(+)-
QqQ 
(2 
SRM) 
WWinf: (MQL) COC, 
1; BE, 1; AMP, 3; COD, 
2; TRAM, 10; AMIT, 
32 
• Multi-residie 
analysis of a 
wide range of 
PPCPs                                       
• Internal 
standard 
quantification 
(1 internal 
standard; 
phenacetin-
ethoxy-1-13C) 
• Silanised 
glassware 
Kaspr
zyk-
Horde
rn et
al. 
[34] WWeff: 
250 mL
(pH 2);                  
500 x 
WWeffa: COC, 49 - 50 
%; BE, 70-98; AMP, 
72-109, COD, 64-86, 
TRAM, 98-144, AMIT, 
1-2 
WWeff: (MQL) COC, 
1; BE,1; AMP, 3; COD, 
2; TRAM, 10; AMIT, 2 
RW: 1000 
mL (pH 
2);                                        
2000 x 
RW: COC, 70; BE, 
131; AMP, 91; COD, 
75; TRAM, 76, AMIT, 
37 
RW: (MQL) COC, 0.2; 
BE, 0.1; AMP, 1; COD, 
0.3; TRAM, 3; AMIT, 
0.3 
5 x 
cocainic
s, 5 x 
ALC, 1 x 
cannabi
noid 
24 h 
compo
site 
sample
s 
Sample
s stored 
at - 20 
°C. 
Sample
s 
centrifu
ged 
SPE - Oasis 
MCX 
150mg                                               
Condition: 
6 mL 
MeOH, 3 
mL H2O, 3 
mL H2O 
(pH 2)                                                                                                                   
Wash: 5 
mL H2O:2 
% NH4                                                                         
Elution: 8 
mL 
MeOH:2 % 
NH4 
WWinf: 
50 mL (5 
x diluted) 
(pH 2);                                 
50 x 
Extract 
evapor
ated at 
35 °C.
Reconst
ituted 
in 1000 
µL 
H2O:10 
% 
MeOH 
RWa, e: COC, 92; BE, 
90; COE, 88; nor-BE, 
90; nor-COC, 82; 
AMP, 65; MAMP, 65; 
MDMA, 95; MDA, 90; 
MDEA, 88; THC-
COOH, 68                                  
None 
repor
ted 
RP-
UPLC-
ESI(+)-
QqQ 
(3 
SRM) 
WWinf: (MDL) COC, 3; 
BE, n.e.; COE, 2; nor-
BE, 1; nor-COC, 5; 
AMP, 54; MAMP, 7; 
MDMA, 18; MDA, 91; 
MDEA, 40; THC-
COOH, 2500 
• Matrix effects 
evaluated: RWe, 
-30 - 50 %                                                                  
• Relative 
recovery: 
WWinf: 57 - 
120 %; WWeff: 
63 - 118 %; RW: 
61 - 120 %                                                              
• Internal 
standard 
quantification 
(9 deuterated 
standards) 
• Silanisation of 
glassware not 
reported 
 
Bijlsm
a et 
al.
[35] 
WWeff: 
50 mL 
(pH 2):                               
50 x 
WWeff: (MDL) COC, 
2; BE, 0.3; COE, 1; 
nor-BE, 0.2; nor-COC, 
2; AMP, 40; MAMP, 1; 
MDMA, 9; MDA, 88; 
MDEA, 9; THC-COOH, 
500 
RW: 50 
mL (pH 
2);                          
50 x 
RW: (MDL) COC, 0.8; 
BE, 0.05; COE, 0.3; 
nor-BE, 2; nor-COC, 2; 
AMP, 2; MAMP, 0.6; 
MDMA, 4; MDA, 17; 
MDEA, 0.5; THC-
COOH, 30  
non-
target 
analysis 
(full 
scan 
screeni
ng 
Not 
report
ed 
Not 
reporte
d 
SPE - Oasis 
MCX 500 
mg                                                                                   
Condition: 
AcN, 
MeOH, 
H2O (pH 2) 
(volumes 
not 
reported)                                                                                                    
Wash: H2O 
(volumes 
not 
WWeff: 
1000 mL 
(pH 2);                               
2000 x 
Extract 
evapor
ated at
45 °C to 
250 µL. 
250 µL 
of H2O 
added 
to 
make a
final 
volume 
of 500 
Not reported None 
repor
ted 
RP-
HPLC-
ESI(+/
-)-
QqQ 
(Full 
scan 
and 
MSn) 
Illicits not quantified • Non target 
analysis                                                 
• Illicits not 
quantified 
• Silanisation of 
glassware not 
reported 
 
Hoge
nboo
m et 
al. [9] 
SW: 1000 
mL (pH 
2);                               
2000 x 
DW: 
1000 mL
(pH 2);                                            
2000 x 
20 
 
reported)                                                             
Elution: 2.5 
mL AcN, 2 
x 2.5 mL 
H2O:5 % 
NH4OH 
µL
3 x 
cocainic
s, 3 x 
ALC, 3 x 
opiates 
24 h 
compo
site 
sample
s - 
volum
e 
propor
tional 
Sample
s 
adjuste
d to pH 
2 at 
collecti
on site 
and 
stored 
at -20 
°C. 
Sample
s 
filtered 
through 
glass 
microfi
ber 
filters 
SPE - Oasis 
MCX 60 mg                                                            
Condition: 
6 mL 
MeOH, 4 
mL H2O, 4 
mL H2O 
(pH 2)                                                                                                                  
Wash: 3 
mL H2O                                                                     
Elution: 4 
mL MeOH, 
4 mL 
MeOH:5% 
NH3 
WWinf: 
50 mL;                                      
250 x 
Extract 
evapor
ated 
(tempe
rature 
not 
reporte
d).
Reconst
ituted 
in 100 
µL AcN 
and 100 
µL 
AcN:H2
O 
(90:10, 
v/v), 5 
mM 
CH3CO
ONH4                                              
SWb: COC, 102±6; BE, 
87±3; EME, 35±3; 
AMP, 102±6; MAMP, 
99±4; MDMA, 100±4; 
MET, 103±3; EDDP, 
61±8; 6ACM, 92±4 
Sampl
e 
centri
fuged 
HILIC-
HPLC-
ESI(+)-
QqQ 
(2 
SRM) 
SW: (MQL) COC, 1; 
BE, 1; EME, 2; AMP, 2; 
MAMP, 1; MDMA, 1; 
MET, 1; EDDP, 1; 
6ACM, 2 
  
• HILIC                                                                         
• Comparison 
of MCX and 
HLB                                                                     
• Matrix effects 
evaluated: SW, 
12 - 51 %                                                                     
• Internal 
standard 
quantification 
(9 deuterated 
standards) 
• Silanisation of 
glassware not 
reported 
 
Van
Nuijs 
et al. 
[20] 
  SW: 50
mL;                                               
250 x 
5 x ALC Grab 
sample
s 
Sample
s stored 
at 4 °C 
until 
analysis
. 
Sample
s 
filtered 
through 
glass 
fiber 
prefilter
s and 
0.45 µm 
nitrocell
ulose 
filters 
SPE - 
SupelMIP - 
Amphetam
ine 25 mg                                                     
Condition: 
1 mL 
MeOH, 1 
mL H2O 
(pH 8)                                                         
Wash: 2 x 
1 mL H2O 
(pH 8), 1 
mL H2O:40 
% AcN                                                                          
Elution: 2 x 
1 mL 
MeOH:1 % 
HCOOH 
WWinf: 
50 mL;                                                         
500 x 
Extract 
evapor
ated 
(tempe
rature 
not 
reporte
d). 
Reconst
ituted 
in 100 
µL 2% 
NH3 in 
MeOH:
H2O 
(1:1) 
Wwinfb, e: AMP, 90; 
MAMP, 75; MDA, 
102; MDMA, 98; 
MDEA, 83                                          
None 
repor
ted 
RP-
HPLC-
ESI(+)-
QqQ 
(2 
SRM) 
WWinf: (MDL) AMP, 
2.7; MAMP, 0.8; 
MDA, 2.2; MDMA, 
2.3; MDEA, 0.5        
• 
Comprehensive 
evaluation of 
MIPs, MCX and 
HLB                                  
• Matrix effects 
evaluated: 
WWinf: 30 - 55 
%; WWeff: 10 - 
45 %                                                                                                  
• Relative 
recoveries: 
WWinf, 92 - 
111 %; WWeff, 
92 - 114 %                                                                                    
• Internal 
standard 
quantification 
(5 deuterated 
standards)  
• Silanisation of 
glassware not 
reported 
 
Gonzá
lez-
Marin
o et 
al. 
[21] 
WWeff: 
50 mL;                                          
500 x 
WWeffb, e: AMP, 75; 
MAMP, 85; MDA, 75; 
MDMA, 87; MDEA, 
75                                         
 
3 x 
cocainic
s, 5 x 
ALC, 2 x 
cannabi
noids, 4 
x 
Grab 
sample
s 
Sample
s 
extracte
d within 
1 day. 
Sample
s 
SPE - Oasis 
HLB 200 
mg                                                                                                       
Condition: 
5mL ethyl 
acetate, 5 
mL 
WWinf: 
100 mL 
(pH8.5);
500 x 
Extract 
(1) 
evapor
ated at 
25 ˚C. 
Extract 
(1) and 
Not reported None 
repor
ted 
GC-EI-
ITMS  
WWinf: (MQL) COC, 
39.6; BE, 26.4; 
COE,19.8; AMP, 23.1; 
MAMP, 23.1; MDMA; 
26.4, MDA, 23.1; 
MDEA, 39.6; HER, 
49.5; MOR, 36.3; 
• Stability 
studies                                            
• Requires 90 
minute 
derivatisation 
step                                                    
• Relative 
Gonzá
lez-
Marin
o et 
al. 
[26]
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opiates filtered 
through 
0.45 µm 
glass 
microfi
bre 
filters 
and 
0.45 µm 
nitrocell
ulose 
filter 
acetone, 5 
mL H2O                                                                                                                             
Wash: 
None                                                                                                                                             
Elution: 2 x 
extracts (1) 
2 mL ethyl 
acetate (2) 
8 mL 
acetone 
(2) 
mixed. 
Sample 
concent
rated to 
100 µL 
and 100 
µL 
MSFA 
(derivat
isation 
agent) 
added 
COD, 19.8; MET, 19.8; 
THC, 9.9; THC-COOH, 
3.3 
recovery: 
WWinf: 63.4 - 
137.2 %; 
WWeff, 85.4 - 
134.2 %; RW, 
73.9 - 124.7 %                                                         
• Internal 
standard 
quantification 
(12 deuterated 
standards) 
• Silanisation of 
glassware not 
reported 
 
WWeff: 
200mL 
(pH 8.5);                                   
1000 x 
Wweff: (MQL) COC, 
9.9; BE, 13.2; COE, 
19.8; AMP, 9.9; 
MAMP, 23.1; MDMA, 
19.8;MDA, 16.5; 
MDEA, 36.3; HER, 
49.5; MOR, 36.3; 
COD, 13.2; MET, 19.8; 
THC, 9.9; THC-COOH, 
3.3  
RW: 500 
mL (pH 
8.5);                                    
2500 x  
RW: (MQL) COC, 3.3; 
BE, 13.2; COE, 9.9; 
AMP, 2.6; MAMP, 6.6; 
MDMA, 6.6; MDA, 
6.6; MDEA, 6.6; HER, 
42.9; MOR, 9.9; COD, 
3.3; MET, 6.6; THC, 
3.0; THC-COOH, 3.3  
12 x 
cocainic
s, 5 x 
ALC, 4 x 
opiates, 
2 x 
urine 
markers
, 
24 h 
compo
site 
sample
s 
Sample 
filtered 
through 
1.2 µm 
glass 
microfi
ber 
filters. 
Sample 
split 
into 
two 
fraction
s. 
Fraction 
1 - (1.2 
L) 
Adjuste
d to pH 
2. 
Fraction 
2 - (100 
mL) 
Adjuste
d to 
0.07 % 
formic 
acid 
(v/v). 
Sample
s stored 
at -20 
˚C and 
analyse
d within 
2 days 
SPE - Strata 
XC 500 mg                                                                                              
Condition: 
10 mL 
MeOH, 10 
mL H2O 
(pH 2)                                                         
Wash: 10 
mL H2O 
(pH 2), 10 
mL H2O:2 
% HCOOH, 
10 mL 
H2O:5 % 
MeOH                                                                                                    
Elution: 10 
mL 
MeOH:2 % 
NH4OH          
WWinf: 
200 mL
(pH 2);                                         
133 x 
Extract 
evapor
ated at 
35 ˚C to 
500 µL. 
Diluted 
with
1000 µL 
of 0.1 % 
HCOOH
:H2O 
Watere: COC, 100; BE, 
85; nor-BE, 70; COE,
103; nor-COC, 99; 
EME, 67; ECG, 19; 
EEE, 35;  AEME, 68; 
AEC, 115; AMP, 63; 
MAMP, 80; MDMA, 
60; MDEA, 55; MBDB, 
62; MOR, 65; 6ACM, 
100; OXY, 65; 
HYD,63; CREA, 50; 
COT, 65; pHYBE, 72; 
mOHBE, 80 
None 
repor
ted 
RP-
HPLC-
ESI(+)-
QqQ 
(1 
SRM) 
WWinf: Direct 
injection: (MDL) COC, 
4;BE, 33; nor-BE, 35; 
COE, 4; nor-COC, 3; 
EME, 32; ECG, 800; 
EEE, 179;  AEME, 35; 
AEC, 2500; AMP, 37; 
MAMP, 15; MDMA, 
15; MDEA, 4; MBDB, 
4; MOR, 670; 6ACM, 
22; OXY, 10; HYD, 16; 
CREA, 8130; COT, 47; 
pHYBE, 18; mOHBE, 
16                                                                                                                                                                
SPE-LC-MS/MS: (MDL) 
COC, 0.03;BE, 0.29; 
nor-BE, 0.37; COE, 
0.03; nor-COC, 0.02; 
EME, 0.36; ECG, 33; 
EEE, 3.9;  AEME, 0.38; 
AEC, 19; AMP, 0.43; 
MAMP, 0.14; MDMA, 
0.19; MDEA, 0.05; 
MBDB, 0.05; MOR, 
7.7; 6ACM, 0.16; OXY, 
0.11; HYD, 0.19; 
CREA, 120; COT, 0.53; 
pHYBE, 0.18; mOHBE, 
0.15 
• Direct 
injection and 
SPE compared                                                                
• Secondary LC 
method 
employed for 
confirmation                                
• Matrix effects 
evaluated: 
WWinfe: Direct 
inj., -15 - 65 %; 
SPE-LC-MS/MS: 
-5 - 72 %                                        
• Internal 
standard 
quantification 
(19 deuterated 
standards) 
• Silanisation of 
glassware not 
reported 
 
Bisceg
lia et 
al.
[36] 
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7 x ALC, 
1 x 
antidep
ressant 
Grab 
sample
s 
Sample
s 
adjuste
d to 
pH2, 
and 
stored 
at 4 °C, 
extracte
d within 
1 day. 
Sample
s 
filtered 
through 
2.7 µm 
and 0.7 
µm 
glass 
microfi
ber 
filters 
SPE - Oasis 
HLB 60mg                                                                                          
Condition: 
2 mL 
MeOH, 2 
mL H2O 
(pH 7.5)                                                              
Wash: 
None                                                                                                      
Elution: 4 
mL MeOH 
WWinf: 
100 mL
(pH 7.5);                                      
200 x 
Extract 
evapor
ated at
40 °C. 
Reconst
ituted 
in 500
µL of LC 
mobile 
phase A 
WWinfa, d: AMP, 86; 
MAMP, 87; MDMA, 
84; MDA, 76; MDEA, 
90; nor-EPH, 22; EPH, 
81; VENL, 125 
0.2 
µm 
PTFE 
filters 
Chiral-
UPLC-
ESI(+)-
QqQ 
(2 
SRM) 
WWinf: (MQLd) AMP, 
4.4; MAMP, 2.9; 
MDMA, 2.4; MDA, 
9.7; MDEA, 2.2; nor-
EPH, 11.3; EPH, 3.1; 
VENL, 5.0                                                                                                
(MDLd) AMP, 0.9; 
MAMP, 0.9; MDMA, 
0.9; MDA, 2.0; MDEA, 
0.6; nor-EPH, 3.4; 
EPH, 1.3; VENL, 1.6                                        
• First 
methodology 
for the chiral 
analysis of 
drugs of abuse 
in the
environment                                                         
• Matrix effects 
evaluated: Win, 
-43.9 - 56.3                                                                                
• Internal
standard 
quantification 
(5 deuterated 
standards)          
• Glassware 
silanised  
 
Kaspr
zyk-
Horde
rn et 
al. 
[37]
WWeff: 
100 mL 
(pH 7.5);                             
200 x 
WWeffa, d: AMP, 86; 
MAMP, 75; MDMA, 
77; MDA, 74; MDEA, 
84; nor-EPH, 55; EPH, 
90; VENL, 122 
WWeff: (MQLd) AMP, 
4.4; MAMP, 3.4; 
MDMA, 2.6; MDA, 
10.1; MDEA, 2.4; nor-
EPH, 4.6; EPH, 2.8; 
VENL, 5.1                                                                                       
(MDLd) AMP, 0.9; 
MAMP, 1.0; MDMA, 
1.0; MDA, 2.0; MDEA, 
0.6; nor-EPH, 1.4; 
EPH, 1.1; VENL, 1.7  
6 x  
opiates, 
3 x ALC, 
2 x 
cocainic
s, 1 x 
cannabi
noid 
24 h 
compo
site 
sample
s - flow 
depen
dant - 
at 
WWTP
. Grab 
sample
s from 
RW 
Sample
s 
adjuste
d to pH 
2 and 
filtered 
through 
glass 
microfi
bre 
filters. 
Sample
s stored 
at 4 °C 
and 
extracte
d within 
2 days 
N/A - large 
volume 
direct 
injection 
WWinf, 
WWeff, 
RW, LW: 
1 mL (pH 
2) 
(transferr
ed to 
HPLC 
vial)  
N/A - 
large 
volume 
direct 
injectio
n 
N/A - large volume 
direct injection 
None 
repor
ted 
RP-
HPLC-
ESI(+)-
QqQ 
(2 
SRM) 
WWinf: (MQL) COC, 
20; BE, 20; AMP, 20; 
MAMP, 20; MDMA, 
20; MOR, 20; COD, 
20; 6ACM, 20; ACOD, 
20; EDDP, 20; MET, 
20; THC-COOH, 100  
• Large volume 
direct injection                                              
• Internal 
standard 
quantification 
(12 deuterated 
standards)                   
• Silanisation of 
glassware not 
reported 
 
Berse
t et al. 
[38] 
5 x 
opiates, 
4 x ALC, 
3 x 
cocainic
s, 2 x 
cannabi
noids 
Grab 
sample
s 
Sample
s 
filtered 
through 
1.6 µm 
glass 
microfi
ber 
filters. 
Sample
s stored 
at -20 
°C and 
extracte
d within 
7 days.   
SPE - Oasis 
HLB 200 
mg                                                              
Condition: 
5 mL 
MeOH, 5 
mL H2O                                                         
Wash: 10 
mL H2O                                                                                         
Elution: 6 
mL MeOH 
SW: 250 
mL;                                         
250 x
Extract 
evapor
ated at
45 °C. 
Reconst
ituted 
in 1000
µL 
H2O:Me
OH 
(75:25, 
v/v) 
SWa: COC, 121±12; 
BE, 100±9; EME, 
96±10; AMP, 96±10; 
MAMP, 113±11; 
MDMA, 125±8; MDA, 
105±10; MOR, 75±10; 
HER, 100±12; 6ACM, 
85±14; COD, 
113±8;MET, 100±9; 
THC, 60±11; THC-
COOH, 67±13 
0.22 
µm 
PTFE 
filter 
RP-
HPLC-
ESI(+)-
QqQ 
(2 
SRM) 
SW: (MQL) COC, 0.06; 
BE, 0.15; EME, 1.37; 
AMP, 0.40; MAMP, 
0.75; MDMA, 0.35; 
MDA, 1.37; MOR, 
0.13; HER, 0.17; 
6ACM, 0.30; COD, 
0.03; MET, 0.03; THC, 
4.07; THC-COOH, 5.13                                                                   
(MDL) COC, 0.02; BE, 
0.05; EME, 0.41; AMP, 
0.12; MAMP, 0.22; 
MDMA, 0.10; MDA, 
0.41; MOR, 0.04; HER, 
0.05; 6ACM, 0.09; 
COD, 0.01; MET, 0.01; 
THC, 1.22; THC-
• 
Comprehensive 
SPE sorbent, 
sample volume 
and sample pH 
investigation                                            
• Second 
injection 
monitoring
fewer 
transitions to 
record two 
transitions for 
selected 
analytes                                                                       
• Matrix effects 
evaluated: 
Vazqu
ez-
Roig 
et al. 
[8] 
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COOH, 1.54  WWinf: SW, 0 - 
20.2 %                                                                            
• Internal 
standard 
quantification 
(6 deuterated 
standards)                     
• Silanisation of 
glassware not 
reported 
2 x 
cocainic
s, 4 x 
ALC 
24 h 
compo
site 
sample
s 
Sample
s stored 
at 4 °C 
and 
extracte
d within 
2 days. 
Sample
s 
filtered 
through 
1.5 µm 
glass 
microfi
ber 
filters 
SPE - Oasis 
MCX 150 
mg                                                                                
Condition: 
6 mL 
MeOH, 10 
mL H2O 
(pH 3.0)                                            
Wash: 3 
mL H2O:5 
% MeOH                                             
Elution: 2 x 
3 mL 
MeOH:5 % 
NH4OH                          
WWinf: 
100 mL 
(pH 3.0);
250 x 
Extract 
evapor
ated to
almost 
dryness 
using a 
vacuum 
centrifu
ge 
apparat
us. 
Reconst
ituted 
in 
H2O:Me
OH 
(1:1) to 
a final 
volume 
of 400 
µL 
Not reported None 
repor
ted 
RP-
HPLC-
ESI(+)-
ITMS 
(1 
SRM) 
WWInf: (MQL) COC, 
20; BE, 20; AMP, 3; 
MAMP, 7; MDA, 22; 
MDMA, 9                                                                                            
(MDL) COC, 6; BE, 6; 
AMP, 1; MAMP, 2; 
MDA, 7; MDMA. 3 
• Filtered 
particulates 
analysed                                                          
• Internal 
standard 
quantification 
(6 deuterated 
standards)                    
• Silanisation of 
glassware not 
reported 
Metc
alfe et 
al.
[39]
WWeff: 
200 mL 
(pH 3.0);                                                          
500 x 
 
2 x 
cocainic
s, 2 x 
ALC, 1 x 
opiates 
24 h 
compo
site 
sample
s - flow 
weight
ed 
Sample
s stored 
at 4 °C 
and 
extracte
d within 
1 day. 
Sample
s 
filtered 
through 
1.0 µm 
glass 
microfi
ber 
filters  
SPE - Oasis 
HLB 500 
mg                                                                                                         
Condition: 
2 x 5 mL 
MeOH, 2 x 
5 mL H2O                                                                      
Wash: 5 
mL H2O                                                                 
Elution: 10 
mL MeOH 
WWinf: 
250 mL;                                                 
500 x
Extracts 
evapor
ated 
(tempe
rature 
not 
reporte
d). 
Reconst
ituted 
in 500 
µL 
MeOH 
WWinfb: AMP, 74; 
COC, BE, MDMA, BUP 
84-89 
None 
repor
ted 
RP-
HPLC-
ESI(+)-
QqQ 
(2 
SRM) 
WWinf: (MQL) COC, 
1.2;, BE, 2.5; AMP, 
12.8; MDMA, 3.0; 
BUP, 11.9 
• Internal 
standard 
quantification 
(5 deuterated 
standards                          
• Silanisation of 
glassware not 
reported 
  
Karola
k et 
al. 
[22] 
WWeff: 
500 mL;                                                
1000 x 
Wweff: (MQL) COC, 
0.1; BE, 0.3; AMP, 2.6; 
MDMA, 0.5; BUP, 2.0 
1 x 
cocainic
, 2 x ALC 
24 h 
compo
site 
sample
s - flow 
depen
dant - 
and 
grab 
sample
s at 
Sample
s stored 
at -20 
°C. 
Sample
s 
filtered 
through 
1.6 µm 
glass 
microfi
SPE - UCT 
XRDAH 500 
mg                                                                                                                          
Condition: 
N.R.                                                                                   
Wash: 6 
mL acetate 
buffer (pH 
5.7), 2 mL 
0.1 M 
acetic acid, 
WWinf: 
300 mL 
(pH 4.5 -
5);                                                               
1500 x 
Extract 
evapor
ated 
(tempe
rature
not 
reporte
d). 
Reconst
ituted 
in 20 µL 
Waterf: BE, 53.7-61.2; 
MAMP, 80.5-85.7, 
MDMA, 86.5-92.0
None 
repor
ted 
RP-
HPLC-
ESI(+)-
QLIT 
(3 
SRM) 
Water: (MQL) BE, 10; 
MAMP, 2; MDMA, 2 
• Relative 
recovery: 
Water, 98 - 102 
%                                                                  
• Internal 
standard 
quantification 
(3 deuterated 
standards)            
• Silanisation of 
glassware not 
Irvine 
et al. 
[40] 
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WWTP ber 
filters  
6 mL 
MeOH                                                                
Elution: 96 
% 
dichlorome
thane:i-
propanol 
(80:20) / 4 
% 
ammonia 
(Volume 
not 
reported) 
MeOH 
and
mixed 
with 
180 µL 
of 0.1 % 
HCOOH
:H2O 
reported 
8 x 
cocainic
s, 10 x 
ALC, 20 
x 
opiates, 
6 x 
antidep
ressants
, 7 x 
benzodi
azepine
s, 3 x 
dissocia
tive 
anesthe
tics, 2 x 
lysergic
s, 5 x 
urine 
markers
, 2 x 
piperazi
nes, 3 x 
other  
Grab 
sample
s 
Sample
s 
adjuste
d to 
pH1.8, 
and 
stored 
at 2 °C, 
extracte
d within 
20 hrs. 
Sample
s 
filtered 
through 
2.7 µm 
and 0.7 
µm 
glass 
microfi
ber 
filters 
SPE – Oasis 
MCX 60 mg 
Condition: 
2 mL 
MeOH, 2 
mL 2% 
HCOOH/H2
O (pH 2) 
Wash: 2 
mL 2% 
HCOOH/H2
O (pH 2), 2 
mL 0.6% 
HCOOH/M
eOH (pH 2) 
Elute: 3 mL 
7% 
NH4OH/M
eOH 
WWinf: 
100 mL 
(pH 1.8);                                 
200 x 
Extract 
evapor
ated at
40 °C. 
Reconst
ituted 
in 500 
µL 0.3 
% 
CH3CO
OH, 5 % 
MeOH/
H2O 
(v/v) 
WWinfb: COC, 91±2; 
BE, 103±19; nor-BE, 
93±4; nor-COC, 88±5; 
COE, 88±2; AME, 
74±7; ECG, 77±5; 
AMP, 10±17; MAMP, 
76±2; MCAT, 33±3; 
BZP, 101±18; TFMPP, 
79±9; MDA, 90±3; 
MDMA, 86±3; MDEA, 
86±6; MBDB, 88±5; 
BDB, 89±5; MES, 
85±18; LSD, 80±2; O-
H-LSD, 78±5; CAFF, 
36±17; PARAX, 
15±26; NIC, 76±9; 
COT, 37±2; HER, 3±0; 
6ACM, 139±16; COD, 
103±4; nor-COD, 
91±3; OXYC, 57±3; 
OXYM, 68±6; MOR, 
75±6; nor-MOR, 
92±6; DICOD, 96±7; 
BUP, 77±5; nor-BUP, 
85±4; MET, 97±6; 
EDDP, 38±4; EMDP, 
55±3; FENT, 96±7; 
nor-FENT, 85±2; PRO, 
90±4; nor-PRO, 99±9; 
TRAM, 69±7; nor-
TRAM, 101±13; TEM, 
15±8; DIAZ, 105±13; 
nor-DIAZ, 71±4; NIT, 
92±3; 7AMN, 36±8; 
OXAZ, 54±5; CHL, 
86±4; DOS, 67±3; 
AMIT, 80±6; nor-
TRIP, 64±8; FLU, 
61±4; nor-FLU, 62±9; 
VENL, 91±15; PCP, 
80±2; KET, 70±5; nor-
KET, 67±7; MAQ, 
98±5; SILD, 81±23; 
EPH, 73±13; nor-EPH, 
95±3 
0.2 
µm 
What
man 
PTFE 
filter 
RP-
UPLC-
ESI(+)-
QqQ 
(2 
SRM) 
WWinf: (MQL) COC, 
0.7; BE, 0.7; nor-BE, 
0.8; nor-COC, 0.8; 
COE, 0.9; AME, 14.2; 
ECG, 15.2; AMP, 5.1; 
MAMP, 0.6; MCAT, 
9.7; BZP, 9.6; TFMPP, 
0.7; MDA, 4.2; 
MDMA, 0.7; MDEA, 
1.1; MBDB, 0.7; BDB, 
2.0; MES, 52.9; LSD, 
0.7; O-H-LSD, 0.9; 
CAFF, 119.0; PARAX, 
83.3; NIC, 4.7; COT, 
34.0; HER, 139.9; 
6ACM, 2.6; COD, 3.7; 
nor-COD, 3.4; OXYC, 
4.9; OXYM, 10.5; 
MOR, 64.8; nor-MOR, 
32.6; DICOD, 5.1; 
BUP, 8.9; nor-BUP, 
5.1; MET, 0.8; EDDP, 
2.0; EMDP, 1.0; FENT, 
0.8; nor-FENT, 1.2; 
PRO, 5.2; nor-PRO, 
21.2; TRAM, 5.1; nor-
TRAM, 7.4; TEM, 16.6; 
DIAZ, 6.0; nor-DIAZ, 
4.9; NIT, 3.2; 7AMN, 
12.9; OXAZ, 5.9; CHL, 
3.1; DOS, 4.5; AMIT, 
4.8; nor-TRIP, 4.9; 
FLU, 3.0; nor-FLU, 2.7; 
VENL, 3.5; PCP, 0.5; 
KET, 1.0; nor-KET, 5.0; 
MAQ, 3.1; SILD, 4.6; 
EPH, 5.6; nor-EPH, 9.5 
• Relative 
recovery: 
WWinf: 48 - 
226 %; WWeff, 
44 - 129 %; RW, 
47 - 205 %                                                         
• Internal 
standard 
quantification 
(31 deuterated 
standards)                           
• Silanised 
glassware 
Baker 
et al. 
[4] 
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WWeff: 
100mL 
(pH 1.8);                                   
200 x 
WWeff: Due to 
number of 
compounds, refer to 
manuscript 
WWeff: Due to 
number of 
compounds, refer to 
manuscript 
RW: 500 
mL (pH 
1.8);                                    
1000 x  
RW: Due to number 
of compounds, refer 
to manuscript 
RW: Due to number 
of compounds, refer 
to manuscript 
ALC: amphetamine-like-compounds, COC: cocaine, BE: benzoylecgonine, EME: ecgonine methyl ester, COE: cocaethylene, nor-COC: 
norcocaine, nor-BE: norbenzoylecgonine, AME: anhydroecgonine methyl ester, ECG: ecgonidine, AMP: amphetamine, MAMP: 
methamphetamine, MCAT: methcathinone COD: codeine, nor-COD: norcodeine,  DICOD: dihydrocodeine, MOR: morphine, M3G: 
morphine-3-glucuronide, 6ACM: 6-acetylmorphine, MET: methadone, OXYC: oxycodone, OXYM: oxymorphone, BUP: buprenorphine, 
nor-BUP: norbuprenorphine TRAM: tramadol, nor-TRAM: nortramadol, DIAZ: diazepam, nor-DIAZ: nordiazepam, NIT, nitrazepam, CHL: 
chlordiazepoxide, DOS: dosulepin, nor-TRIP: nortriptyline, FLU: Fluoxetine,  VENL: venlafaxine, OXAZ: oxazepam, TEM: temazepam, 
7AMN: 7-aminonitrazepam, KET: Ketamine, nor-KET: norketamine, FENT: fentanyl, nor-FENT: norfentanyl, PRO: propoxyphene, nor-
PRO: norpropoxyphene, BZP: benzylpiperazine, TFMPP: Trifluoromethylphenylpiperazine, MES: mescaline, MAQ: methaqualone, SILD: 
sildenafil, CAFF: caffeine, PARAX: paraxanthine, NIC: nicotine, COT: continine, CREA: creatinine, EPH: ephedrine, nor-EPH: 
norephedrine, HER: heroin, FLUN: flunitrazepam, HYDC: hydrocodone, AMIT: amitriptyline, WWinf: wastewater influent, WWeff: 
wastewater effluent, RW: river water, SW: surface water, DW: drinking water  
a Absolute recovery calculation: matrix spiked before SPE, against standard solution 
b Absolute recovery calculation: matrix spiked before SPE, against matrix spiked after SPE 
c Absolute recovery calculation: Compounds spiked before SPE, and IS added during reconstitution 
d Average recovery value of enantiomers 
e Value extracted from graph, therefore should be considered an approximate value 
f On column detection limit (ng, 20 µL injection) 
g Filter membrane not reported 
n.e = not estimated due to high concentration found in the "blank" sample 
n.r. = not reported in manuscript 
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Table 2 – Influence of silanisation on the recovery of compounds during evaporation (n = 3) 
Compound Comparison of silanised and non-silanised SPE extract vials, recovery (%) 
 
7 % (v/v) NH4OH/MeOH 
 
MeOH 
  non-silanised silanised   non-silanised silanised 
Stimulants 
             
Cocaine 64 ± 2 98 ± 4 
 
87 ± 3 95 ± 5 
Benzoylecgonine 101 ± 4 97 ± 7 
 
95 ± 1 95 ± 3 
Ecgonine methyl ester 37 ± 2 72 ± 4 
 
76 ± 4 100 ± 3 
Norbenzoylecgonine 96 ± 2 94 ± 4 
 
96 ± 1 81 ± 4 
Norcocaine 73 ± 1 99 ± 7 
 
86 ± 1 95 ± 4 
Cocaethylene 70 ± 3 95 ± 5 
 
90 ± 0 93 ± 2 
Anhydroecgonine methyl ester 28 ± 3 75 ± 1 
 
32 ± 4 78 ± 3 
Ecgonidine  114 ± 2 67 ± 10 
 
117 ± 3 44 ± 1 
Amphetamine   16 ± 3 88 ± 4 
 
22 ± 2 67 ± 3 
Methamphetamine  23 ± 4 89 ± 1 
 
30 ± 3 81 ± 2 
Methcathinone 16 ± 3 67 ± 4 
 
20 ± 1 33 ± 2 
BZP 37 ± 2 86 ± 2 
 
55 ± 4 60 ± 1 
TFMPP 37 ± 5 90 ± 3 
 
54 ± 1 87 ± 3 
              
Hallucinogens 
             
MDA  41 ± 3 99 ± 5 
 
76 ± 1 83 ± 3 
MDMA 40 ± 5 96 ± 6 
 
75 ± 0 84 ± 3 
MDEA 35 ± 4 97 ± 5 
 
74 ± 3 81 ± 4 
MBDB 27 ± 4 93 ± 2 
 
64 ± 1 88 ± 2 
BDB 27 ± 3 92 ± 5 
 
58 ± 1 79 ± 3 
Mescaline 76 ± 2 96 ± 9 
 
79 ± 2 94 ± 6 
LSD 91 ± 0 93 ± 3 
 
87 ± 2 93 ± 3 
O-H-LSD 83 ± 4 96 ± 7 
 
80 ± 1 96 ± 3 
              
Human indicators 
             
Caffeine 36 ± 2 99 ± 6 
 
36 ± 2 90 ± 3 
1,7-dimethylxanthine 117 ± 5 111 ± 10 
 
106 ± 3 91 ± 4 
Nicotine 11 ± 2 50 ± 13 
 
10 ± 1 48 ± 3 
Continine 44 ± 2 89 ± 12 
 
52 ± 3 53 ± 0 
Creatinine 83 ± 4 40 ± 11 
 
106 ± 4 3 ± 0 
              
Opioids and morphine derivatives 
             
Heroin 71 ± 7 68 ± 4 
 
89 ± 3 85 ± 4 
6-acetylmorphine 107 ± 5 118 ± 8 
 
91 ± 2 91 ± 3 
Codeine 95 ± 3 99 ± 9 
 
94 ± 1 73 ± 3 
Norcodeine 94 ± 8 97 ± 6 
 
92 ± 1 68 ± 2 
Oxycodone 75 ± 3 82 ± 5 
 
81 ± 2 67 ± 2 
Oxymorphone 101 ± 5 83 ± 9 
 
102 ± 0 46 ± 1 
Morphine 110 ± 5 102 ± 12 
 
106 ± 1 58 ± 1 
Normorphine 104 ± 4 92 ± 10 
 
97 ± 2 57 ± 1 
Dihydrocodeine 99 ± 1 100 ± 8 
 
97 ± 2 77 ± 2 
Buprenorphine 81 ± 2 89 ± 1 
 
78 ± 0 81 ± 3 
Norbuprenorphine 97 ± 2 95 ± 4 
 
89 ± 1 88 ± 4 
Methadone 50 ± 2 90 ± 4 
 
67 ± 1 79 ± 5 
EDDP 16 ± 2 89 ± 2 
 
60 ± 3 85 ± 3 
EMDP 8 ± 2 30 ± 1 
 
1 ± 0 64 ± 6 
Fentanyl 93 ± 2 98 ± 4 
 
90 ± 1 90 ± 1 
Norfentanyl 96 ± 4 98 ± 6 
 
90 ± 1 87 ± 2 
Propoxyphene  45 ± 4 96 ± 5 
 
64 ± 3 92 ± 2 
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Norpropoxyphene 676 ± 7 638 ± 51 
 
119 ± 5 246 ± 14 
Tramadol 37 ± 3 89 ± 5 
 
72 ± 2 83 ± 3 
Nortramadol 87 ± 7 98 ± 13 
 
81 ± 2 89 ± 1 
              
Benzodiazepines 
             
Temazepam 90 ± 2 89 ± 3 
 
86 ± 3 90 ± 0 
Diazepam  93 ± 3 88 ± 5 
 
90 ± 1 97 ± 4 
Nordiazepam  91 ± 5 85 ± 2 
 
84 ± 2 76 ± 3 
Nitrazepam 73 ± 3 66 ± 3 
 
80 ± 6 69 ± 6 
7-aminonitrazepam 78 ± 2 94 ± 6 
 
58 ± 5 82 ± 7 
Oxazepam 91 ± 3 87 ± 4 
 
86 ± 2 101 ± 4 
Chlordiazepoxide 94 ± 3 107 ± 7 
 
86 ± 3 87 ± 1 
              
Antidepressants  
             
Dosulepin 82 ± 1 90 ± 6 
 
47 ± 2 47 ± 4 
Amitriptyline 58 ± 3 90 ± 3 
 
45 ± 0 58 ± 3 
Nortriptyline 83 ± 2 79 ± 4 
 
39 ± 2 47 ± 5 
Fluoxetine 71 ± 2 82 ± 7 
 
19 ± 2 25 ± 4 
Norfluoxetine 72 ± 5 74 ± 5 
 
19 ± 1 27 ± 4 
Venlafaxine 61 ± 4 100 ± 5 
 
84 ± 0 95 ± 6 
              
Dissociative anaesthetics 
             
Phencyclidine  20 ± 4 86 ± 6 
 
26 ± 2 95 ± 3 
Ketamine  20 ± 3 84 ± 3 
 
22 ± 2 88 ± 2 
Norketamine  20 ± 3 74 ± 3 
 
20 ± 3 63 ± 3 
              
Other 
             
Methaqualone 33 ± 2 83 ± 4 
 
21 ± 2 94 ± 4 
Sildenafil 86 ± 4 82 ± 9 
 
40 ± 2 56 ± 5 
              
Drug precursors 
             
Ephedrine  32 ± 5 100 ± 7 
 
59 ± 2 59 ± 5 
Norephedrine 42 ± 5 114 ± 22   62 ± 5 33 ± 2 
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Table 3 – Stability of analytes (n = 2) in WWTP influent stored over a 72 hour period in raw (unfiltered) wastewater 
Compound Difference (%) to time-point 0 ± SD (%) 
 
Raw (unfiltered) wastewater, pH 7.4, stored at 2 ˚C 
 
Raw (unfiltered) wastewater, pH 7.4, stored at 19 ˚C 
  12 hours 24 hours 72 hours   12 hours 24 hours 72 hours 
Stimulants 
                   
Cocaine -5.1 ± 2.8 -11.8 ± 3.6 -8.2 ± 3.9 
 
-7.7 ± 1.0 -12.3 ± 2.8 -23.1 ± 2.1 
Benzoylecgonine 2.5 ± 1.4 0.5 ± 0.2 0.5 ± 1.4 
 
5.5 ± 3.0 7.4 ± 5.4 11.7 ± 6.4 
Norbenzoylecgonine -2.9 ± 1.8 -7.5 ± 2.9 -6.0 ± 0.8 
 
3.5 ± 6.1 0.6 ± 4.0 -4.4 ± 0.0 
Norcocaine -14.7 ± 2.6 -19.5 ± 4.3 -14.4 ± 1.0 
 
-9.9 ± 5.4 -20.6 ± 1.7 -31.5 ± 1.4 
Cocaethylene -4.0 ± 6.2 -5.4 ± 4.3 -9.4 ± 7.6 
 
-6.8 ± 6.1 -8.6 ± 9.1 -19.0 ± 2.8 
Anhydroecgonine methyl ester 12.0 ± 2.6 7.2 ± 1.1 12.6 ± 5.3 
 
19.8 ± 0.1 26.5 ± 11.7 52.7 ± 5.3 
Ecgonidine  -0.8 ± 16.7 5.4 ± 3.9 24.0 ± 6.2 
 
30.8 ± 1.1 20.4 ± 7.6 83.0 ± 7.4 
Amphetamine   6.9 ± 2.6 26.0 ± 1.8 36.8 ± 0.8 
 
46.8 ± 5.6 73.8 ± 0.4 88.2 ± 13.0 
Methamphetamine  -10.0 ± 16.3 -14.4 ± 8.5 -6.0 ± 9.7 
 
8.1 ± 5.9 5.5 ± 1.9 12.0 ± 7.9 
Methcathinone -50.7 ± 12.4 -57.4 ± 2.7 -60.3 ± 3.3 
 
-56.5 ± 0.7 -66.4 ± 1.8 -77.8 ± 6.0 
BZP 70.0 ± 15.5 78.3 ± 12.9 80.7 ± 7.4 
 
55.6 ± 21.7 78.4 ± 8.4 115.0 ± 25.3 
TFMPP 25.6 ± 8.2 28.3 ± 5.6 34.5 ± 4.8 
 
23.5 ± 23.9 39.1 ± 6.4 36.9 ± 2.0 
                    
Hallucinogens 
                   
MDA  0.0 ± 2.2 -2.0 ± 3.7 -3.5 ± 9.7 
 
3.4 ± 5.4 -2.2 ± 1.2 -10.5 ± 1.2 
MDMA -3.8 ± 1.8 -6.6 ± 0.3 -3.1 ± 0.6 
 
1.4 ± 1.6 2.8 ± 1.6 -0.4 ± 0.7 
MDEA 4.5 ± 0.0 -1.6 ± 1.9 0.4 ± 2.5 
 
-1.5 ± 0.5 2.4 ± 4.1 -12.1 ± 4.0 
MBDB -17.7 ± 2.7 -17.4 ± 0.4 -14.3 ± 0.8 
 
-8.6 ± 3.1 -10.2 ± 2.6 -21.7 ± 7.1 
BDB -35.0 ± 18.7 -38.3 ± 8.8 -33.0 ± 8.6 
 
-20.5 ± 7.3 -19.5 ± 0.4 -31.2 ± 9.3 
Mescaline -8.1 ± 8.9 -12.9 ± 8.9 -10.2 ± 9.1 
 
-7.1 ± 0.9 -17.1 ± 9.7 -26.7 ± 8.1 
LSD -6.1 ± 2.4 -13.6 ± 0.4 -9.9 ± 1.6 
 
-3.5 ± 1.5 -6.8 ± 1.3 -20.4 ± 1.7 
O-H-LSD 5.3 ± 8.6 1.7 ± 6.1 -2.8 ± 4.9 
 
-4.7 ± 17.5 -9.1 ± 14.0 -13.6 ± 0.8 
                    
Human indicators 
                   
Caffeine 6.3 ± 4.1 2.7 ± 17.9 30.3 ± 9.1 
 
8.4 ± 21.3 22.9 ± 25.8 45.0 ± 20.0 
1,7-dimethylxanthine -25.0 ± 15.5 -26.0 ± 0.8 -19.9 ± 11.9 
 
-15.3 ± 16.8 -25.2 ± 4.8 -40.8 ± 17.4 
Nicotine 0.2 ± 2.2 1.0 ± 1.3 -2.0 ± 1.6 
 
3.8 ± 2.3 0.9 ± 1.4 1.0 ± 1.5 
Continine 23.9 ± 27.8 4.4 ± 3.5 37.1 ± 5.1 
 
56.5 ± 35.0 61.4 ± 67.1 163.2 ± 21.0 
                    
Opioids and morphine derivatives 
                  
Heroin -66.2 ± 3.7 -82.3 ± 0.6 -97.5 ± 0.1 
 
-79.4 ± 0.6 -95.5 ± 0.3 -99.9 ± 0.1 
6-acetylmorphine -26.4 ± 3.3 -32.5 ± 0.5 -54.6 ± 0.3 
 
-12.0 ± 5.1 -41.5 ± 2.1 -76.6 ± 0.4 
Codeine 6.9 ± 5.6 8.4 ± 5.2 15.2 ± 3.0 
 
12.4 ± 3.6 11.7 ± 2.9 9.5 ± 2.1 
Norcodeine -1.6 ± 0.7 -3.9 ± 5.2 4.4 ± 2.1 
 
4.5 ± 3.0 -1.4 ± 2.1 -9.6 ± 2.5 
Oxycodone 8.3 ± 9.6 1.7 ± 4.9 6.8 ± 6.4 
 
9.6 ± 0.4 10.0 ± 0.4 5.8 ± 2.1 
Oxymorphone 22.2 ± 4.5 21.3 ± 9.6 26.4 ± 10.3 
 
31.0 ± 0.3 31.2 ± 3.6 42.9 ± 2.4 
Morphine 46.2 ± 0.0 62.4 ± 4.8 83.5 ± 0.0 
 
48.9 ± 0.2 74.6 ± 11.8 89.1 ± 4.5 
Morphine-3β-glucuronide -80.5 ± 3.0 -90.3 ± 0.2 -98.9 ± 0.2 
 
-84.7 ± 0.7 -98.3 ± 0.3 <MQL 
  
Normorphine 10.6 ± 7.8 14.4 ± 0.1 12.4 ± 0.5 
 
4.3 ± 3.9 12.7 ± 0.0 3.1 ± 0.3 
Dihydrocodeine -5.9 ± 8.3 -6.6 ± 5.1 -8.3 ± 3.3 
 
-6.0 ± 7.0 -1.2 ± 2.7 -1.2 ± 10.6 
Buprenorphine 4.3 ± 2.3 -4.7 ± 6.7 -3.0 ± 3.4 
 
-5.9 ± 4.3 -1.9 ± 5.1 -17.4 ± 1.3 
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Norbuprenorphine 6.5 ± 1.5 3.6 ± 5.4 0.7 ± 0.5 
 
-3.7 ± 2.3 -0.1 ± 10.3 -5.5 ± 6.6 
Methadone -5.8 ± 5.5 -14.4 ± 7.6 -10.9 ± 9.3 
 
-6.7 ± 1.0 -4.2 ± 4.1 -23.4 ± 1.6 
EDDP -14.8 ± 6.5 -15.3 ± 5.3 -17.1 ± 9.9 
 
-12.8 ± 2.1 -17.7 ± 1.9 -71.9 ± 2.5 
EMDP -9.3 ± 0.2 -8.4 ± 1.6 -16.6 ± 3.4 
 
-17.7 ± 10.7 -7.2 ± 0.0 -41.3 ± 3.7 
Fentanyl -10.8 ± 1.9 -14.0 ± 1.7 -16.2 ± 0.8 
 
-8.3 ± 11.1 -14.0 ± 1.8 -61.6 ± 0.8 
Norfentanyl 1.9 ± 2.1 -8.8 ± 4.1 -18.6 ± 6.1 
 
-13.5 ± 9.1 -19.9 ± 0.8 -23.1 ± 1.8 
Propoxyphene  -1.1 ± 3.0 -10.5 ± 10.1 0.0 ± 14.7 
 
-1.8 ± 4.1 10.1 ± 9.2 24.6 ± 3.5 
Norpropoxyphene 48.7 ± 4.1 72.6 ± 22.2 115.7 ± 29.5 
 
64.0 ± 9.0 114.6 ± 13.1 123.3 ± 59.1 
Tramadol -16.2 ± 5.9 -18.0 ± 4.8 -17.6 ± 3.0 
 
-11.0 ± 3.8 -19.5 ± 6.1 -32.7 ± 0.6 
Nortramadol -49.8 ± 12.0 -60.8 ± 3.8 -56.4 ± 10.8 
 
-44.2 ± 4.2 -61.1 ± 6.6 -63.0 ± 0.8 
                    
Benzodiazepines 
                   
Temazepam -5.7 ± 2.7 1.8 ± 1.8 1.7 ± 0.8 
 
19.4 ± 21.0 17.3 ± 2.7 -1.1 ± 14.2 
Diazepam  -13.2 ± 12.4 -15.3 ± 15.6 -15.1 ± 16.1 
 
-3.0 ± 8.3 -9.3 ± 18.4 -17.1 ± 13.8 
Nordiazepam  15.2 ± 10.1 6.3 ± 6.9 5.7 ± 2.7 
 
15.6 ± 1.2 21.4 ± 21.7 49.7 ± 5.1 
Nitrazepam -29.8 ± 10.0 -57.1 ± 3.9 -81.5 ± 1.3 
 
-61.9 ± 1.5 -87.4 ± 3.5 -99.8 ± 0.1 
7-aminonitrazepam 6.4 ± 10.0 9.3 ± 2.5 44.4 ± 12.7 
 
29.8 ± 14.2 42.1 ± 0.7 40.5 ± 3.3 
Oxazepam -6.2 ± 8.4 -11.4 ± 10.0 -1.3 ± 8.0 
 
2.4 ± 12.3 7.9 ± 2.9 1.3 ± 15.4 
Chlordiazepoxide 1.7 ± 18.9 4.5 ± 13.1 -23.6 ± 4.5 
 
-14.4 ± 6.2 -12.7 ± 31.2 12.8 ± 3.4 
                    
Antidepressants  
                   
Dosulepin -31.5 ± 1.5 -50.0 ± 5.9 -40.8 ± 1.8 
 
-7.4 ± 4.3 -16.2 ± 20.1 -72.3 ± 6.5 
Amitriptyline -18.5 ± 1.3 -37.9 ± 11.3 -22.9 ± 2.0 
 
10.1 ± 6.6 6.8 ± 33.4 -61.2 ± 7.2 
Nortriptyline -34.5 ± 6.2 -58.8 ± 9.3 -42.0 ± 9.4 
 
-7.8 ± 11.6 -11.7 ± 44.0 -78.9 ± 8.6 
Fluoxetine -5.5 ± 1.5 -37.0 ± 1.1 -27.7 ± 0.5 
 
8.2 ± 8.8 1.0 ± 20.3 -54.8 ± 1.6 
Norfluoxetine -13.8 ± 17.0 -49.4 ± 3.2 -46.2 ± 10.1 
 
1.9 ± 11.4 4.8 ± 57.4 -56.1 ± 10.2 
Venlafaxine -5.7 ± 1.5 -16.6 ± 8.1 -24.9 ± 2.9 
 
-20.5 ± 15.9 -29.2 ± 3.6 -43.6 ± 3.8 
                    
Dissociative anaesthetics 
                   
Phencyclidine  -1.9 ± 0.9 -3.1 ± 1.9 -1.2 ± 1.1 
 
-3.2 ± 1.6 0.6 ± 7.0 -25.2 ± 3.5 
Ketamine  -1.9 ± 1.1 -4.1 ± 1.4 -1.4 ± 1.0 
 
-0.8 ± 1.2 1.7 ± 3.7 0.5 ± 5.0 
Norketamine  -6.9 ± 0.9 -10.9 ± 3.3 -5.1 ± 0.0 
 
-2.7 ± 2.7 -5.2 ± 2.5 2.6 ± 5.2 
                    
Other 
                   
Methaqualone -11.9 ± 12.3 -17.1 ± 17.9 -2.2 ± 11.4 
 
-2.7 ± 6.9 1.1 ± 17.8 -10.1 ± 1.1 
Sildenafil 3.4 ± 8.3 5.8 ± 18.4 27.9 ± 17.0 
 
11.5 ± 19.0 7.1 ± 28.5 -53.4 ± 13.7 
                    
Drug precursors 
                   
Ephedrine -38.1 ± 16.6 -25.6 ± 16.6 -32.8 ± 20.5 
 
-40.4 ± 4.3 -49.2 ± 1.9 -56.6 ± 0.1 
Norephedrine -59.3 ± 10.1 -63.6 ± 6.3 -79.9 ± 3.7   -65.1 ± 3.0 -73.3 ± 1.9 -83.6 ± 2.0 
 
  
30 
 
Table 4 – Stability of analytes (n = 2) in WWTP influent stored over a 72 hour period in filtered wastewater at pH 1.8 
Compound Difference (%) to time-point 0 ± SD (%) 
 
Filtered wastewater, pH 1.8, stored at 2 ˚C 
 
Filtered wastewater, pH 1.8, stored at 19 ˚C 
  12 hours 24 hours 72 hours   12 hours 24 hours 72 hours 
Stimulants 
                   
Cocaine -0.6 ± 6.5 0.7 ± 3.5 -5.0 ± 4.2 
 
-7.9 ± 1.0 -9.0 ± 1.0 -6.4 ± 2.7 
Benzoylecgonine 0.9 ± 3.6 -0.4 ± 1.9 -9.4 ± 3.5 
 
-4.6 ± 5.0 -5.1 ± 4.3 -6.2 ± 0.1 
Norbenzoylecgonine 2.5 ± 2.5 0.0 ± 0.4 -11.4 ± 3.3 
 
-3.0 ± 5.1 -2.6 ± 1.8 -4.1 ± 2.3 
Norcocaine -1.3 ± 3.5 -3.7 ± 1.2 -7.9 ± 3.5 
 
-0.4 ± 3.3 -7.6 ± 1.0 -7.7 ± 5.8 
Cocaethylene 0.0 ± 0.5 -0.5 ± 5.5 -6.6 ± 9.1 
 
-3.9 ± 2.7 -3.1 ± 3.1 -3.9 ± 2.6 
Anhydroecgonine methyl ester -2.6 ± 7.6 -2.3 ± 6.6 -7.2 ± 4.8 
 
-10.5 ± 4.8 -11.1 ± 1.0 -14.5 ± 2.9 
Ecgonidine  1.9 ± 6.8 11.8 ± 4.5 2.3 ± 15.0 
 
-8.7 ± 9.9 -5.1 ± 29.8 -10.0 ± 14.1 
Amphetamine   -6.4 ± 7.6 -7.6 ± 7.3 -8.7 ± 4.3 
 
-7.6 ± 2.8 -10.6 ± 3.4 -11.3 ± 3.0 
Methamphetamine  -7.3 ± 11.8 -8.1 ± 15.6 -14.3 ± 16.2 
 
-8.1 ± 5.8 -3.9 ± 1.0 -8.2 ± 0.9 
Methcathinone 5.9 ± 20.1 4.8 ± 13.5 0.8 ± 23.9 
 
-5.5 ± 14.1 -4.9 ± 11.3 1.0 ± 9.2 
BZP 2.0 ± 5.0 4.9 ± 8.2 8.4 ± 11.0 
 
-3.7 ± 1.9 -1.0 ± 3.1 1.4 ± 1.0 
TFMPP 0.9 ± 1.5 3.9 ± 6.7 3.7 ± 4.8 
 
-0.9 ± 9.5 -0.4 ± 9.1 -1.2 ± 7.7 
                    
Hallucinogens 
                   
MDA  2.6 ± 2.1 10.0 ± 3.1 -0.5 ± 4.0 
 
-5.8 ± 3.6 -3.1 ± 1.3 -4.1 ± 0.3 
MDMA -6.0 ± 4.4 -7.5 ± 3.1 -11.4 ± 5.0 
 
-2.7 ± 4.8 -5.0 ± 2.7 -3.2 ± 0.4 
MDEA -1.4 ± 4.1 -1.2 ± 5.9 -7.3 ± 7.1 
 
-3.3 ± 8.4 -6.8 ± 1.6 -7.5 ± 2.1 
MBDB -0.8 ± 5.4 -2.8 ± 6.1 -9.6 ± 4.1 
 
-5.4 ± 9.0 -2.2 ± 7.4 -4.5 ± 5.6 
BDB -3.8 ± 7.0 -13.1 ± 4.7 -21.8 ± 2.2 
 
-2.5 ± 11.6 2.6 ± 0.8 -4.5 ± 2.0 
Mescaline -1.8 ± 1.8 -9.3 ± 0.5 -14.0 ± 7.7 
 
-1.1 ± 1.0 -3.9 ± 1.3 -7.3 ± 1.4 
LSD -2.7 ± 0.5 -3.5 ± 3.7 -16.0 ± 0.5 
 
-6.1 ± 11.5 -3.9 ± 2.7 -6.6 ± 3.5 
O-H-LSD 1.6 ± 9.5 1.8 ± 7.1 -3.8 ± 16.3 
 
-4.3 ± 12.3 -4.8 ± 5.1 -2.6 ± 3.3 
                    
Human indicators 
                   
Caffeine 0.0 ± 2.4 -11.9 ± 9.5 -15.2 ± 5.1 
 
-8.0 ± 3.6 -7.7 ± 15.6 -3.1 ± 10.7 
1,7-dimethylxanthine 4.2 ± 9.2 0.7 ± 13.9 1.9 ± 19.4 
 
-11.4 ± 3.2 -19.9 ± 4.5 -15.2 ± 5.5 
Nicotine -1.4 ± 0.5 -7.8 ± 4.4 -7.5 ± 0.4 
 
-9.6 ± 3.8 -15.2 ± 2.2 -17.2 ± 1.5 
Continine 3.0 ± 16.7 -7.2 ± 16.6 -13.5 ± 30.1 
 
-7.1 ± 13.3 -3.5 ± 31.2 4.7 ± 29.8 
                    
Opioids and morphine derivatives 
                  
Heroin 2.1 ± 4.3 3.9 ± 3.9 -7.5 ± 3.0 
 
-3.3 ± 3.5 -6.5 ± 1.6 -13.2 ± 1.6 
6-acetylmorphine -0.6 ± 1.5 -5.0 ± 2.9 -9.2 ± 6.6 
 
-4.7 ± 0.1 -5.9 ± 0.5 -10.2 ± 2.1 
Codeine 2.1 ± 2.9 -1.5 ± 0.4 -4.3 ± 3.2 
 
-1.3 ± 0.7 -1.3 ± 1.8 -0.6 ± 3.3 
Norcodeine 1.3 ± 1.6 -2.1 ± 3.6 -7.0 ± 3.8 
 
-2.1 ± 0.4 -2.9 ± 0.5 -4.3 ± 0.0 
Oxycodone -3.6 ± 0.3 -3.1 ± 2.0 -9.0 ± 1.4 
 
-2.1 ± 4.0 -3.4 ± 2.2 -8.7 ± 2.9 
Oxymorphone -4.2 ± 8.8 -5.5 ± 3.7 -11.9 ± 4.6 
 
-4.6 ± 8.4 -5.0 ± 5.1 -9.7 ± 6.5 
Morphine 2.4 ± 8.4 -1.4 ± 3.9 -5.5 ± 2.3 
 
-8.2 ± 10.4 -8.9 ± 5.5 -9.3 ± 0.7 
Morphine-3β-glucuronide 3.1 ± 18.4 6.7 ± 3.1 13.4 ± 18.5 
 
-4.9 ± 15.7 6.7 ± 22.2 -5.2 ± 1.0 
Normorphine 5.3 ± 3.1 1.6 ± 9.0 -4.0 ± 2.7 
 
-2.1 ± 13.2 -6.8 ± 3.3 -4.5 ± 1.4 
Dihydrocodeine 0.5 ± 3.6 -1.2 ± 2.1 -7.1 ± 4.1 
 
-3.8 ± 9.0 -4.5 ± 8.8 -2.6 ± 7.3 
Buprenorphine -0.2 ± 1.6 -0.1 ± 1.3 -6.9 ± 2.7 
 
-0.3 ± 4.1 0.6 ± 1.5 1.1 ± 2.8 
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Norbuprenorphine 3.3 ± 1.2 2.7 ± 0.3 -4.4 ± 1.2 
 
-0.6 ± 0.2 -1.7 ± 0.0 -3.4 ± 1.0 
Methadone -0.4 ± 1.4 -3.1 ± 0.8 -11.0 ± 0.9 
 
-6.4 ± 4.6 -4.4 ± 1.2 -6.3 ± 6.0 
EDDP -1.5 ± 2.3 4.1 ± 9.7 -7.6 ± 8.4 
 
-3.0 ± 7.1 -2.5 ± 6.0 -1.2 ± 11.6 
EMDP -5.4 ± 11.2 -17.7 ± 11.6 -28.6 ± 4.7 
 
-12.5 ± 0.6 -17.2 ± 4.9 -23.7 ± 0.8 
Fentanyl 2.8 ± 2.2 -2.4 ± 0.6 -7.5 ± 4.3 
 
-0.6 ± 2.3 0.8 ± 0.9 1.7 ± 0.1 
Norfentanyl -4.0 ± 2.1 -7.0 ± 3.0 -9.8 ± 0.4 
 
-2.8 ± 2.5 -2.2 ± 5.8 -5.4 ± 7.4 
Propoxyphene  -3.3 ± 10.4 1.5 ± 6.1 -12.7 ± 6.4 
 
-4.2 ± 0.4 -0.4 ± 1.7 -4.0 ± 1.8 
Norpropoxyphene -3.5 ± 5.7 -10.3 ± 12.4 -21.2 ± 0.8 
 
-5.3 ± 14.1 -10.2 ± 1.1 -14.6 ± 4.1 
Tramadol 2.6 ± 12.4 -4.1 ± 9.6 -7.1 ± 10.0 
 
1.8 ± 2.7 1.4 ± 2.3 2.3 ± 1.7 
Nortramadol -9.5 ± 3.1 -16.7 ± 0.9 -22.7 ± 0.2 
 
11.0 ± 9.9 1.1 ± 3.0 -0.6 ± 15.0 
                    
Benzodiazepines 
                   
Temazepam -2.7 ± 9.9 -18.0 ± 0.4 -23.4 ± 5.1 
 
-22.3 ± 2.9 -23.0 ± 0.4 -62.7 ± 0.1 
Diazepam  -3.1 ± 14.7 -6.2 ± 14.9 -23.3 ± 12.9 
 
-2.7 ± 1.6 -7.4 ± 2.0 -21.1 ± 3.5 
Nordiazepam  0.8 ± 17.6 2.7 ± 16.1 -4.0 ± 14.7 
 
0.9 ± 7.8 1.8 ± 15.6 -22.0 ± 0.3 
Nitrazepam -16.7 ± 9.4 -24.9 ± 4.9 -35.1 ± 7.7 
 
-10.5 ± 10.4 -25.2 ± 9.5 -41.8 ± 1.9 
7-aminonitrazepam 5.9 ± 10.8 11.0 ± 10.0 18.9 ± 15.2 
 
9.7 ± 3.1 1.2 ± 8.2 5.6 ± 11.1 
Oxazepam -0.2 ± 1.3 -1.4 ± 7.3 -8.6 ± 13.6 
 
-8.2 ± 0.6 -9.0 ± 4.4 -29.4 ± 1.1 
Chlordiazepoxide -3.8 ± 17.7 -4.5 ± 9.7 -14.1 ± 13.7 
 
9.7 ± 10.4 4.2 ± 15.2 -8.1 ± 3.1 
                    
Antidepressants  
                   
Dosulepin -7.6 ± 16.4 -8.2 ± 9.5 -25.4 ± 9.4 
 
1.1 ± 0.2 4.6 ± 6.3 -2.4 ± 14.2 
Amitriptyline -5.4 ± 15.1 -6.9 ± 11.2 -23.6 ± 8.7 
 
-1.6 ± 5.8 -2.6 ± 8.1 -8.7 ± 10.5 
Nortriptyline -11.9 ± 18.1 -18.1 ± 15.0 -32.6 ± 13.6 
 
-4.2 ± 8.5 -5.9 ± 8.7 -20.9 ± 14.8 
Fluoxetine -1.4 ± 6.3 -6.1 ± 7.4 -15.1 ± 6.9 
 
-4.6 ± 3.3 -3.5 ± 1.8 -14.6 ± 0.6 
Norfluoxetine -10.1 ± 18.8 -13.0 ± 16.3 -36.4 ± 11.5 
 
-2.8 ± 1.5 -7.7 ± 3.1 -32.6 ± 4.6 
Venlafaxine -2.8 ± 3.5 -8.0 ± 3.1 -12.7 ± 7.8 
 
2.3 ± 10.5 -0.7 ± 6.7 3.9 ± 6.4 
                    
Dissociative anaesthetics 
                   
Phencyclidine  -6.5 ± 4.4 -4.8 ± 0.4 -12.4 ± 1.6 
 
-3.2 ± 6.3 -7.8 ± 5.5 -2.3 ± 9.2 
Ketamine  2.2 ± 1.7 0.7 ± 1.1 -3.2 ± 2.9 
 
-3.9 ± 0.7 -2.5 ± 6.7 -3.0 ± 6.1 
Norketamine  3.8 ± 2.4 2.2 ± 0.6 -0.8 ± 4.6 
 
-4.7 ± 2.7 -5.0 ± 3.4 -3.1 ± 0.8 
                    
Other 
                   
Methaqualone -8.8 ± 12.2 -13.7 ± 6.2 -19.6 ± 9.4 
 
-6.6 ± 0.8 -11.3 ± 7.5 -17.9 ± 2.5 
Sildenafil 3.0 ± 9.8 7.9 ± 3.7 -2.1 ± 1.1 
 
-1.9 ± 3.1 9.1 ± 0.9 10.4 ± 0.5 
                    
Drug precursors 
                   
Ephedrine -3.9 ± 2.4 -5.9 ± 7.2 -0.4 ± 10.6 
 
-6.1 ± 3.2 -3.1 ± 8.0 1.7 ± 11.2 
Norephedrine -4.4 ± 9.9 2.6 ± 8.2 -1.3 ± 10.6   -2.0 ± 1.3 4.0 ± 6.6 4.5 ± 9.5 
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Table 5 – Stability of analytes (n = 2) in WWTP influent stored over a 72 hour period in filtered wastewater at pH 7.4 
Compound Difference (%) to time-point 0 ± SD (%) 
 
Filtered wastewater, 7.4, stored at 2 ˚C 
 
Filtered wastewater, pH 7.4, stored at 19 ˚C 
  12 hours 24 hours 72 hours   12 hours 24 hours 72 hours 
Stimulants 
                   
Cocaine -4.9 ± 0.5 -4.3 ± 0.5 -9.6 ± 2.4 
 
-12.1 ± 1.3 -13.6 ± 0.7 -28.3 ± 0.1 
Benzoylecgonine 2.7 ± 2.0 1.1 ± 3.5 3.4 ± 5.3 
 
0.7 ± 2.2 9.1 ± 1.4 17.3 ± 6.1 
Norbenzoylecgonine -3.1 ± 1.1 -5.2 ± 4.0 -1.9 ± 6.4 
 
-4.9 ± 1.8 -1.4 ± 0.2 -0.1 ± 3.7 
Norcocaine -4.6 ± 0.8 -3.7 ± 0.4 -7.5 ± 1.6 
 
-7.8 ± 5.5 -7.6 ± 2.6 -9.2 ± 2.4 
Cocaethylene -1.7 ± 3.3 -4.3 ± 6.2 -8.7 ± 3.4 
 
-9.4 ± 3.5 -7.1 ± 2.0 -15.5 ± 1.9 
Anhydroecgonine methyl ester 9.4 ± 6.6 28.4 ± 5.4 41.1 ± 5.6 
 
-0.9 ± 2.2 22.4 ± 3.4 45.3 ± 3.8 
Ecgonidine  3.0 ± 3.4 15.1 ± 15.8 27.1 ± 21.6 
 
6.0 ± 4.9 38.0 ± 5.9 43.3 ± 0.3 
Amphetamine   23.4 ± 9.7 28.9 ± 6.2 44.3 ± 9.7 
 
14.7 ± 1.8 21.1 ± 0.6 21.3 ± 2.9 
Methamphetamine  2.9 ± 0.6 5.9 ± 2.9 3.5 ± 1.3 
 
-2.7 ± 9.9 3.7 ± 7.9 -6.1 ± 5.2 
Methcathinone -29.3 ± 1.7 -34.6 ± 3.1 -42.8 ± 1.2 
 
-18.0 ± 8.9 -13.6 ± 8.8 -42.1 ± 10.5 
BZP 25.1 ± 9.9 49.3 ± 3.9 60.2 ± 5.0 
 
8.8 ± 5.1 20.8 ± 3.1 17.8 ± 5.8 
TFMPP 10.0 ± 3.4 7.9 ± 10.9 -22.9 ± 16.9 
 
4.7 ± 0.2 -32.4 ± 3.0 -50.5 ± 19.5 
                    
Hallucinogens 
                   
MDA  3.7 ± 4.4 0.3 ± 6.0 -0.4 ± 5.3 
 
2.2 ± 8.6 -2.1 ± 10.9 -9.2 ± 0.7 
MDMA 0.8 ± 2.7 4.8 ± 6.7 -5.9 ± 4.8 
 
-5.3 ± 2.1 -5.5 ± 0.4 -4.7 ± 4.3 
MDEA -2.2 ± 0.0 -4.8 ± 0.9 -3.5 ± 3.6 
 
-4.0 ± 6.2 -4.2 ± 1.6 -6.1 ± 4.1 
MBDB -6.2 ± 1.3 -8.8 ± 4.6 -9.4 ± 0.9 
 
-5.8 ± 5.0 -5.3 ± 6.4 -4.9 ± 2.8 
BDB -11.9 ± 3.0 -10.6 ± 5.6 -14.5 ± 6.4 
 
-15.0 ± 8.1 -13.1 ± 5.0 -5.9 ± 5.2 
Mescaline -5.5 ± 1.7 -10.5 ± 0.7 -20.1 ± 3.2 
 
-11.2 ± 5.1 -10.1 ± 7.7 -21.3 ± 17.4 
LSD 1.3 ± 4.8 3.0 ± 7.3 0.4 ± 0.3 
 
-6.6 ± 1.4 -2.9 ± 0.4 -4.1 ± 2.3 
O-H-LSD 7.0 ± 1.6 13.4 ± 1.7 42.4 ± 24.1 
 
-6.8 ± 2.9 28.3 ± 5.6 83.4 ± 9.5 
                    
Human indicators 
                   
Caffeine 12.0 ± 8.7 17.3 ± 1.1 29.7 ± 11.4 
 
-3.4 ± 1.2 22.9 ± 4.8 47.7 ± 8.0 
1,7-dimethylxanthine -6.6 ± 9.4 -18.3 ± 10.6 -8.9 ± 22.2 
 
-3.9 ± 5.7 1.1 ± 4.7 52.9 ± 4.2 
Nicotine -3.9 ± 0.9 -1.2 ± 4.8 1.1 ± 2.9 
 
-2.7 ± 4.2 -1.2 ± 0.9 3.6 ± 7.5 
Continine 31.7 ± 24.2 12.6 ± 12.0 70.9 ± 68.7 
 
-17.1 ± 15.0 58.2 ± 23.2 207.7 ± 40.8 
                    
Opioids and morphine derivatives 
                  
Heroin -21.4 ± 3.7 -38.7 ± 3.5 -68.4 ± 0.5 
 
-37.2 ± 1.9 -63.4 ± 0.9 -94.5 ± 0.3 
6-acetylmorphine -1.8 ± 2.0 -11.0 ± 3.3 -11.3 ± 0.3 
 
-4.9 ± 8.8 -7.9 ± 3.3 -23.6 ± 9.7 
Codeine 13.1 ± 4.8 15.9 ± 7.1 23.8 ± 2.6 
 
9.3 ± 3.4 16.1 ± 1.8 18.4 ± 1.9 
Norcodeine -0.4 ± 1.4 -3.8 ± 6.1 -2.3 ± 1.1 
 
-4.5 ± 3.0 -4.5 ± 2.1 -6.7 ± 3.8 
Oxycodone 10.0 ± 9.6 12.8 ± 0.6 5.2 ± 1.3 
 
-3.9 ± 0.7 3.0 ± 3.9 -3.1 ± 4.2 
Oxymorphone 18.2 ± 8.9 20.3 ± 8.7 13.7 ± 2.6 
 
4.3 ± 0.4 10.8 ± 2.3 19.3 ± 3.2 
Morphine 33.2 ± 9.3 35.0 ± 11.2 45.3 ± 5.2 
 
39.8 ± 3.3 49.0 ± 2.4 58.8 ± 6.5 
Morphine-3β-glucuronide -51.0 ± 3.2 -77.7 ± 0.0 -93.7 ± 0.1 
 
-84.7 ± 0.4 -96.1 ± 0.3 -99.1 ± 0.2 
Normorphine 2.7 ± 7.5 -0.7 ± 11.9 -0.4 ± 11.8 
 
8.9 ± 2.8 6.8 ± 2.6 -0.1 ± 5.7 
Dihydrocodeine 2.2 ± 0.4 1.1 ± 1.4 1.0 ± 1.6 
 
3.3 ± 0.5 9.4 ± 1.3 9.3 ± 1.6 
Buprenorphine 3.4 ± 4.5 2.8 ± 0.7 2.1 ± 1.9 
 
-1.2 ± 8.0 -3.1 ± 2.0 -7.4 ± 4.2 
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Norbuprenorphine -0.4 ± 4.9 4.2 ± 0.5 16.9 ± 2.5 
 
-7.5 ± 3.2 -3.3 ± 1.1 10.0 ± 6.4 
Methadone 4.2 ± 3.5 -3.4 ± 6.9 -11.1 ± 5.7 
 
1.9 ± 4.8 -4.7 ± 1.1 -11.3 ± 1.9 
EDDP -2.3 ± 3.8 -13.2 ± 4.3 -16.9 ± 1.1 
 
2.6 ± 19.9 -15.5 ± 0.8 -17.5 ± 6.6 
EMDP -4.4 ± 11.5 6.0 ± 6.6 12.6 ± 10.6 
 
-7.8 ± 0.1 9.7 ± 6.1 33.0 ± 36.5 
Fentanyl 0.0 ± 0.3 -1.8 ± 0.3 -4.8 ± 1.3 
 
0.6 ± 2.0 -3.6 ± 0.4 -6.1 ± 1.6 
Norfentanyl -8.5 ± 4.5 1.6 ± 4.4 9.7 ± 15.4 
 
-5.1 ± 0.0 1.2 ± 2.4 21.4 ± 0.2 
Propoxyphene  -4.3 ± 3.4 -6.7 ± 1.8 -7.9 ± 1.1 
 
-0.9 ± 0.6 -15.4 ± 2.1 -18.9 ± 0.6 
Norpropoxyphene 71.2 ± 7.8 96.5 ± 4.8 132.4 ± 18.9 
 
109.8 ± 20.7 143.7 ± 28.4 175.8 ± 23.8 
Tramadol -6.0 ± 3.3 -13.2 ± 1.3 -16.6 ± 2.1 
 
-7.0 ± 7.9 -13.5 ± 1.2 -17.6 ± 0.3 
Nortramadol -23.1 ± 3.9 -40.8 ± 2.3 -38.3 ± 3.3 
 
-16.2 ± 5.4 -34.4 ± 4.3 -37.0 ± 4.6 
                    
Benzodiazepines 
                   
Temazepam 4.8 ± 10.3 -0.9 ± 13.5 -3.4 ± 8.0 
 
2.3 ± 15.7 11.6 ± 8.3 7.5 ± 17.0 
Diazepam  -23.4 ± 12.9 -25.2 ± 10.4 -27.7 ± 7.2 
 
-18.4 ± 2.5 -36.7 ± 2.9 -44.0 ± 1.8 
Nordiazepam  13.8 ± 11.3 21.5 ± 29.8 20.0 ± 6.0 
 
1.9 ± 1.2 7.8 ± 4.7 -1.2 ± 7.3 
Nitrazepam -13.8 ± 3.3 -21.8 ± 9.5 -40.1 ± 4.2 
 
-57.4 ± 2.1 -77.2 ± 1.4 -97.2 ± 0.2 
7-aminonitrazepam 7.0 ± 5.0 -8.1 ± 0.0 -2.0 ± 6.6 
 
65.4 ± 7.6 95.4 ± 12.7 135.8 ± 36.3 
Oxazepam 6.0 ± 7.2 4.4 ± 9.6 1.9 ± 8.2 
 
1.5 ± 3.9 -2.6 ± 2.7 5.3 ± 3.3 
Chlordiazepoxide -8.7 ± 5.1 -11.4 ± 11.1 -19.4 ± 9.6 
 
-12.5 ± 2.8 -20.8 ± 8.6 -51.3 ± 0.4 
                    
Antidepressants  
                   
Dosulepin -23.7 ± 11.3 -54.2 ± 3.6 -77.1 ± 5.7 
 
-22.5 ± 1.2 -73.3 ± 3.1 -83.8 ± 7.4 
Amitriptyline -7.4 ± 3.2 -41.2 ± 0.3 -72.6 ± 3.3 
 
-11.6 ± 8.8 -68.8 ± 4.1 -81.9 ± 6.7 
Nortriptyline -28.0 ± 8.8 -57.6 ± 0.5 -85.0 ± 0.0 
 
-16.8 ± 3.2 -80.5 ± 4.0 -88.1 ± 2.6 
Fluoxetine 8.3 ± 6.7 1.1 ± 14.8 -4.8 ± 24.4 
 
1.8 ± 7.0 -10.7 ± 8.3 -11.4 ± 5.0 
Norfluoxetine 8.7 ± 10.1 -25.0 ± 20.3 3.8 ± 1.9 
 
-15.7 ± 0.6 -23.1 ± 5.4 4.8 ± 4.8 
Venlafaxine -6.5 ± 0.7 -1.0 ± 1.9 0.7 ± 11.4 
 
-2.9 ± 3.6 1.5 ± 5.0 18.3 ± 9.0 
                    
Dissociative anaesthetics 
                   
Phencyclidine  -10.5 ± 2.1 -8.3 ± 1.0 -1.6 ± 1.2 
 
-0.1 ± 12.6 -6.0 ± 5.6 2.5 ± 0.4 
Ketamine  4.5 ± 0.8 2.2 ± 5.4 4.8 ± 2.4 
 
-5.0 ± 5.8 -0.1 ± 0.5 1.6 ± 1.8 
Norketamine  2.1 ± 1.3 -0.1 ± 0.9 1.9 ± 1.4 
 
-3.8 ± 7.1 5.3 ± 5.2 2.8 ± 7.4 
                    
Other 
                   
Methaqualone -3.1 ± 4.0 7.4 ± 3.3 5.9 ± 11.5 
 
-10.2 ± 11.7 -27.6 ± 6.7 -24.5 ± 7.8 
Sildenafil 3.9 ± 0.2 -3.0 ± 1.6 -40.2 ± 11.8 
 
13.5 ± 2.7 -24.6 ± 16.3 -43.4 ± 26.7 
                    
Drug precursors 
                   
Ephedrine -16.1 ± 1.6 -27.5 ± 5.6 -25.4 ± 7.2 
 
4.0 ± 0.1 0.6 ± 5.9 -3.4 ± 11.3 
Norephedrine -40.2 ± 20.2 -59.6 ± 1.2 -64.5 ± 0.0   -4.4 ± 0.6 -29.7 ± 3.8 -39.0 ± 4.0 
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Table 6 - Percentage of analytes after three days reporting a stability change greater than 15 % 
 
  
 
 
 
WWTP influent storage condition Percentage of analytes with stability change > 15 % 
 12 hours 24 hours 72 hours 
Raw (filtered) wastewater, pH 2, 2 ˚C 2 8 25 
Raw (filtered) wastewater, pH 7.4, 2 ˚C 23 35 45 
Raw (filtered) wastewater, pH 2, 19 ˚C 2 8 17 
Raw (filtered) wastewater, pH 7.4, 19 ˚C 20 42 58 
Raw (unfiltered) wastewater, pH 7.4, 2 ˚C 34 43 54 
Raw (unfiltered) wastewater, pH 7.4, 19 ˚C 35 46 69 
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Table 7 – Summary of recoveries obtained with each parameter 
      Key  
(recovery 
change): 
  ≤± 15 %   >± 15 %   >±30 %   >±50 % 
Compound Range of recoveries obtained with each parameter (%) 
  Stabilitya   Vaccum 
filtration
b
 
  Evaporation in 
silanised/non-
silanised vialsc 
  Evaporation 
temperature
d
 
  Pre LC-
MS/MS filter
e
 
Stimulants 
                   
Cocaine 1 - -28 
 
10
1 
- 98 
 
98 - 64 
 
10
7 
- 90 
 
10
1 
- 
9
8 
Benzoylecgonine 17 - -9 
 
10
1 
- 94 
 
10
1 
- 95 
 
11
0 
- 92 
 
99 - 
9
6 
Norbenzoylecgonine 3 - -11 
 
10
3 
- 97 
 
96 - 81 
 
10
4 
- 81 
 
99 - 
9
4 
Norcocaine 0 - -31 
 
10
6 
- 
10
0  
99 - 73 
 
10
3 
- 90 
 
10
1 
- 
9
6 
Cocaethylene 0 - -19 
 
10
9 
- 
10
2  
95 - 70 
 
10
8 
- 90 
 
10
1 
- 
9
8 
Anhydroecgonine methyl 
ester 
53 - -14 
 
10
4 
- 99 
 
78 - 28 
 
93 - 40 
 
10
3 
- 
9
1 
Ecgonidine  83 - -10 
 
10
5 
- 
10
0  
11
7 
- 44 
 
78 - 44 
 
10
1 
- 
7
4 
Amphetamine   88 - -11 
 
11
0 
- 97 
 
88 - 16 
 
96 - 51 
 
10
3 
- 
9
6 
Methamphetamine  12 - -14 
 
10
8 
- 99 
 
89 - 23 
 
95 - 59 
 
10
3 
- 
9
9 
Methcathinone 6 - -78 
 
10
5 
- 99 
 
67 - 16 
 
85 - 12 
 
10
1 
- 
9
8 
BZP 
11
5 
- -4 
 
98 - 75 
 
86 - 37 
 
97 - 60 
 
10
4 
- 
9
7 
TFMPP 39 - -50 
 
10
6 
- 
10
1  
90 - 37 
 
10
0 
- 70 
 
10
3 
- 
9
8 
                    
Hallucinogens 
                   
MDA  10 - -11 
 
10
4 
- 
10
1  
99 - 41 
 
10
2 
- 83 
 
10
4 
- 
9
8 
MDMA 5 - -11 
 
10
2 
- 98 
 
96 - 40 
 
10
2 
- 84 
 
10
1 
- 
9
8 
MDEA 5 - -12 
 
10
3 
- 98 
 
97 - 35 
 
10
6 
- 81 
 
10
1 
- 
9
8 
MBDB -1 - -22 
 
10
5 
- 
10
2  
93 - 27 
 
97 - 75 
 
10
1 
- 
9
7 
BDB 3 - -38 
 
10
8 
- 
10
2  
92 - 27 
 
96 - 73 
 
10
0 
- 
9
6 
Mescaline -1 - -27 
 
10
5 
- 96 
 
96 - 76 
 
11
2 
- 82 
 
10
1 
- 
9
7 
LSD 3 - -20 
 
10
9 
- 98 
 
93 - 87 
 
10
8 
- 90 
 
10
1 
- 
9
7 
O-H-LSD 83 - -14 
 
10
5 
- 99 
 
96 - 80 
 
10
8 
- 92 
 
99 - 
9
6 
                    
Human indicators 
                   
Caffeine 48 - -15 
 
10
3 
- 99 
 
99 - 36 
 
10
8 
- 81 
 
10
3 
- 
9
6 
1,7-dimethylxanthine 53 - -41 
 
10
6 
- 94 
 
11
7 
- 91 
 
14
4 
- 91 
 
10
1 
- 
9
8 
Nicotine 4 - -17 
 
10
7 
- 24 
 
50 - 10 
 
75 - 18 
 
10
5 
- 
9
3 
Continine 
20
8 
- -17 
 
10
4 
- 
10
1  
89 - 44 
 
96 - 53 
 
10
8 
- 
7
7 
                    
Opioids and morphine 
derivatives                   
Heroin 4 - -100 
 
10
4 
- 99 
 
89 - 68 
 
91 - 34 
 
98 - 
9
5 
6-acetylmorphine -1 - -77 
 
10
6 
- 98 
 
11
8 
- 91 
 
16
4 
- 91 
 
10
3 
- 
9
8 
Codeine 24 - -4 
 
10
4 
- 97 
 
99 - 73 
 
99 - 73 
 
10
2 
- 
9
9 
Norcodeine 5 - -10 
 
10
8 
- 95 
 
97 - 68 
 
10
1 
- 68 
 
10
1 
- 
9
7 
Oxycodone 13 - -9 
 
10
4 
- 98 
 
82 - 67 
 
89 - 1 
 
10
2 
- 
9
9 
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Oxymorphone 43 - -12 
 
10
4 
- 
10
0  
10
2 
- 46 
 
92 - 1 
 
10
2 
- 
8
0 
Morphine 89 - -9 
 
10
5 
- 97 
 
11
0 
- 58 
 
10
3 
- 58 
 
10
2 
- 
8
3 
Normorphine 14 - -7 
 
10
5 
- 96 
 
10
4 
- 57 
 
93 - 57 
 
10
3 
- 
7
5 
Dihydrocodeine 9 - -8 
 
10
2 
- 95 
 
10
0 
- 77 
 
10
3 
- 77 
 
10
2 
- 
9
6 
Buprenorphine 4 - -17 
 
11
0 
- 
10
3  
89 - 78 
 
96 - 81 
 
10
3 
- 
9
6 
Norbuprenorphine 17 - -8 
 
10
5 
- 99 
 
97 - 88 
 
10
2 
- 88 
 
10
2 
- 
9
8 
Methadone 4 - -23 
 
10
9 
- 
10
3  
90 - 50 
 
95 - 79 
 
10
2 
- 
9
7 
EDDP 4 - -72 
 
99 - 95 
 
89 - 16 
 
97 - 80 
 
10
1 
- 
9
6 
EMDP 33 - -41 
 
10
2 
- 97 
 
64 - 1 
 
91 - 17 
 
99 - 
9
5 
Fentanyl 3 - -62 
 
10
3 
- 95 
 
98 - 90 
 
10
2 
- 90 
 
10
2 
- 
9
8 
Norfentanyl 21 - -23 
 
10
6 
- 
10
3  
98 - 87 
 
10
3 
- 87 
 
99 - 
9
6 
Propoxyphene  25 - -19 
 
10
9 
- 95 
 
96 - 45 
 
11
5 
- 77 
 
10
1 
- 
9
4 
Norpropoxyphene 
17
6 
- -21 
 
10
7 
- 
10
6  
67
6 
- 
11
9  
71
7 
- 
15
2  
10
0 
- 
9
4 
Tramadol 3 - -33 
 
98 - 96 
 
89 - 37 
 
93 - 78 
 
10
2 
- 
9
7 
Nortramadol 11 - -63 
 
10
3 
- 
10
0  
98 - 81 
 
10
9 
- 87 
 
10
2 
- 
9
8 
                    
Benzodiazepines 
                   
Temazepam 19 - -63 
 
10
5 
- 96 
 
90 - 86 
 
10
6 
- 79 
 
10
1 
- 
9
7 
Diazepam  -3 - -44 
 
10
7 
- 
10
1  
97 - 88 
 
10
8 
- 82 
 
10
2 
- 
9
8 
Nordiazepam  50 - -22 
 
10
4 
- 96 
 
91 - 76 
 
10
2 
- 70 
 
10
0 
- 
9
0 
Nitrazepam -10 - -100 
 
96 - 96 
 
80 - 66 
 
95 - 44 
 
95 - 
8
2 
7-aminonitrazepam 
13
6 
- -8 
 
95 - 91 
 
94 - 58 
 
11
7 
- 73 
 
10
1 
- 
9
5 
Oxazepam 8 - -29 
 
10
4 
- 98 
 
10
1 
- 86 
 
11
6 
- 80 
 
10
0 
- 
9
5 
Chlordiazepoxide 13 - -51 
 
11
4 
- 
10
1  
10
7 
- 86 
 
11
3 
- 87 
 
10
2 
- 
9
8 
                    
Antidepressants  
                   
Dosulepin 5 - -84 
 
10
5 
- 95 
 
90 - 47 
 
92 - 47 
 
10
3 
- 
9
8 
Amitriptyline 10 - -82 
 
10
4 
- 91 
 
90 - 45 
 
93 - 58 
 
10
2 
- 
9
8 
Nortriptyline -4 - -88 
 
10
4 
- 93 
 
83 - 39 
 
85 - 47 
 
10
2 
- 
9
8 
Fluoxetine 8 - -55 
 
10
8 
- 96 
 
82 - 19 
 
92 - 25 
 
10
2 
- 
9
6 
Norfluoxetine 9 - -56 
 
10
5 
- 96 
 
74 - 19 
 
81 - 27 
 
10
2 
- 
9
8 
Venlafaxine 18 - -44 
 
10
9 
- 
10
1  
10
0 
- 61 
 
10
4 
- 91 
 
10
1 
- 
9
7 
                    
Dissociative anaesthetics 
                   
Phencyclidine  3 - -25 
 
11
1 
- 
10
6  
95 - 20 
 
10
6 
- 41 
 
10
1 
- 
9
7 
Ketamine  5 - -5 
 
10
2 
- 97 
 
88 - 20 
 
97 - 47 
 
10
0 
- 
9
7 
Norketamine  5 - -11 
 
10
0 
- 91 
 
74 - 20 
 
89 - 47 
 
99 - 
9
7 
                    
Other 
                   
Methaqualone 7 - -28 
 
11
4 
- 
10
1  
94 - 21 
 
10
9 
- 63 
 
97 - 
9
2 
Sildenafil 28 - -53 
 
11
3 
- 84 
 
86 - 40 
 
88 - 56 
 
10
2 
- 
9
5 
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Drug precursors 
                   
Ephedrine/Pseudoephedrine  4 - -57 
 
10
5 
- 
10
2  
10
0 
- 32 
 
10
5 
- 59 
 
10
0 
- 
9
7 
Norephedrine 5 - -84   
10
7 
- 97   
11
4 
- 33   
12
2 
- 31   
10
0 
- 
9
5 
aStability of analytes in various storage conditions encountered during sample collection and storage 
bFiltration of spiked river water through glass fibre filters (see supplementary material) 
cEvaporation of SPE extracts in silanised and nonsilanised vials 
dEvaporation of SPE extracts at temperatures 20 - 50 ˚C 
eRecovery of compounds after filtration through various pre-LC-MS/MS filters (see supplementary material) 
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Figure S1 – Stability of analytes on Oasis MCX cartridges, extracted from the spiked WWTP influent, and stored at -20 ˚C over a 6 week 
period (n = 2 at each time-point) 
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Table S1 - Selected pharmaceuticals and their properties 
 
Compound CAS Formula MW Pka  LogP Supplier 
        Experimentala Calculatedb Experimentala Calculatedb   
Stimulants and their metabolites         
Cocaine 50-36-2 C17H21NO4 303.4 8.6 (20°) 8.9 2.3 2.3 LGC 
Benzoylecgonine 519-09-5 C16H19NO4 289.3  10.8, 3.3 −1.3 2.3 LGC 
Norbenzoylecgonine 60426-41-7 C15H17NO4 275.3  10.4, 3.4  2.6 LGC 
Norcocaine N/A C16H19NO4 289.3  9.0  3.1 LGC 
Cocaethylene 529-38-4 C18H23NO4 317.4  9.0  2.8 LGC 
Anhydroecgonine methyl ester 43021-26-7 C10H
15NO2 181.2  8.0  0.4 LGC 
Ecgonidine  74242-55-0 C8H11NO2 153.2  9.6, 3.8  1.5 LGC 
Amphetamine   300-62-9             C9H13N 135.2 10.1 9.9 1.8 1.8 LGC 
Methamphetamine  
R-(-):33817-09-3,  
S-(+):537-46-2                                                                           
C10H15N 149.2 10.1 10.4 2.1 2.2 LGC 
Methcathinone 49656-78-2 C10H13NO 163.2  7.1  0.4 Sigma-Aldrich 
BZP (Benzylpiperazine) N/A C11H16N2 176.3  9.3, 3.4  1.1 LGC 
TFMPP (Trifluoromethylphenylpiperazine) N/A C11H13F3N2 230.2  8.8, 2.1  1.3 LGC 
         
Hallucinogens and their metabolites         
MDA (Methylenedioxyamphetamine) 4764-17-4 C10H13NO2 179.2  9.9 1.64 1.6 LGC 
MDMA (Methylenedioxymethamphetamine) 4254210-9 C11H15NO2 193.2 (benzene, pH 9.0) 9.4 10.3  2.1 LGC 
MDEA (Methylenedioxyethylamphetamine) 82801-81-8 C12H17NO2 207.3  10.3  2.6 LGC 
MBDB (Methylbenzodioxolylbutanamine) 145225-00-9 C12H17NO2 207.3  10.5  2.6 LGC 
BDB (Benzodioxolylbutanamine) N/A C11H15NO2 193.2  10  2.2 LGC 
Mescaline 832-92-8 C11H17NO3 211.3 9.6 9.6 0.8 0.5 LGC 
LSD (Lysergic acid diethylamide) 50-37-3 C20H25N3O 323.4 7.5 7.4   2.9 2.7 LGC 
O-H-LSD (2-oxo-3-hydroxy lysergic acid diethylamide) N/A C20H25N3O3 355.4  11.7, 6.8  -1.9 LGC 
         
Human indicators         
Caffeine 58-08-2 C8H10N4O2 194.2 14.0 (25°), 10.4 (40°) 0.5  −0.07 -0.6 Sigma-Aldrich 
1,7-dimethylxanthine 611-59-6 C7H8N4O2 180.2  8.5, 0.2   -0.9 Sigma-Aldrich 
Nicotine 54-11-5 C10H14N2 162.2 7.9, 3.2, (25°) 8.0, 3.2   1.2 0.6 Sigma-Aldrich 
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Continine 486-56-6 C10H12N2O 176.2  4.7  0.07 Sigma-Aldrich 
Creatinine 60-27-5 C4H7N3O 113.1  6.9  -0.8 Fisher-Acros 
         
Opioids, morphine derivatives and their metabolites        
Heroin 561-27-3 C21H23NO5 369.4 7.6 (23°) 7.9 1.58 1.6 LGC 
6-acetylmorphine 2784-73-8 C19H21NO4 327.4  9.4, 8.0  1.6 LGC 
Codeine 76-57-3 C18H21NO3 299.4 8.2 (20°) 13.4, 8.2 0.6 1.4 Sigma-Aldrich 
Norcodeine 467-15-2 C17H19NO3 285.3 9.2 (25°) 13.3, 9.3 0.7 0.5 LGC 
Oxycodone 76-42-6 C18H21NO4 315.4 8.9 (20°) 13.1, 7.6 0.7 1.6 LGC 
Oxymorphone 76-41-5 C17H19NO4 301.3 9.3, 8.5  13.5, 9.2, 7.6 0 1.2 LGC 
Morphine 57-27-2 C17H19NO3 285.3 9.9, 8.0 (20°) 13.5, 9.5, 8.3 –0.1 0.9 LGC 
Normorphine 466-97-7 C16H17NO3 271.3 9.8 (25°) 13.4, 9.5, 9.2 −2.8 0.0 LGC 
Dihydrocodeine 125-28-0 C18H23NO3 301.4 8.8 (25°) 8.4    0.6 LGC 
Buprenorphine 52485-79-7 C29H41NO4 467.6 8.5, 10.0 9.5, 8.3 5.0 2.8 LGC 
Norbuprenorphine 78715-23-8 C25H35NO4 413.6  9.8, 9.1  1.2 LGC 
Methadone 76-99-3 C21H27NO 309.4 
8.94 (25°),  
8.3 (20°) 
9.1 3.9 3.9 Sigma-Aldrich 
EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine) 66729-78-0 C21H25N 291.4  8.4  5.0 LGC 
EMDP (2-ethyl-5-methyl-3,3-diphenylpyraline) N/A C20H23N 277.4  8.1  5.8 LGC 
Fentanyl 437-38-7 C22H28N2O 336.5  8.9, 0.3 2.3 3.7 LGC 
Norfentanyl N/A C14H20N2O 232.3  9.8, 0.3  1.7 LGC 
Propoxyphene  469-62-5 C22H29NO2 339.5 6.3 9.2 4.2 4.1 LGC 
Norpropoxyphene 159208-83-0 C21H27NO2 325.4  10.1  3.7 LGC 
Tramadol 36282-47-0 C16H25NO2 263.4 9.4, 8.3 9.6 3.0 2.3 Sigma-Aldrich 
Nortramadol N/A C15H23NO2 249.4  10.6  1.7 LGC 
         
Benzodiazepines and their metabolites         
Temazepam 846-50-4 C16H13ClN2O2 300.7 1.6 11.7, 1.6 2.2 2.2 LGC 
Diazepam 439-15-5 C16H13ClN2O 284.7 3.3 (20°) 3.4 2.7 2.8 LGC 
Nordiazepam  1088-11-5 C15H11ClN2O 270.7 12.0, 3.5  11.7, 3.2 2.9 2.8 LGC 
Nitrazepam 146-22-5 C15H11N3O3 281.3 10.8, 3.2 (20°) 11.4, 2.6 2.1 2.4 Sigma-Aldrich 
7-aminonitrazepam 4928-02-3 C15H13N3O 251.3  12.3, 4.3, 2.3  1.1 LGC 
 42 
 
Oxazepam 604-75-1 C15H11ClN2O2 286.7 11.6, 1.7 (20°) 12.8, 10.9, 1.2 2.2 2.2 LGC 
Chlordiazepoxide 58-25-3 C16H14ClN3O 299.8 4.8 8.6, 6.5 2.4 2.8 LGC 
         
Antidepressants and their metabolites         
Dosulepin 113-53-1 C19H21NS 295.4  9.1 2.8 4.3 LGC 
Amitriptyline 549-18-8 C20H23N 277.4 9.4 (25°) 9.2 5.0 4.4 Sigma-Aldrich 
Nortriptyline 894-71-3 C19H21N 263.4 9.7 10.0 1.7 4.0 Sigma-Aldrich 
Fluoxetine 59333-67-4 C17H18F3NO 309.3  10.1 1.8 3.9 LGC 
Norfluoxetine N/A C16H16F3NO 295.3  9.1  3.8 LGC 
Venlafaxine 99300-78-4 C17H27NO2 277.4  9.3 0.4 2.5 Sigma-Aldrich 
         
Dissociative anesthetics and their metabolites        
PCP (phencyclidine) 77-10-1 C17H25N 243.4 8.5 8.2 4.7 4.3 LGC 
Ketamine  1867-66-9 C13H16ClNO 237.7 7.5 6.5 3.1 3.0 Sigma-Aldrich 
Norketamine  N/A C12H14ClNO 223.7 6.7 6.3  2.4 LGC 
         
Other         
Methaqualone 72-44-6 C16H14N2O 250.3 2.5 3.0 4.3 2.5 LGC 
Sildenafil 139755-83-23 C22H30N6O4S 474.6 8.7 6.0, 0.6  1.6 LGC 
         
Drug precursors         
Ephedrine 50-98-6 C10H15NO 165.2 9.6 (25°) 9.5 1.1 1.0 LGC 
Norephedrine 154-41-6 C9H13NO 151.2  12.1, 8.5  0.4 Sigma-Aldrich 
Pseudoephedrine  345-78-8 C10H15NO 165.2 9.8 9.5 0.9 1.0 Sigma-Aldrich 
 
a Moffat, A.C.; Osselton, D. M.; Widdop, B. Clarke's analysis of drugs and poisons, pharmaceutical press 2004, http://www.medicinescomplete.com/mc/clarke/current/, accessed June 2009 
b ACD/I-lab accessed via ACD/chemsketch, version 12.0, Advanced chemistry development Inc. Toronto, ON, Canada. www.acdlabs.com 
 
 
 43 
 
Table S2 – Absolute recovery of analytes in basic methanol after the evaporation of solvent 
Compound Evaporation from 7% (v/v) NH4OH/MeOH, recovery (%) (n = 3)               
 
Evaporation temperature                             
  20 °C   30 °C   40 °C   50 °C   60 °C 
Stimulants 
                   
Cocaine 100 ± 5 
 
96 ± 2 
 
98 ± 4 
 
92 ± 3 
 
90 ± 2 
Cocaine-d3 100 ± 6  
97 ± 1 
 
97 ± 5 
 
92 ± 2 
 
92 ± 1 
Benzoylecgonine 101 ± 5 
 
94 ± 3 
 
97 ± 7 
 
92 ± 6 
 
95 ± 2 
Benzoylecgonine-d8 103 ± 6  
95 ± 5 
 
97 ± 8 
 
92 ± 2 
 
93 ± 3 
Ecgonine methyl ester 81 ± 5 
 
78 ± 5 
 
72 ± 4 
 
45 ± 2 
 
37 ± 9 
Ecgonine methyl ester-d3 92 ± 18  
95 ± 11 
 
84 ± 6 
 
60 ± 6 
 
43 ± 18 
Norbenzoylecgonine 102 ± 2 
 
93 ± 2 
 
94 ± 4 
 
91 ± 5 
 
93 ± 3 
Norcocaine 100 ± 5 
 
98 ± 2 
 
99 ± 7 
 
90 ± 2 
 
90 ± 3 
Cocaethylene 96 ± 1 
 
94 ± 1 
 
95 ± 5 
 
93 ± 3 
 
90 ± 3 
Cocaethylene-d8 94 ± 1  
96 ± 2 
 
93 ± 4 
 
95 ± 1 
 
91 ± 1 
Anhydroecgonine methyl ester 91 ± 5 
 
93 ± 1 
 
75 ± 1 
 
56 ± 10 
 
40 ± 2 
Ecgonidine  78 ± 4 
 
77 ± 3 
 
67 ± 10 
 
61 ± 2 
 
57 ± 11 
Amphetamine   85 ± 2 
 
96 ± 4 
 
88 ± 4 
 
66 ± 12 
 
51 ± 3 
Amphetamine-d11 92 ± 7  
102 ± 2 
 
95 ± 2 
 
76 ± 14 
 
61 ± 2 
Methamphetamine  90 ± 7 
 
95 ± 6 
 
89 ± 1 
 
68 ± 11 
 
59 ± 5 
Methamphetamine-d14 92 ± 7  
94 ± 2 
 
85 ± 2 
 
69 ± 12 
 
58 ± 4 
Methcathinone 84 ± 7 
 
85 ± 8 
 
67 ± 4 
 
45 ± 12 
 
32 ± 5 
BZP 97 ± 7 
 
93 ± 4 
 
86 ± 2 
 
78 ± 6 
 
79 ± 7 
TFMPP 98 ± 3 
 
93 ± 1 
 
90 ± 3 
 
76 ± 6 
 
70 ± 8 
                    
Hallucinogens 
                   
MDA  99 ± 3 
 
102 ± 3 
 
99 ± 5 
 
87 ± 4 
 
87 ± 6 
MDA-d5 101 ± 7  
96 ± 5 
 
92 ± 7 
 
83 ± 2 
 
88 ± 4 
MDMA 102 ± 5 
 
99 ± 1 
 
96 ± 6 
 
88 ± 4 
 
89 ± 8 
MDMA-d5 101 ± 7  
98 ± 2 
 
96 ± 8 
 
89 ± 3 
 
86 ± 3 
MDEA 106 ± 3 
 
96 ± 1 
 
97 ± 5 
 
88 ± 4 
 
87 ± 4 
MDEA-d5 99 ± 4  
98 ± 1 
 
90 ± 6 
 
88 ± 4 
 
86 ± 4 
MBDB 95 ± 3 
 
95 ± 2 
 
93 ± 2 
 
78 ± 6 
 
75 ± 8 
MBDB-d5 95 ± 3  
95 ± 1 
 
91 ± 4 
 
83 ± 3 
 
77 ± 6 
BDB 94 ± 1 
 
96 ± 2 
 
92 ± 5 
 
76 ± 4 
 
73 ± 8 
Mescaline 111 ± 8 
 
96 ± 3 
 
96 ± 9 
 
83 ± 4 
 
82 ± 4 
Mescaline-d9 107 ± 9  
97 ± 6 
 
91 ± 6 
 
82 ± 3 
 
82 ± 2 
LSD 92 ± 1 
 
90 ± 3 
 
93 ± 3 
 
92 ± 3 
 
90 ± 2 
LSD-d3 91 ± 4  
95 ± 1 
 
92 ± 3 
 
94 ± 2 
 
92 ± 1 
O-H-LSD 103 ± 1 
 
102 ± 9 
 
96 ± 7 
 
92 ± 5 
 
94 ± 3 
                    
Human indicators 
                   
Caffeine 108 ± 4 
 
96 ± 2 
 
99 ± 6 
 
89 ± 5 
 
81 ± 8 
Caffeine-d9 105 ± 8  
100 ± 3 
 
95 ± 6 
 
91 ± 5 
 
83 ± 6 
1,7-dimethylxanthine 118 ± 5 
 
110 ± 4 
 
111 ± 10 
 
104 ± 4 
 
108 ± 2 
Nicotine 75 ± 16 
 
71 ± 33 
 
50 ± 13 
 
21 ± 6 
 
18 ± 13 
Nicotine-d4 72 ± 11  
72 ± 32 
 
50 ± 14 
 
22 ± 7 
 
19 ± 13 
Continine 96 ± 6 
 
91 ± 3 
 
89 ± 12 
 
80 ± 1 
 
62 ± 11 
Creatinine 20 ± 2 
 
28 ± 12 
 
40 ± 11 
 
38 ± 4 
 
29 ± 5 
                    
Opioids and morphine derivatives 
            
Heroin 72 ± 5 
 
46 ± 1 
 
68 ± 4 
 
81 ± 4 
 
81 ± 3 
Heroin-d9 84 ± 5  
44 ± 2 
 
69 ± 6 
 
81 ± 5 
 
81 ± 5 
6-acetylmorphine 123 ± 3 
 
134 ± 6 
 
118 ± 8 
 
105 ± 3 
 
111 ± 2 
Codeine 98 ± 2 
 
97 ± 3 
 
99 ± 9 
 
96 ± 5 
 
97 ± 3 
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Codeine-d6 99 ± 4  
102 ± 2 
 
99 ± 7 
 
99 ± 2 
 
99 ± 1 
Norcodeine 101 ± 4 
 
98 ± 3 
 
97 ± 6 
 
92 ± 6 
 
93 ± 1 
Oxycodone 87 ± 3 
 
89 ± 2 
 
82 ± 5 
 
61 ± 5 
 
57 ± 6 
Oxycodone-d6 94 ± 2  
95 ± 0 
 
85 ± 7 
 
70 ± 5 
 
64 ± 5 
Oxymorphone 92 ± 5 
 
88 ± 3 
 
83 ± 9 
 
67 ± 7 
 
56 ± 1 
Morphine 103 ± 4 
 
102 ± 4 
 
102 ± 12 
 
100 ± 9 
 
92 ± 5 
Morphine-d6 103 ± 6  
101 ± 3 
 
99 ± 11 
 
100 ± 8 
 
88 ± 9 
Normorphine 93 ± 2 
 
90 ± 2 
 
92 ± 10 
 
90 ± 6 
 
81 ± 5 
Dihydrocodeine 103 ± 4 
 
99 ± 2 
 
100 ± 8 
 
101 ± 4 
 
100 ± 2 
Dihydrocodeine-d6 96 ± 7  
97 ± 7 
 
96 ± 7 
 
93 ± 1 
 
96 ± 3 
Buprenorphine 90 ± 3 
 
90 ± 0 
 
89 ± 1 
 
88 ± 5 
 
88 ± 4 
Buprenorphine-d4 88 ± 4  
90 ± 1 
 
85 ± 4 
 
87 ± 5 
 
88 ± 4 
Norbuprenorphine 96 ± 2 
 
96 ± 1 
 
95 ± 4 
 
92 ± 4 
 
92 ± 4 
Methadone 92 ± 1 
 
94 ± 6 
 
90 ± 4 
 
89 ± 5 
 
86 ± 3 
Methadone-d9 91 ± 2  
96 ± 2 
 
90 ± 6 
 
91 ± 2 
 
88 ± 3 
EDDP 84 ± 3 
 
84 ± 5 
 
89 ± 2 
 
87 ± 6 
 
82 ± 8 
EDDP-d3 85 ± 4  
84 ± 2 
 
89 ± 0 
 
89 ± 5 
 
85 ± 6 
EMDP 73 ± 9 
 
70 ± 28 
 
30 ± 1 
 
26 ± 2 
 
17 ± 6 
Fentanyl 97 ± 3 
 
98 ± 3 
 
98 ± 4 
 
96 ± 3 
 
100 ± 2 
Fentanyl-d5 96 ± 2  
97 ± 4 
 
95 ± 3 
 
95 ± 3 
 
95 ± 4 
Norfentanyl 100 ± 4 
 
96 ± 2 
 
98 ± 6 
 
92 ± 5 
 
95 ± 4 
Propoxyphene  98 ± 4 
 
99 ± 1 
 
96 ± 5 
 
82 ± 6 
 
77 ± 4 
Propoxyphene-d11 95 ± 7  
100 ± 3 
 
95 ± 3 
 
84 ± 1 
 
79 ± 5 
Norpropoxyphene 717 ± 50 
 
635 ± 10 
 
638 ± 51 
 
454 ± 1 
 
326 ± 32 
Norpropoxyphene-d5 584 ± 45  
532 ± 34 
 
512 ± 34 
 
366 ± 10 
 
256 ± 16 
Tramadol 93 ± 2 
 
84 ± 2 
 
89 ± 5 
 
83 ± 3 
 
79 ± 3 
Nortramadol 101 ± 9 
 
100 ± 11 
 
98 ± 13 
 
87 ± 8 
 
95 ± 9 
                    
Benzodiazepines 
                   
Temazepam 94 ± 3 
 
96 ± 3 
 
89 ± 3 
 
81 ± 7 
 
79 ± 7 
Temazepam-d5 93 ± 5  
95 ± 6 
 
86 ± 3 
 
80 ± 8 
 
76 ± 8 
Diazepam  95 ± 4 
 
91 ± 1 
 
88 ± 5 
 
83 ± 6 
 
82 ± 10 
Diazepam-d5 94 ± 3  
94 ± 3 
 
87 ± 2 
 
83 ± 6 
 
83 ± 9 
Nordiazepam  92 ± 6 
 
88 ± 2 
 
85 ± 2 
 
74 ± 6 
 
70 ± 6 
Nitrazepam 87 ± 5 
 
76 ± 5 
 
66 ± 3 
 
54 ± 3 
 
44 ± 5 
7-aminonitrazepam 114 ± 2 
 
117 ± 5 
 
94 ± 6 
 
73 ± 2 
 
76 ± 1 
Oxazepam 91 ± 8 
 
94 ± 2 
 
87 ± 4 
 
80 ± 6 
 
80 ± 8 
Oxazepam-d5 93 ± 4  
93 ± 2 
 
86 ± 3 
 
80 ± 6 
 
81 ± 8 
Chlordiazepoxide 113 ± 1 
 
108 ± 1 
 
107 ± 7 
 
99 ± 5 
 
105 ± 7 
                    
Antidepressants  
                   
Dosulepin 92 ± 5 
 
90 ± 0 
 
90 ± 6 
 
87 ± 1 
 
88 ± 4 
Amitriptyline 93 ± 3 
 
92 ± 1 
 
90 ± 3 
 
84 ± 3 
 
80 ± 2 
Nortriptyline 85 ± 3 
 
82 ± 4 
 
79 ± 4 
 
75 ± 3 
 
75 ± 4 
Fluoxetine 92 ± 6 
 
87 ± 4 
 
82 ± 7 
 
73 ± 4 
 
78 ± 1 
Fluoxetine-d6 88 ± 5  
87 ± 1 
 
81 ± 4 
 
75 ± 5 
 
74 ± 3 
Norfluoxetine 80 ± 2 
 
81 ± 2 
 
74 ± 5 
 
66 ± 5 
 
66 ± 1 
Venlafaxine 99 ± 3 
 
100 ± 4 
 
100 ± 5 
 
92 ± 5 
 
91 ± 4 
                    
Dissociative anesthetics 
                   
Phencyclidine  89 ± 5 
 
97 ± 2 
 
86 ± 6 
 
58 ± 14 
 
41 ± 5 
PCP-d5 84 ± 7  
93 ± 3 
 
80 ± 3 
 
59 ± 14 
 
43 ± 7 
Ketamine  95 ± 5 
 
93 ± 7 
 
84 ± 3 
 
65 ± 8 
 
47 ± 1 
Ketamine-d4 94 ± 4  
92 ± 2 
 
80 ± 1 
 
63 ± 10 
 
44 ± 1 
Norketamine  86 ± 4 
 
89 ± 9 
 
74 ± 3 
 
57 ± 4 
 
48 ± 8 
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Other 
                   
Methaqualone 93 ± 3 
 
89 ± 5 
 
83 ± 4 
 
73 ± 6 
 
63 ± 5 
Methaqualone-d7 94 ± 2  
90 ± 2 
 
86 ± 6 
 
81 ± 5 
 
72 ± 4 
Sildenafil 86 ± 6 
 
82 ± 2 
 
82 ± 9 
 
85 ± 5 
 
86 ± 4 
                    
Drug precursors 
                   
Ephedrine  103 ± 11 
 
105 ± 5 
 
100 ± 7 
 
83 ± 5 
 
89 ± 6 
Norephedrine 114 ± 9   122 ± 6   114 ± 22   109 ± 6   107 ± 2 
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Table S3 – Absolute recovery of analytes in methanol after the evaporation of solvent 
Compound Evaporation from MeOH, recovery (%) (n=3)                     
 
Evaporation temperature                             
  20°C   30°C   40°C   50°C   60°C 
Stimulants       
 
      
 
      
 
      
 
      
Cocaine 99 ± 6 
 
101 ± 1 
 
95 ± 5 
 
107 ± 6 
 
105 ± 1 
Cocaine-d3 95 ± 3  
96 ± 2 
 
89 ± 4 
 
101 ± 7 
 
101 ± 2 
Benzoylecgonine 97 ± 2 
 
98 ± 0 
 
95 ± 3 
 
107 ± 3 
 
110 ± 3 
Benzoylecgonine-d8 100 ± 5  
101 ± 6 
 
96 ± 4 
 
110 ± 8 
 
115 ± 5 
Ecgonine methyl ester 108 ± 8 
 
107 ± 7 
 
100 ± 3 
 
83 ± 19 
 
112 ± 8 
Ecgonine methyl ester-d3 102 ± 8  
106 ± 10 
 
98 ± 9 
 
72 ± 13 
 
105 ± 5 
Norbenzoylecgonine 86 ± 3 
 
87 ± 0 
 
81 ± 4 
 
104 ± 12 
 
100 ± 5 
Norcocaine 99 ± 4 
 
103 ± 2 
 
95 ± 4 
 
103 ± 4 
 
103 ± 2 
Cocaethylene 101 ± 3 
 
103 ± 1 
 
93 ± 2 
 
108 ± 3 
 
106 ± 3 
Cocaethylene-d8 93 ± 2  
95 ± 1 
 
90 ± 2 
 
101 ± 7 
 
101 ± 1 
Anhydroecgonine methyl ester 88 ± 3 
 
89 ± 2 
 
78 ± 3 
 
65 ± 11 
 
66 ± 3 
Ecgonidine  49 ± 1 
 
48 ± 3 
 
44 ± 1 
 
55 ± 14 
 
51 ± 2 
Amphetamine   67 ± 8 
 
74 ± 1 
 
67 ± 3 
 
66 ± 5 
 
85 ± 3 
Amphetamine-d11 74 ± 9  
81 ± 3 
 
72 ± 2 
 
72 ± 1 
 
90 ± 2 
Methamphetamine  85 ± 10 
 
94 ± 2 
 
81 ± 2 
 
84 ± 11 
 
95 ± 3 
Methamphetamine-d14 87 ± 7  
93 ± 3 
 
80 ± 2 
 
81 ± 13 
 
92 ± 2 
Methcathinone 40 ± 3 
 
46 ± 5 
 
33 ± 2 
 
31 ± 3 
 
12 ± 1 
BZP 70 ± 4 
 
73 ± 1 
 
60 ± 1 
 
68 ± 10 
 
63 ± 3 
TFMPP 100 ± 3 
 
96 ± 1 
 
87 ± 3 
 
89 ± 7 
 
89 ± 3 
                    
Hallucinogens 
                   
MDA  89 ± 6 
 
94 ± 3 
 
83 ± 3 
 
93 ± 7 
 
102 ± 3 
MDA-d5 86 ± 8  
91 ± 4 
 
79 ± 2 
 
88 ± 5 
 
98 ± 2 
MDMA 92 ± 9 
 
97 ± 3 
 
84 ± 3 
 
93 ± 5 
 
98 ± 4 
MDMA-d5 91 ± 8  
93 ± 5 
 
83 ± 1 
 
95 ± 7 
 
97 ± 2 
MDEA 88 ± 1 
 
89 ± 2 
 
81 ± 4 
 
93 ± 4 
 
93 ± 1 
MDEA-d5 85 ± 5  
87 ± 3 
 
78 ± 1 
 
92 ± 9 
 
91 ± 2 
MBDB 90 ± 4 
 
93 ± 0 
 
88 ± 2 
 
92 ± 9 
 
97 ± 3 
MBDB-d5 89 ± 4  
91 ± 2 
 
85 ± 2 
 
92 ± 7 
 
94 ± 1 
BDB 77 ± 6 
 
83 ± 1 
 
79 ± 3 
 
86 ± 7 
 
90 ± 5 
Mescaline 108 ± 8 
 
112 ± 4 
 
94 ± 6 
 
98 ± 5 
 
105 ± 2 
Mescaline-d9 103 ± 5  
107 ± 4 
 
90 ± 1 
 
97 ± 9 
 
106 ± 1 
LSD 96 ± 5 
 
100 ± 2 
 
93 ± 3 
 
108 ± 6 
 
101 ± 5 
LSD-d3 92 ± 6  
94 ± 5 
 
86 ± 1 
 
102 ± 9 
 
98 ± 2 
O-H-LSD 106 ± 5 
 
108 ± 3 
 
96 ± 3 
 
103 ± 5 
 
104 ± 5 
                    
Human indicators 
                   
Caffeine 96 ± 3 
 
98 ± 6 
 
90 ± 3 
 
101 ± 10 
 
99 ± 5 
Caffeine-d9 94 ± 4  
95 ± 5 
 
88 ± 4 
 
99 ± 8 
 
104 ± 0 
1,7-dimethylxanthine 93 ± 2 
 
96 ± 1 
 
91 ± 4 
 
121 ± 19 
 
144 ± 3 
Nicotine 61 ± 5 
 
64 ± 2 
 
48 ± 3 
 
27 ± 7 
 
26 ± 4 
Nicotine-d4 64 ± 5  
67 ± 4 
 
52 ± 2 
 
30 ± 8 
 
29 ± 3 
Continine 56 ± 2 
 
57 ± 1 
 
53 ± 0 
 
81 ± 1 
 
70 ± 2 
Creatinine 3 ± 0 
 
3 ± 0 
 
3 ± 0 
 
18 ± 21 
 
5 ± 0 
                    
Opioids and morphine derivatives 
              
Heroin 91 ± 1 
 
90 ± 3 
 
85 ± 4 
 
90 ± 8 
 
34 ± 0 
Heroin-d9 97 ± 2  
92 ± 9 
 
86 ± 1 
 
90 ± 9 
 
29 ± 1 
6-acetylmorphine 93 ± 5 
 
97 ± 1 
 
91 ± 3 
 
115 ± 11 
 
164 ± 5 
Codeine 77 ± 5 
 
80 ± 2 
 
73 ± 3 
 
93 ± 22 
 
85 ± 6 
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Codeine-d6 74 ± 5  
77 ± 2 
 
71 ± 3 
 
99 ± 23 
 
83 ± 1 
Norcodeine 72 ± 4 
 
74 ± 2 
 
68 ± 2 
 
89 ± 20 
 
80 ± 2 
Oxycodone 80 ± 5 
 
85 ± 2 
 
67 ± 2 
 
63 ± 21 
 
1 ± 0 
Oxycodone-d6 86 ± 5  
88 ± 3 
 
68 ± 2 
 
65 ± 20 
 
1 ± 0 
Oxymorphone 53 ± 1 
 
53 ± 1 
 
46 ± 1 
 
48 ± 24 
 
1 ± 0 
Morphine 59 ± 3 
 
61 ± 1 
 
58 ± 1 
 
82 ± 24 
 
74 ± 2 
Morphine-d6 60 ± 4  
61 ± 4 
 
57 ± 1 
 
95 ± 30 
 
76 ± 1 
Normorphine 57 ± 1 
 
58 ± 2 
 
57 ± 1 
 
78 ± 24 
 
74 ± 2 
Dihydrocodeine 80 ± 3 
 
82 ± 3 
 
77 ± 2 
 
96 ± 25 
 
89 ± 4 
Dihydrocodeine-d6 79 ± 1  
82 ± 4 
 
74 ± 2 
 
101 ± 21 
 
91 ± 1 
Buprenorphine 90 ± 3 
 
90 ± 2 
 
81 ± 3 
 
96 ± 7 
 
90 ± 3 
Buprenorphine-d4 89 ± 2  
89 ± 2 
 
78 ± 2 
 
95 ± 11 
 
89 ± 2 
Norbuprenorphine 99 ± 3 
 
99 ± 1 
 
88 ± 4 
 
102 ± 8 
 
98 ± 4 
Methadone 87 ± 1 
 
89 ± 2 
 
79 ± 5 
 
95 ± 7 
 
85 ± 1 
Methadone-d9 82 ± 3  
86 ± 1 
 
74 ± 2 
 
94 ± 11 
 
85 ± 2 
EDDP 97 ± 2 
 
96 ± 2 
 
85 ± 3 
 
80 ± 7 
 
82 ± 1 
EDDP-d3 95 ± 2  
96 ± 1 
 
85 ± 3 
 
83 ± 6 
 
83 ± 3 
EMDP 91 ± 4 
 
90 ± 7 
 
64 ± 6 
 
25 ± 2 
 
28 ± 1 
Fentanyl 96 ± 3 
 
98 ± 1 
 
90 ± 1 
 
102 ± 7 
 
98 ± 5 
Fentanyl-d5 101 ± 3  
101 ± 3 
 
90 ± 3 
 
104 ± 12 
 
101 ± 2 
Norfentanyl 92 ± 2 
 
93 ± 1 
 
87 ± 2 
 
99 ± 5 
 
103 ± 2 
Propoxyphene  109 ± 7 
 
115 ± 2 
 
92 ± 2 
 
105 ± 9 
 
97 ± 4 
Propoxyphene-d11 103 ± 6  
110 ± 5 
 
93 ± 3 
 
103 ± 8 
 
98 ± 2 
Norpropoxyphene 187 ± 63 
 
261 ± 8 
 
246 ± 14 
 
517 ± 154 
 
152 ± 9 
Norpropoxyphene-d5 167 ± 57  
224 ± 9 
 
200 ± 8 
 
418 ± 115 
 
111 ± 8 
Tramadol 85 ± 4 
 
89 ± 2 
 
83 ± 3 
 
90 ± 6 
 
78 ± 2 
Nortramadol 98 ± 10 
 
109 ± 12 
 
89 ± 1 
 
106 ± 8 
 
104 ± 5 
                    
Benzodiazepines 
                   
Temazepam 100 ± 6 
 
106 ± 3 
 
90 ± 0 
 
92 ± 7 
 
89 ± 5 
Temazepam-d5 102 ± 9  
107 ± 6 
 
90 ± 2 
 
91 ± 2 
 
89 ± 2 
Diazepam  108 ± 2 
 
107 ± 1 
 
97 ± 4 
 
99 ± 7 
 
102 ± 5 
Diazepam-d5 110 ± 4  
113 ± 1 
 
98 ± 2 
 
100 ± 7 
 
103 ± 2 
Nordiazepam  102 ± 7 
 
99 ± 2 
 
76 ± 3 
 
93 ± 25 
 
73 ± 7 
Nitrazepam 95 ± 9 
 
92 ± 8 
 
69 ± 6 
 
53 ± 4 
 
49 ± 7 
7-aminonitrazepam 109 ± 8 
 
103 ± 6 
 
82 ± 7 
 
93 ± 16 
 
100 ± 5 
Oxazepam 116 ± 5 
 
116 ± 3 
 
101 ± 4 
 
99 ± 10 
 
102 ± 5 
Oxazepam-d5 116 ± 5  
118 ± 3 
 
99 ± 4 
 
97 ± 8 
 
102 ± 2 
Chlordiazepoxide 99 ± 3 
 
98 ± 2 
 
87 ± 1 
 
96 ± 5 
 
94 ± 4 
                    
Antidepressants  
                   
Dosulepin 55 ± 4 
 
55 ± 4 
 
47 ± 4 
 
89 ± 27 
 
58 ± 5 
Amitriptyline 65 ± 6 
 
63 ± 4 
 
58 ± 3 
 
84 ± 16 
 
63 ± 3 
Nortriptyline 58 ± 10 
 
53 ± 5 
 
47 ± 5 
 
83 ± 20 
 
52 ± 3 
Fluoxetine 29 ± 7 
 
26 ± 4 
 
25 ± 4 
 
55 ± 31 
 
30 ± 1 
Fluoxetine-d6 24 ± 6  
22 ± 4 
 
21 ± 2 
 
49 ± 32 
 
26 ± 2 
Norfluoxetine 33 ± 10 
 
27 ± 5 
 
27 ± 4 
 
57 ± 32 
 
33 ± 1 
Venlafaxine 98 ± 5 
 
100 ± 2 
 
95 ± 6 
 
102 ± 2 
 
104 ± 3 
                    
Dissociative anesthetics 
                   
Phencyclidine  100 ± 5 
 
106 ± 4 
 
95 ± 3 
 
81 ± 20 
 
86 ± 4 
PCP-d5 96 ± 11  
107 ± 4 
 
97 ± 3 
 
82 ± 20 
 
87 ± 5 
Ketamine  95 ± 2 
 
97 ± 0 
 
88 ± 2 
 
79 ± 9 
 
83 ± 4 
Ketamine-d4 92 ± 3  
94 ± 1 
 
84 ± 3 
 
76 ± 11 
 
79 ± 2 
Norketamine  78 ± 4 
 
77 ± 5 
 
63 ± 3 
 
61 ± 13 
 
47 ± 1 
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Other 
                   
Methaqualone 109 ± 3 
 
109 ± 3 
 
94 ± 4 
 
95 ± 10 
 
90 ± 5 
Methaqualone-d7 113 ± 6  
113 ± 7 
 
102 ± 3 
 
102 ± 5 
 
103 ± 1 
Sildenafil 62 ± 2 
 
65 ± 4 
 
56 ± 5 
 
88 ± 19 
 
68 ± 6 
                    
Drug precursors 
                   
Ephedrine  63 ± 6 
 
68 ± 3 
 
59 ± 5 
 
73 ± 8 
 
78 ± 3 
Norephedrine 31 ± 6   33 ± 4   33 ± 2   71 ± 43   54 ± 3 
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Table S4 - Stability study - Concentration of compounds in control wastewater sample at time-point zero  
Compound 
Concentration of compound at 
time-point 0 (ng L-1 ± SD) 
Stimulants    
Cocaine 77.4 ± 5.4 
Benzoylecgonine 519.5 ± 35.3 
Norbenzoylecgonine 18.4 ± 1.6 
Norcocaine <MQL   
Cocaethylene 6.9 ± 0.5 
Anhydroecgonine methyl ester <MQL   
Ecgonidine  <MQL   
Amphetamine   15.9 ± 1.4 
Methamphetamine  <MQL   
Methcathinone <MQL   
BZP 46.1 ± 0.7 
TFMPP 10.0 ± 0.9 
    
Hallucinogens    
MDA  <MQL   
MDMA 55.0 ± 6.2 
MDEA <MQL   
MBDB <MQL   
BDB <MQL   
Mescaline <MQL   
LSD <MQL   
O-H-LSD <MQL   
    
Human indicators    
Caffeine 52419.2 ± 694.2 
1,7-dimethylxanthine 30059.8 ± 107.2 
Nicotine 4589.9 ± 36.8 
Continine 1.0 ± 1.1 
    
Opioids and morphine derivatives   
Heroin <MQL   
6-acetylmorphine 2.1 ± 0.3 
Codeine 1951.3 ± 28.9 
Norcodeine 67.4 ± 3.0 
Oxycodone 8.4 ± 1.0 
Oxymorphone 8.0 ± 0.7 
Morphine 408.3 ± 8.2 
Morphine-3β-glucuronide 177.1 ± 1.9 
Normorphine 132.3 ± 10.0 
Dihydrocodeine 189.3 ± 16.8 
Buprenorphine <MQL   
Norbuprenorphine <MQL   
Methadone 58.9 ± 4.4 
EDDP 35.7 ± 2.3 
EMDP <MQL   
Fentanyl <MQL   
Norfentanyl <MQL   
Propoxyphene  <MQL   
Norpropoxyphene 374.7 ± 33.7 
Tramadol 968.2 ± 31.2 
Nortramadol 86.1 ± 7.8 
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Benzodiazepines    
Temazepam 140.7 ± 2.2 
Diazepam  0.0 ± 0.0 
Nordiazepam  10.0 ± 1.1 
Nitrazepam <MQL   
7-aminonitrazepam <MQL   
Oxazepam 34.4 ± 1.4 
Chlordiazepoxide <MQL   
    
Antidepressants     
Dosulepin 60.0 ± 2.8 
Amitriptyline 122.7 ± 7.5 
Nortriptyline <MQL   
Fluoxetine 36.9 ± 0.4 
Norfluoxetine 10.6 ± 0.6 
Venlafaxine 124.7 ± 9.2 
    
Dissociative anesthetics    
Phencyclidine  <MQL   
Ketamine  96.5 ± 6.0 
Norketamine  16.5 ± 1.0 
    
Other    
Methaqualone <MQL   
Sildenafil 30.3 ± 3.7 
    
Drug precursors    
Ephedrine  449.3 ± 18.4 
Norephedrine <MQL   
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This section discusses the following sample preparation parameters: (i) the effect of SPE sorbent; (ii) 
recovery of analytes during vacuum filtration through glass fibre filters and (iii) pre LC-MS filter 
membranes. 
 
1. EXPERIMENTAL 
 
1.1 Solid phase extraction sorbent 
 
To assess the recovery efficiency of Oasis® HLB and MCX SPE sorbents (3 cm
3
, 60 mg), UHQ water (100 mL) was 
spiked with 50 ng of each compound, with exception of norpropoxyphene and creatinine at 100 ng, and cannabinoids 
at 150 ng. The sample was extracted using the protocols described below. After elution into silanised vials, extracts 
were subsequently evaporated at 40 °C under a stream of nitrogen and reconstituted in 0.3 % CH3COOH, 5 % 
MeOH/H2O (v/v) (500 µl). 
 
Oasis HLB protocol 
 
Oasis HLB (60 mg, Waters, UK) cartridges were conditioned with methanol (2 ml, flow rate 3 ml min
-1
) followed by 
equilibration with water (2 ml, pH 7, flow rate 3 ml min
-1
). Then, 100 mL of sample (pH 7, adjusted with NaOH) was 
passed through each cartridge (flow rate 6 ml min
-1
). Elution was performed with methanol (4 mL, flow rate 3 ml 
min
-1
) into silanised vials. 
 
Oasis MCX protocol 
 
Oasis MCX (60 mg, Waters, UK) cartridges were conditioned with methanol (2 ml, flow rate 3 ml min
-1
) followed by 
equilibration with 2 % (v/v) HCOOH/H2O (2 ml, pH 1.8, flow rate 3 ml min
-1
). Then, 100 mL of sample (pH 1.8, 
adjusted with HCl) was passed through each cartridge (flow rate 6 ml min
-1
). Elution was performed with methanol (2 
mL) and 7 % (v/v) NH4OH/MeOH (2mL, 3 ml min
-1
) into silanised vials. 
 
1.2 Syringe filters membrane investigation 
 
Filtration of samples prior to injection into the UPLC system is vital in order to maintain guard columns and sub-2 µm 
analytical columns. Various different filter membranes (see list below) were assessed to ensure that target analytes 
were not removed. Compounds were spiked into sample diluent, 0.3 % CH3COOH, 5 % MeOH/H2O (v/v), at a 
concentration of 50 µg L
-1
, with exception of norpropoxyphene and creatinine at 100 µg L
-1
 and cannabinoids at 150 
µg L
-1
.  Aliquots of this sample (500 µL) were then filtered through each of the membranes (each membrane was 
discarded after one 500 µL sample) and analysed by LC-MS/MS. The evaluated membranes were as follows:   
 
- Phenex – RC (Phenomenex, UK): Diameter 4mm, 0.2µm membrane; membrane, hydrophilic regenerated 
cellulose; application, broad range of aqueous and mixed-organic solutions 
- Phenex – PTFE (Phenomenex, UK): Diameter 4mm, 0.2µm membrane; membrane, hydrophobic PTFE; 
application, organic based, highly acidic or basic samples and solvents 
- Phenex – NY (Phenomenex, UK): Diameter 4mm, 0.2µm membrane; membrane inherently hydrophilic; 
application, many aqueous and mixed organic samples 
- IC Millex – LG (Millipore, UK): Diameter 13mm, 0.2µm membrane; membrane, hydrophilic PTFE; 
application, aqueous and mild organic solutions for ion chromatography 
- Millex – LG (Millipore, UK): Diameter 4mm, 0.2µm membrane; membrane, hydrophilic PTFE; application 
aqeous and organic solutions 
- Millex – GV (Millipore, UK); Diameter 4mm, 0.22µm membrane; membrane hydrophilic PVDF, 
application aqueous and mild organic solutions 
- Whatman – PTFE (Whatman, UK): Diameter 13mm, 0.2µm membrane; membrane hydrophobic PTFE; 
application, organic based samples 
1.3 Filtration of environmental samples 
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The potential removal of compounds during vacuum filtration was investigated. Filters assessed were GF/D (2.7 µm), 
GF/C (1.2 µm) and GF/F (0.7 µm) (Whatman, UK). UHQ water (100ml) was spiked with 50 ng of each compound, 
except norpropoxyphene and creatinine at 100 ng, and cannabinoids at 150 ng. Each sample was passed through one 
filter only, before undergoing the SPE procedure with Oasis® MCX sorbent as discussed in section 0 
2 RESULTS AND DISCUSSION 
 
2.1  Solid phase extraction sorbent 
 
Optimisation of SPE sorbents involved the Oasis HLB and Oasis MCX. Overall, the recovery of the 
majority of compounds was similar with both sorbent protocols. Recoveries are presented for all 
compounds in Figure S2. Key differences included the ability of the MCX to extract ecgonine methyl 
ester, anhydroecgonine methyl ester and ecgonidine, whereas, the HLB protocol provided higher 
recoveries for benzodiazepines and heroin (the higher recovery is more likely a result of the extraction 
solvent as discussed previously, see main manuscript section 3.1). An additional advantage of the 
Oasis MCX is the need to adjust samples to an acidic pH for extraction. Adjustment to an acidic pH 
has been shown to promote the stability of nearly all compounds. Furthermore, as compounds are 
retained through ion –exchange interactions using the MCX, it is possible to incorporate more 
effective wash steps that could lower matrix effects as oppose to the HLB [1]. The ability to extract 
the cocaine metabolites, incorporate a wash step, and promote stability of samples resulted in the 
Oasis MCX sorbent being selected for future work. The impact of the insufficient recovery of heroin 
can be overcome to some extent with the inclusion of its metabolites 6-acetylmorphine, while the 
recovery of benzodiazepines was higher with the HLB, it was still above or around 80 % with the 
MCX. 
 
2.2 Syringe filter membrane investigation 
 
Filtration of samples to remove particulates is a well known and well documented preventative 
measure in liquid chromatography [2]. Although syringe filters may remove non-dissolved 
particulates and protect the chromatographic system, they could also be responsible for the adsorption 
of target analytes dissolved in the sample of interest [3]. Bijlsma et al. [4] investigated the use of 0.2 
µm polypropylene and PTFE (manufacturer not reported in the manuscript) filter membranes, 
however this group reported recoveries <70 % for cocaine, cocaethylene, norcocaine and THC-
COOH. Other groups have reported the use of PTFE filters [5,6] and GHP [7], but recoveries from 
these membranes were not reported in the respective manuscripts. To determine a suitable syringe 
filter for the suite of compounds selected in this study, a range of different membranes were 
investigated (see section 1.2).  
 
The majority of compounds achieved a recovery greater than 90 % with all membranes evaluated. 
However, there were a small number of compounds below this threshold and these compounds have 
been highlighted in Table S5. Low recoveries of 74, 75 and 84 % were found for ecgonidine using the 
Phenomenex RC, and Millipore PTFE and LG respectively. The same three filters were also 
responsible for low recovery of creatinine, oxymorphone and normorphine. The recovery of morphine 
was below 90 % for both Millipore RC and LG. The highest removal of compounds was associated 
with THC and THC-COOH using Phenomenex nylon, Millipore PTFE, LG, PVDF and Whatman 
PTFE. Of the evaluated syringe filters, only the Phenomenex PTFE achieved a recovery > 90 % for all 
studied compounds. For this reason, the filter was selected for further method development. However 
it was found that when tested with wastewater samples the filter was only able to filter a very small 
quantity of the 500 µL sample before it blocked. The blockage of the filter was more likely a result of 
the filter diameter (4 mm) rather than the membrane itself. Utilisation of a larger diameter would have 
been likely to have solved this issue. Nevertheless, as the Whatman PTFE (13 mm) was readily 
available in the laboratory and recovered all but one compound > 90 % (nitrazepam, 85 %), this filter 
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was tested with wastewater and found to be suitable (THC-COOH and THC were not quantified in the 
final methodology). 
 
2.3 Environmental sample filtration 
 
After the collection of environmental samples, the particulates which are contained in the sample must 
be removed to make the sample amenable to the next analytical step. All procedures that use SPE for 
extraction employ vacuum filtration beforehand (see main manuscript Table 1). This is typically 
achieved by filtering samples through glass microfibre filters. To ensure that the vacuum filtration did 
not lead to the removal of analytes, three glass fibre filters with different pore sizes were evaluated.  
Table S6 lists the recoveries of compounds after filtration. Recoveries were calculated against the 
same sample that had undergone the same analytical procedure, but without the vacuum filtration of 
samples. The vacuum filtration of samples through glass microfibre filters did not influence the 
recovery of target analytes; therefore the spiking of internal standards after filtration is acceptable. 
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Figure S2 – SPE sorbent evaluation, total recovery of Oasis HLB and MCX for all compounds from UHQ water (n = 3)    
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Table S5 – Filter membrane investigation (recoveries < 90 % highlighted) 
Compound Syringe filter membrane recovery (%) (n=2) 
  
Phenomenex 
Nylon 
  
Phenomenex 
PTFE 
  
Phenomenex 
RC 
  
Millipore 
PTFE 
  
Millipore                
LG 
  
Millipore           
PVDF 
  
Whatman     
PTFE 
Stimulants 
                           
Cocaine 100 ± 0 
 
100 ± 1 
 
100 ± 3 
 
101 ± 1 
 
100 ± 0 
 
98 ± 1 
 
98 ± 0 
Cocaine-d3 100 ± 2  
98 ± 2 
 
100 ± 2 
 
100 ± 3 
 
99 ± 1 
 
98 ± 2 
 
97 ± 1 
Benzoylecgonine 99 ± 2 
 
97 ± 2 
 
98 ± 0 
 
99 ± 2 
 
96 ± 1 
 
99 ± 0 
 
98 ± 3 
Benzoylecgonine-d8 98 ± 0  
97 ± 1 
 
100 ± 0 
 
100 ± 1 
 
98 ± 1 
 
101 ± 0 
 
101 ± 3 
Ecgonine methyl ester 104 ± 2 
 
98 ± 1 
 
87 ± 0 
 
99 ± 0 
 
99 ± 2 
 
96 ± 3 
 
101 ± 1 
Ecgonine methyl ester-d3 100 ± 1  
98 ± 1 
 
98 ± 3 
 
102 ± 1 
 
99 ± 0 
 
100 ± 7 
 
102 ± 2 
Norbenzoylecgonine 99 ± 1 
 
97 ± 1 
 
96 ± 1 
 
99 ± 1 
 
94 ± 1 
 
98 ± 3 
 
98 ± 1 
Norcocaine 101 ± 1 
 
99 ± 1 
 
98 ± 1 
 
99 ± 1 
 
96 ± 0 
 
100 ± 0 
 
98 ± 4 
Cocaethylene 101 ± 1 
 
99 ± 1 
 
98 ± 1 
 
100 ± 3 
 
99 ± 2 
 
98 ± 0 
 
98 ± 1 
Cocaethylene-d8 99 ± 2  
100 ± 2 
 
101 ± 3 
 
100 ± 2 
 
99 ± 1 
 
98 ± 1 
 
98 ± 0 
Anhydroecgonine methyl ester 103 ± 2 
 
98 ± 2 
 
91 ± 7 
 
98 ± 4 
 
96 ± 3 
 
100 ± 4 
 
100 ± 0 
Ecgonidine  99 ± 3 
 
101 ± 1 
 
74 ± 6 
 
75 ± 8 
 
84 ± 7 
 
93 ± 2 
 
100 ± 2 
Amphetamine   99 ± 1 
 
97 ± 1 
 
103 ± 2 
 
99 ± 3 
 
96 ± 1 
 
102 ± 3 
 
101 ± 2 
Amphetamine-d11 98 ± 1  
98 ± 0 
 
99 ± 1 
 
102 ± 1 
 
100 ± 2 
 
98 ± 3 
 
96 ± 3 
Methamphetamine  103 ± 1 
 
99 ± 1 
 
100 ± 1 
 
100 ± 1 
 
99 ± 0 
 
100 ± 1 
 
100 ± 0 
Methamphetamine-d14 99 ± 1  
99 ± 0 
 
101 ± 0 
 
100 ± 1 
 
98 ± 1 
 
98 ± 3 
 
100 ± 0 
Methcathinone 100 ± 1 
 
99 ± 1 
 
100 ± 0 
 
101 ± 1 
 
98 ± 1 
 
101 ± 0 
 
100 ± 1 
BZP 104 ± 7 
 
103 ± 6 
 
97 ± 8 
 
99 ± 6 
 
104 ± 4 
 
104 ± 7 
 
102 ± 3 
TFMPP 101 ± 2 
 
101 ± 1 
 
98 ± 3 
 
102 ± 1 
 
98 ± 1 
 
101 ± 2 
 
103 ± 0 
                            
Hallucinogens 
                           
MDA  104 ± 1 
 
99 ± 1 
 
98 ± 1 
 
99 ± 3 
 
100 ± 1 
 
101 ± 0 
 
102 ± 1 
MDA-d5 99 ± 2  
99 ± 1 
 
101 ± 1 
 
98 ± 2 
 
100 ± 0 
 
100 ± 3 
 
100 ± 1 
MDMA  101 ± 3 
 
100 ± 3 
 
100 ± 1 
 
99 ± 1 
 
98 ± 1 
 
100 ± 0 
 
100 ± 0 
MDMA-d5 99 ± 0  
99 ± 3 
 
100 ± 0 
 
99 ± 1 
 
96 ± 1 
 
99 ± 1 
 
101 ± 0 
MDEA 101 ± 0 
 
98 ± 0 
 
100 ± 1 
 
101 ± 2 
 
99 ± 0 
 
100 ± 2 
 
100 ± 3 
MBDB 98 ± 1 
 
98 ± 1 
 
100 ± 1 
 
101 ± 0 
 
97 ± 1 
 
99 ± 3 
 
99 ± 3 
MBDB-d5 100 ± 0  
98 ± 0 
 
99 ± 4 
 
101 ± 1 
 
98 ± 1 
 
99 ± 0 
 
102 ± 2 
BDB 99 ± 0 
 
96 ± 2 
 
97 ± 1 
 
98 ± 0 
 
97 ± 1 
 
98 ± 1 
 
100 ± 0 
Mescaline 100 ± 1 
 
99 ± 3 
 
101 ± 1 
 
97 ± 0 
 
97 ± 4 
 
100 ± 1 
 
101 ± 1 
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Mescaline-d9 100 ± 2  
99 ± 1 
 
98 ± 3 
 
100 ± 1 
 
99 ± 1 
 
99 ± 0 
 
101 ± 1 
LSD 100 ± 1 
 
100 ± 2 
 
101 ± 0 
 
100 ± 1 
 
99 ± 1 
 
98 ± 1 
 
97 ± 3 
LSD-d3 100 ± 2  
98 ± 2 
 
97 ± 2 
 
97 ± 3 
 
99 ± 2 
 
98 ± 2 
 
101 ± 1 
O-H-LSD 98 ± 3 
 
98 ± 0 
 
98 ± 1 
 
98 ± 2 
 
96 ± 0 
 
98 ± 1 
 
99 ± 0 
                            
Human indicators 
                           
Caffeine 101 ± 3 
 
98 ± 1 
 
100 ± 0 
 
102 ± 2 
 
96 ± 3 
 
101 ± 2 
 
103 ± 2 
Caffeine-d9 98 ± 2  
99 ± 1 
 
98 ± 1 
 
98 ± 3 
 
97 ± 2 
 
99 ± 0 
 
100 ± 1 
1,7-dimethylxanthine 101 ± 2 
 
98 ± 1 
 
99 ± 1 
 
100 ± 1 
 
99 ± 1 
 
100 ± 2 
 
99 ± 1 
Nicotine 95 ± 13 
 
101 ± 12 
 
98 ± 13 
 
103 ± 11 
 
93 ± 6 
 
105 ± 15 
 
99 ± 14 
Nicotine-d4 100 ± 15  
106 ± 12 
 
99 ± 13 
 
101 ± 13 
 
88 ± 4 
 
106 ± 11 
 
99 ± 13 
Continine 99 ± 0 
 
98 ± 1 
 
108 ± 2 
 
78 ± 14 
 
77 ± 13 
 
92 ± 0 
 
96 ± 0 
Creatinine 106 ± 5 
 
102 ± 2 
 
64 ± 7 
 
60 ± 8 
 
81 ± 4 
 
87 ± 5 
 
104 ± 3 
                            
Opioids and morphine derivatives 
                           
Heroin 98 ± 0 
 
97 ± 1 
 
98 ± 2 
 
98 ± 0 
 
95 ± 1 
 
98 ± 2 
 
98 ± 1 
Heroin-d9 102 ± 4  
99 ± 2 
 
100 ± 2 
 
101 ± 1 
 
98 ± 2 
 
95 ± 1 
 
95 ± 4 
6-acetylmorphine 103 ± 2 
 
99 ± 1 
 
99 ± 0 
 
99 ± 1 
 
100 ± 1 
 
99 ± 2 
 
98 ± 2 
Codeine 102 ± 3 
 
99 ± 1 
 
100 ± 1 
 
102 ± 1 
 
100 ± 1 
 
100 ± 1 
 
100 ± 2 
Codeine-d6 100 ± 8  
101 ± 0 
 
99 ± 1 
 
101 ± 1 
 
100 ± 1 
 
100 ± 0 
 
99 ± 1 
Norcodeine 99 ± 1 
 
97 ± 2 
 
97 ± 0 
 
101 ± 1 
 
99 ± 3 
 
101 ± 2 
 
101 ± 2 
Oxycodone 100 ± 1 
 
102 ± 0 
 
101 ± 0 
 
100 ± 0 
 
99 ± 1 
 
99 ± 0 
 
99 ± 1 
Oxycodone-d6 103 ± 2  
100 ± 0 
 
100 ± 0 
 
101 ± 2 
 
100 ± 1 
 
100 ± 0 
 
100 ± 0 
Oxymorphone 102 ± 3 
 
96 ± 1 
 
80 ± 6 
 
84 ± 7 
 
85 ± 6 
 
99 ± 3 
 
99 ± 2 
Morphine 102 ± 2 
 
98 ± 1 
 
91 ± 10 
 
85 ± 5 
 
83 ± 8 
 
98 ± 2 
 
100 ± 0 
Morphine-d6 99 ± 2  
100 ± 1 
 
83 ± 11 
 
77 ± 9 
 
72 ± 5 
 
88 ± 7 
 
96 ± 6 
Normorphine 103 ± 1 
 
100 ± 0 
 
75 ± 8 
 
77 ± 8 
 
77 ± 10 
 
96 ± 2 
 
99 ± 3 
Dihydrocodeine 101 ± 0 
 
99 ± 1 
 
99 ± 1 
 
102 ± 2 
 
96 ± 2 
 
100 ± 1 
 
99 ± 1 
Dihydrocodeine-d6 101 ± 1  
99 ± 2 
 
98 ± 1 
 
99 ± 0 
 
99 ± 3 
 
100 ± 0 
 
99 ± 0 
Buprenorphine 103 ± 1 
 
99 ± 0 
 
98 ± 2 
 
100 ± 1 
 
96 ± 0 
 
100 ± 1 
 
100 ± 1 
Buprenorphine-d4 105 ± 1  
100 ± 1 
 
101 ± 1 
 
101 ± 0 
 
100 ± 1 
 
98 ± 2 
 
99 ± 1 
Norbuprenorphine 102 ± 1 
 
99 ± 1 
 
98 ± 1 
 
101 ± 1 
 
98 ± 0 
 
98 ± 0 
 
98 ± 3 
Methadone 101 ± 2 
 
98 ± 3 
 
99 ± 0 
 
102 ± 1 
 
97 ± 1 
 
98 ± 1 
 
101 ± 2 
Methadone-d9 98 ± 2  
99 ± 1 
 
98 ± 0 
 
99 ± 0 
 
95 ± 0 
 
98 ± 2 
 
98 ± 3 
EDDP 101 ± 1 
 
99 ± 1 
 
99 ± 0 
 
101 ± 0 
 
98 ± 1 
 
96 ± 4 
 
98 ± 1 
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EDDP-d3 103 ± 1  
100 ± 0 
 
99 ± 0 
 
102 ± 1 
 
100 ± 0 
 
97 ± 3 
 
98 ± 1 
EMDP 99 ± 3 
 
98 ± 1 
 
97 ± 1 
 
98 ± 2 
 
95 ± 2 
 
98 ± 0 
 
99 ± 3 
Fentanyl 102 ± 1 
 
99 ± 1 
 
99 ± 1 
 
101 ± 1 
 
98 ± 1 
 
100 ± 1 
 
100 ± 2 
Fentanyl-d5 101 ± 0  
98 ± 0 
 
97 ± 3 
 
99 ± 1 
 
96 ± 1 
 
99 ± 1 
 
99 ± 1 
Norfentanyl 99 ± 1 
 
98 ± 1 
 
97 ± 0 
 
99 ± 2 
 
97 ± 0 
 
96 ± 1 
 
99 ± 1 
Propoxyphene  100 ± 0 
 
97 ± 1 
 
97 ± 2 
 
98 ± 0 
 
94 ± 0 
 
99 ± 1 
 
101 ± 1 
Propoxyphene-d11 102 ± 0  
99 ± 0 
 
97 ± 3 
 
101 ± 3 
 
97 ± 1 
 
98 ± 1 
 
100 ± 2 
Norpropoxyphene 95 ± 2 
 
96 ± 1 
 
99 ± 4 
 
100 ± 1 
 
94 ± 2 
 
98 ± 3 
 
98 ± 4 
Norpropoxyphene-d5 96 ± 1  
98 ± 4 
 
99 ± 0 
 
100 ± 2 
 
97 ± 3 
 
97 ± 2 
 
100 ± 1 
Tramadol 99 ± 3 
 
99 ± 1 
 
99 ± 1 
 
102 ± 1 
 
99 ± 0 
 
97 ± 1 
 
98 ± 3 
Nortramadol 101 ± 3 
 
98 ± 1 
 
101 ± 2 
 
100 ± 3 
 
99 ± 1 
 
102 ± 3 
 
102 ± 2 
                            
Benzodiazepines 
                           
Temazepam 101 ± 1 
 
97 ± 1 
 
100 ± 4 
 
98 ± 1 
 
97 ± 1 
 
99 ± 3 
 
97 ± 4 
Temazepam-d5 96 ± 9  
97 ± 4 
 
100 ± 1 
 
103 ± 3 
 
95 ± 2 
 
101 ± 2 
 
101 ± 2 
Diazepam  98 ± 1 
 
100 ± 1 
 
102 ± 2 
 
100 ± 1 
 
100 ± 0 
 
102 ± 1 
 
98 ± 1 
Diazepam-d5 99 ± 2  
100 ± 4 
 
101 ± 0 
 
101 ± 3 
 
100 ± 4 
 
101 ± 1 
 
96 ± 2 
Nordiazepam  96 ± 2 
 
96 ± 0 
 
96 ± 3 
 
96 ± 2 
 
90 ± 1 
 
100 ± 1 
 
90 ± 3 
Nitrazepam 95 ± 2 
 
93 ± 2 
 
93 ± 1 
 
88 ± 3 
 
82 ± 1 
 
92 ± 2 
 
85 ± 1 
7-aminonitrazepam 101 ± 1 
 
99 ± 0 
 
99 ± 1 
 
99 ± 0 
 
95 ± 1 
 
98 ± 1 
 
95 ± 1 
Oxazepam 97 ± 2 
 
98 ± 2 
 
99 ± 1 
 
100 ± 2 
 
95 ± 2 
 
97 ± 0 
 
97 ± 4 
Oxazepam-d5 98 ± 5  
97 ± 2 
 
99 ± 2 
 
100 ± 1 
 
98 ± 2 
 
98 ± 4 
 
99 ± 3 
Chlordiazepoxide 100 ± 2 
 
100 ± 2 
 
98 ± 2 
 
102 ± 2 
 
99 ± 3 
 
99 ± 0 
 
102 ± 1 
                            
Antidepressants  
                           
Dosulepin 103 ± 1 
 
99 ± 2 
 
100 ± 0 
 
100 ± 0 
 
99 ± 2 
 
99 ± 3 
 
98 ± 2 
Amitriptyline 102 ± 1 
 
100 ± 0 
 
102 ± 2 
 
102 ± 1 
 
99 ± 2 
 
98 ± 0 
 
99 ± 3 
Nortriptyline 102 ± 1 
 
99 ± 0 
 
99 ± 0 
 
98 ± 2 
 
98 ± 0 
 
98 ± 3 
 
99 ± 3 
Fluoxetine 101 ± 3 
 
99 ± 1 
 
98 ± 2 
 
102 ± 1 
 
96 ± 4 
 
101 ± 0 
 
100 ± 0 
Fluoxetine-d6 100 ± 1  
98 ± 2 
 
96 ± 3 
 
99 ± 0 
 
99 ± 2 
 
102 ± 5 
 
99 ± 0 
Norfluoxetine 99 ± 3 
 
98 ± 0 
 
100 ± 2 
 
102 ± 3 
 
99 ± 4 
 
100 ± 5 
 
100 ± 1 
Venlafaxine 99 ± 1 
 
98 ± 1 
 
100 ± 2 
 
100 ± 3 
 
97 ± 0 
 
101 ± 1 
 
99 ± 3 
                            
Dissociative anesthetics 
                           
Phencyclidine  101 ± 2 
 
99 ± 2 
 
99 ± 2 
 
101 ± 2 
 
98 ± 2 
 
97 ± 2 
 
100 ± 1 
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PCP-d5 101 ± 1  
97 ± 3 
 
100 ± 1 
 
101 ± 2 
 
98 ± 2 
 
98 ± 3 
 
98 ± 0 
Ketamine  100 ± 3 
 
98 ± 1 
 
97 ± 1 
 
100 ± 1 
 
97 ± 0 
 
99 ± 2 
 
98 ± 0 
Ketamine-d4 101 ± 3  
97 ± 2 
 
98 ± 0 
 
101 ± 3 
 
98 ± 1 
 
98 ± 0 
 
99 ± 3 
Norketamine  97 ± 2 
 
98 ± 2 
 
97 ± 0 
 
99 ± 3 
 
97 ± 2 
 
97 ± 3 
 
97 ± 1 
                            
Cannabinoids 
                           
THC <MDL     
 
101 ± 6 
 
103 ± 1 
 
89 ± 4 
 
29 ± 4 
 
91 ± 3 
 
7 ± 1 
THC-COOH <MDL     
 
100 ± 4 
 
95 ± 4 
 
56 ± 8 
 
5 ± 0 
 
71 ± 3 
 
<MDL   
THC-d3 <MDL      
103 ± 6 
 
104 ± 1 
 
91 ± 4 
 
30 ± 4 
 
91 ± 4 
 
7 ± 2 
                            
Other 
                           
Methaqualone 97 ± 1 
 
96 ± 1 
 
96 ± 2 
 
96 ± 1 
 
92 ± 3 
 
97 ± 3 
 
92 ± 1 
Methaqualone-d7 96 ± 0  
97 ± 0 
 
98 ± 3 
 
102 ± 0 
 
95 ± 1 
 
99 ± 0 
 
98 ± 1 
Sildenafil 101 ± 0 
 
100 ± 1 
 
101 ± 0 
 
102 ± 2 
 
95 ± 1 
 
100 ± 1 
 
96 ± 3 
Pheacetin-ethoxy-1-13C 98 ± 4 
 
96 ± 1 
 
98 ± 0 
 
97 ± 3 
 
95 ± 1 
 
98 ± 3 
 
98 ± 1 
                            
Drug precursors 
                           
Ephedrine  99 ± 1 
 
100 ± 1 
 
99 ± 1 
 
100 ± 0 
 
97 ± 0 
 
99 ± 1 
 
100 ± 1 
Norephedrine 99 ± 2   100 ± 0   99 ± 0   99 ± 1   95 ± 3   98 ± 0   100 ± 0 
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Table S6 – Recovery of analytes after filtration through glass fibre filters 
Compound Microfibre filter recovery (%) (n=3)         
  GF/D 2.7 µm   GF/C 1.2 µm   GF/F 0.7 µm 
Stimulants 
           
Cocaine 101 ± 2 
 
100 ± 4 
 
98 ± 1 
Cocaine-d3 -    
100 ± 4 
 
98 ± 1 
Benzoylecgonine 101 ± 1 
 
96 ± 3 
 
94 ± 1 
Benzoylecgonine-d8 95 ± 1  
98 ± 3 
 
96 ± 1 
Ecgonine methyl ester 107 ± 4 
 
103 ± 1 
 
110 ± 7 
Ecgonine methyl ester-d3 111 ± 10  
101 ± 2 
 
101 ± 1 
Norbenzoylecgonine 103 ± 2 
 
97 ± 3 
 
97 ± 1 
Norcocaine 100 ± 2 
 
106 ± 4 
 
100 ± 2 
Cocaethylene 102 ± 1 
 
109 ± 3 
 
104 ± 2 
Cocaethylene-d8 100 ± 3  
104 ± 3 
 
103 ± 1 
Anhydroecgonine methyl ester 99 ± 2 
 
103 ± 4 
 
104 ± 3 
Ecgonidine  100 ± 1 
 
105 ± 1 
 
101 ± 1 
Amphetamine   110 ± 3 
 
97 ± 4 
 
99 ± 3 
Amphetamine-d11 110 ± 6  
99 ± 3 
 
99 ± 3 
Methamphetamine  108 ± 1 
 
101 ± 4 
 
99 ± 3 
Methamphetamine-d14 103 ± 3  
104 ± 4 
 
100 ± 2 
Methcathinone 105 ± 7 
 
104 ± 5 
 
99 ± 5 
BZP 98 ± 2 
 
82 ± 16 
 
75 ± 14 
TFMPP 105 ± 5 
 
106 ± 4 
 
101 ± 4 
            
Hallucinogens 
           
MDA  104 ± 1 
 
102 ± 4 
 
101 ± 2 
MDA-d5 105 ± 4  
101 ± 2 
 
101 ± 3 
MDMA 98 ± 2 
 
102 ± 2 
 
101 ± 3 
MDMA-d5 103 ± 1  
102 ± 2 
 
100 ± 2 
MDEA 98 ± 1 
 
103 ± 5 
 
101 ± 3 
MBDB 102 ± 3 
 
105 ± 6 
 
104 ± 3 
MBDB-d5 103 ± 2  
103 ± 4 
 
100 ± 3 
BDB 108 ± 3 
 
105 ± 5 
 
102 ± 2 
Mescaline 105 ± 2 
 
103 ± 2 
 
96 ± 2 
Mescaline-d9 102 ± 2  
107 ± 1 
 
96 ± 1 
LSD 101 ± 3 
 
109 ± 10 
 
98 ± 5 
LSD-d3 97 ± 4  
109 ± 11 
 
112 ± 5 
O-H-LSD 105 ± 1 
 
102 ± 3 
 
99 ± 1 
            
Human indicators 
           
Caffeine 103 ± 5 
 
100 ± 1 
 
99 ± 1 
Caffeine-d9 103 ± 0  
98 ± 1 
 
98 ± 1 
1,7-dimethylxanthine 106 ± 2 
 
97 ± 4 
 
94 ± 1 
Nicotine 82 ± 13 
 
107 ± 18 
 
24 ± 16 
Nicotine-d4 70 ± 17  
96 ± 15 
 
21 ± 14 
Continine 101 ± 1 
 
104 ± 4 
 
104 ± 5 
Creatinine 100 ± 4 
 
96 ± 0 
 
104 ± 4 
            
Opioids and morphine derivatives 
           
Heroin 104 ± 6 
 
100 ± 6 
 
99 ± 12 
Heroin-d9 91 ± 12  
83 ± 16 
 
80 ± 18 
6-acetylmorphine 100 ± 2 
 
106 ± 3 
 
98 ± 0 
Codeine 104 ± 1 
 
97 ± 3 
 
98 ± 1 
Codeine-d6 -    
97 ± 3 
 
98 ± 2 
Norcodeine 108 ± 2 
 
95 ± 5 
 
99 ± 2 
Oxycodone 98 ± 6 
 
104 ± 5 
 
100 ± 3 
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Oxycodone-d6 100 ± 6  
102 ± 2 
 
101 ± 0 
Oxymorphone 100 ± 2 
 
104 ± 4 
 
100 ± 2 
Morphine 99 ± 3 
 
97 ± 2 
 
105 ± 2 
Morphine-d6 101 ± 3  
100 ± 3 
 
104 ± 3 
Normorphine 96 ± 4 
 
103 ± 3 
 
105 ± 3 
Dihydrocodeine 102 ± 2 
 
95 ± 2 
 
98 ± 1 
Dihydrocodeine-d6 104 ± 2  
93 ± 4 
 
97 ± 2 
Buprenorphine 103 ± 5 
 
104 ± 1 
 
110 ± 5 
Buprenorphine-d4 100 ± 3  
109 ± 1 
 
107 ± 4 
Norbuprenorphine 105 ± 5 
 
103 ± 0 
 
99 ± 3 
Methadone 106 ± 4 
 
109 ± 2 
 
103 ± 8 
Methadone-d9 106 ± 4  
113 ± 7 
 
106 ± 6 
EDDP 96 ± 6 
 
95 ± 8 
 
99 ± 3 
EDDP-d3 99 ± 3  
99 ± 6 
 
100 ± 4 
EMDP 102 ± 3 
 
97 ± 2 
 
101 ± 5 
Fentanyl 103 ± 3 
 
96 ± 2 
 
95 ± 2 
Fentanyl-d5 101 ± 4  
102 ± 5 
 
120 ± 6 
Norfentanyl 104 ± 7 
 
106 ± 0 
 
103 ± 5 
Propoxyphene  109 ± 6 
 
95 ± 4 
 
105 ± 5 
Propoxyphene-d11 104 ± 5  
104 ± 0 
 
108 ± 5 
Norpropoxyphene 106 ± 2 
 
106 ± 3 
 
107 ± 7 
Norpropoxyphene-d5 100 ± 4  
94 ± 5 
 
95 ± 8 
Tramadol 98 ± 2 
 
98 ± 2 
 
96 ± 1 
Nortramadol 102 ± 2 
 
100 ± 5 
 
103 ± 1 
            
Benzodiazepines 
           
Temazepam 105 ± 3 
 
96 ± 4 
 
104 ± 2 
Temazepam-d5 101 ± 4  
109 ± 7 
 
104 ± 4 
Diazepam  101 ± 2 
 
107 ± 5 
 
104 ± 2 
Diazepam-d5 101 ± 6  
107 ± 4 
 
103 ± 3 
Nordiazepam  99 ± 5 
 
104 ± 6 
 
96 ± 3 
Nitrazepam 96 ± 2 
 
96 ± 11 
 
96 ± 2 
7-aminonitrazepam 91 ± 2 
 
94 ± 6 
 
95 ± 2 
Oxazepam 98 ± 7 
 
104 ± 3 
 
103 ± 1 
Oxazepam-d5 97 ± 7  
127 ± 5 
 
101 ± 1 
Chlordiazepoxide 101 ± 2 
 
114 ± 3 
 
110 ± 4 
            
Antidepressants  
           
Dosulepin 99 ± 4 
 
105 ± 7 
 
95 ± 8 
Amitriptyline 100 ± 2 
 
104 ± 6 
 
91 ± 6 
Nortriptyline 104 ± 5 
 
104 ± 6 
 
93 ± 6 
Fluoxetine 100 ± 3 
 
108 ± 10 
 
96 ± 6 
Fluoxetine-d6 94 ± 7  
79 ± 12 
 
97 ± 10 
Norfluoxetine 99 ± 5 
 
105 ± 7 
 
96 ± 15 
Venlafaxine 101 ± 1 
 
109 ± 2 
 
103 ± 2 
            
Dissociative anesthetics 
           
Phencyclidine  108 ± 5 
 
111 ± 7 
 
106 ± 5 
PCP-d5 104 ± 5  
109 ± 7 
 
104 ± 4 
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Ketamine  97 ± 3 
 
102 ± 2 
 
98 ± 2 
Ketamine-d4 96 ± 3  
104 ± 2 
 
103 ± 1 
Norketamine  100 ± 6 
 
91 ± 9 
 
100 ± 2 
            
Other 
           
Methaqualone 101 ± 2 
 
114 ± 6 
 
106 ± 2 
Methaqualone-d7 104 ± 1  
109 ± 4 
 
103 ± 1 
Sildenafil 113 ± 7 
 
101 ± 1 
 
84 ± 12 
Pheacetin-ethoxy-1-
13
C 104 ± 1 
 
103 ± 4 
 
103 ± 6 
            
Drug precursors 
           
Ephedrine  104 ± 3 
 
105 ± 3 
 
102 ± 2 
Norephedrine 107 ± 1   97 ± 2   103 ± 1 
 
 
 
 
 
